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Cover: 
Contemplation (1938) Paul Klee (1879–1940). 
Artwork is in the public domain.
Klee was an influential  20th century abstract painter. At the age of 57 he was 
diagnosed with progressive scleroderma. After diagnosis, there was a steep 
decline in productivity and marked change in style. However, he still managed to 
produce more than 1000 works in the last years of his life. A number of these are 
thought to be inspired by his disease and reflect fear, suffering and death. Other 
drawings reflect his view on scleroderma and the disfigurement of his body.
Although “Contemplation”  does not seem to be influenced by his disease, the 
meanings of the hieroglyphic-like lines in the painting are still  as enigmatic as the 
processes underlying systemic sclerosis. Hopefully this thesis, contemplating 
genetics, will provide a key to decipher a small part of this disease. 
Whether Klee would be happy with this comparison is unlikely, considering his 
quotation: “The worst state of affairs is when science begins to concern itself with 
art.”
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General introduction
A brief history
Although systemic  sclerosis (SSc) is a rare disease, the characteristic  feature of 
hardened skin (scleroderma) has been mentioned throughout the history of 
medicine. Scleroderma originates from the Greek words skleros (hard or indurated) 
and derma (skin). Hippocrates (400 B.C.) first used the term scleroderma, for 
describing hardened skin (Aphorism V:71). Hippocrates notes "In those persons in 
whom the skin is stretched, parched, and hard, the disease terminates without 
sweats." Whether Hippocrates really encountered a patient with SSc is not 
deductible from his notations (1). A more precise description was not provided until 
1753. Doctor Carlo Curzio from Naples describes in a published monograph a 17-
year-old woman with symptoms of hardness of the skin (differing in degree from 
place to place), tightness around the mouth, and hardness around the neck. He 
also noted loss of warmth in the skin, but normal pulse, respiration and digestion. 
Intriguingly, and in sharp contrast to the current clinical  practice, Dr. Curzio was 
able to cure the disease fully in this female, by prescribing warm milk and vapor 
baths, bleeding from the foot, and small  doses of quicksilver. After 11 months the 
skin became soft again (2). Although more reports on scleroderma followed, it was 
not until 1945 that Robert H. Goetz first described the concept of scleroderma as a 
systemic disease. To accentuate this, he introduced the term progressive systemic 
sclerosis (3).
Epidemiology
SSc is a rare connective tissue disease and prevalence varies geographically (4). 
This fact initially hampered thorough epidemiological studies. More extensive 
research illustrating the prevalence, incidence and risk factors for SSc appeared 
after the first common disease description for SSc was published by the American 
Rheumatism Association in 1980 (Table 1) (5). Now, prevalence is estimated 
between 3 and 24 per 100,000 persons and interestingly, appears to be higher in 
the United States and Australia compared to Japan and Europe (6-10). In Europe 
there seems to be a North to South gradient with North Europeans having a lower 
prevalence of SSc (8). One of the most interesting populations is the Choctaws 
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Indians, a Native American tribe in Oklahoma. An extremely high prevalence of 
SSc was obsered (469/100,000) based on 14 SSc  cases over a four year period in 
full  blood Choctaws. This prevalence was significantly higher than the prevalence 
observed in non Choctaws Native Americans in Oklahoma (9.5/100,000) (11). 
Noteworthy, no significant contributing environmental  factor was found in a case–
control  study and a role for a genetic component was confirmed by the association 
of the HLA region of these Native Americans with disease risk. SSc  is present more 
frequently in women, with ratios varying from 3:1 to 14:1 (8). This finding may be 
explained by differences in environmental exposures, hormonal milieu and the 
different genetic makeup in the sense of harboring two X chromosomes (12, 13). In 
addition to the higher incidence rate of disease in females, SSc  is more frequently 
found in populations originating from Africa. For instance, a study conducted in the 
USA found a SSc incidence of 3.1/100,000/year in black women in disparity to 
2.7/100.000/year in white women (14). Interestingly, the diffuse cutaneous systemic 
sclerosis (dcSSc) subform accounted for 60% versus 27% of the cases in black 
compared to white SSc females (7). Furthermore, black patients developed SSc at 
an earlier age than Caucasian patients. A study performed in France postulated 
similar findings (15).
Table 1. ARA/ACR criteria for SSc
Criteria Phenotype
Major: Proximal scleroderma
Minor (2): Sclerodactyly
Digital pitting scars/loss of  substance of finger pads
Bibasilar pulmonary fibrosis
Pathogenesis and pathophysiology
Systemic  sclerosis is an autoimmune disease characterized by extensive fibrosis of 
the skin and internal organs. These hallmark manifestations comprise 
vasculopathy, immune system activation and exaggerated collagen deposition in 
extracellular matrix (fibrosis). Although the disease has an impressive appearance 
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and high mortality, the pathogenesis remains poorly understood. Endothelial cell 
activation, vascular damage and immune activation are generally regarded as the 
first events. The vascular damage is followed by the extravasation of inflammatory 
cells, including monocytes and lymphocytes. Eventually, fibroblasts are activated. 
These activated fibroblasts start producing excessive extracellular matrix, 
commencing the fibrotic features of SSc. In time, when looking in advanced 
lesional  skin, inflammation seems to be halted again (16-22). Environmental, 
genetic and epigenetic factors are thought to underlie the onset of SSc  and are 
discussed in the following paragraphs. A schematic view of the processes involved 
is provided in Figure 1.
Figure 1. Processes involved in systemic sclerosis pathogenesis
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Vascular abnormalities
Vasculopathy in SSc comprises Raynaud's phenomenon, increased vascular wall 
thickness, vascular occlusion, devascularization, and thickening of the basement 
membrane. More recently, it was discovered that changes in the nailfold capillaries 
are one of the first signs in SSc (16,17) Vasculopathy is also the most common 
process involved in the major complications of SSc, namely myocardial 
dysfunction, pulmonary arterial hypertension and scleroderma renal crisis (17). 
Thinning of the media, intimal proliferation and fibrosis of the adventitia strike 
arterioles during the course of the disease. Next to these processes there is 
reduced vasodilatory capacity, hypoxia, oxidative stress and increased 
adhesiveness of the blood vessels to lymphocytes (16-18). Endothelial  cells play 
an undefined role in SSc  pathogenesis; they seem to be both targets of immune 
activity and immune activity mediators (18).
The immune cell  infiltrates around blood vessels of SSc patients mainly consist of 
CD4+ Tcells, consequently these cells are the best studied immune cells in SSc 
(19,20). Of interest, T regulatory cells, the immune activity-diminishing counterparts 
of CD4+ cells, seem to be impaired in SSc (21). CD4+ T cell  cytokines are, in 
concert with monocyte-derived cytokines, elevated in the serum of SSc patients. 
These cytokines include IL-1, IL-2, IL-4 and IL-6. Intriguingly, IL-2 can induce the 
secretion of active TGFβ by monocytes. TGFβ is able to activate fibroblasts to 
secrete more extracellular matrix. Activated fibroblasts start producing both 
cytokines and growth factors including CTGF and TGFβ, CTGF mRNA remains 
overexpressed in SSc fibroblasts and fibrotic  skin lesions (22). This phenomenon 
might contribute to an autocrine loop; in turn there is increased ICAM-1 expression 
on fibroblasts, which increases the adhesion of lymphocytes. Although all these 
processes need further scientific  exploration and validation, they currently provide 
the best explanation for the disease perpetuating processes in SSc taking into 
account cell-cell interactions and cytokines (16-22). Next to the abovementioned 
cytokines, IL-8, IL-10, IL-13, IL-17, TGFβ, PDGF, TNF-α, IFN-γ, and IL-2 receptor 
are increased in the serum of SSs patients as well, but their role in pathogenesis is 
still a matter of intense scientific debate. 
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Clinical manifestations
Systemic  sclerosis can be divided into two clinical  phenotypes, limited and diffuse 
cutaneous SSc. Both have their own clinical characteristics as comprehensively 
displayed in Table 2. These differences have been used by LeRoy to postulate 
classification criteria for SSc phenotypes. Briefly, patients with lcSSc have a 
disease course progressing more slowly and the skin changes do not extend 
beyond the elbows and knees into the proximal extremities or trunk. Internal  organ 
involvement is highly variable in lcSSc. Patients with dcSSc develop more rapidly 
progressing skin fibrosis and severe internal  organ involvement (23). Autoantibody 
production is different between subtypes as well; anticentromeric antibodies are 
seen almost exclusively in 70-80% of the lcSSc patients and anti-topoisomerase 
antibodies in 30% of dcSSc patients.
Table 2. LeRoy classification of systemic sclerosis phenotypes
SSc subset Symptom
Diffuse
Onset of Raynaud's within 1 year of onset of skin changes 
(puffy or hidebound skin)
Truncal and acral skin involvement
Presence of tendon friction rubs
Early and significant incidence of interstitial lung disease, 
oliguric renal failure, diffuse gastrointestinal disease, and 
myocardial involvement
Absence of anticentromere antibodies
Nailfold capillary dilation and capillary destruction
Antitopoisomerase antibodies (30% of patients)
Limited
Raynaud's phenomenon for years (occasionally decades)
Skin involvement limited to hands, face, feet, and forearms 
(acral) or absent
A significant late incidence of pulmonary hypertension, with or 
without interstitial lung disease, trigeminal neuralgia, skin 
calcifications, telangiectasias
A high incidence of anticentromere antibodies (70%-80%)
Dilated nailfold capillary loops, usually without capillary 
dropout
Raynaud's phenomenon is a triphasic (pallor, cyanosis and red engorgement) color 
change of the fingers and toes, which is usually induced by cold or stress. 
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Raynaud's phenomenon is not always accompanied by SSc  development; 
however, SSc is always preceded by it. In lcSSc, it is present multiple years before 
skin changes or internal  organ complications occur. In dcSSc, it precedes the onset 
of skin and organ manifestations not more than one year. The first skin changes in 
the early phase consist of skin edema, mainly affecting fingers and hands. Next to 
this, painful  ischemic  digital  ulceration frequently develops. Particularly in dcSSc, 
the edema is rapidly followed by development of firm, indurated skin over the 
extremities, trunk, and face. In lcSSc  the edema and skin thickening are confined 
to the distal extremities. The skin keeps on thickening until  approximately the first 5 
years of disease are passed (16,17).
Organ involvement in SSc is widespread. Involvement of lungs, heart and kidney 
are the most devastating and most deadly complications. For that reason they will 
be described below. An extensive overview of all complications occurring in SSc is 
provided in table 3 (16,17,24). 
Table 3. Complications and symptoms of Systemic Sclerosis
System Manifestation
Cutaneous
Diffuse edema of hands and feet (early stages)
Progressive skin tightening
Sclerodactyly
Calcinosis
Telangiectasias
Digital ulcers and pits
Contractures
Hyperpigmentation, hypopigmentation, salt and pepper skin
Characteristic facies
Vascular
Raynaud's phenomenon
Nailfold capillary changes
Digital ischemia and ulcers
Vasculitic leg ulcers
Pulmonary
Interstitial lung disease, including alveolitis and interstitial 
fibrosis
Pulmonary hypertension
Recurrent aspiration pneumonitis caused by esophageal 
reflux and dysmotility
Decreased thoracic compliance
Respiratory muscle weakness
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System Manifestation
Cardiac
Cardiomyopathy (systolic and diastolic dysfunction): 
Congestive heart failure
Conduction defects
Septal infarction pattern
Ventricular conduction abnormalities
Arrhythmias
Heart blocks
Pericarditis or pericardial effusion
Renal Scleroderma renal crisis (hypertension, renal failure MAHA)
Musculoskeletal 
and 
Rheumatologic
Arthralgia
Tendon friction rubs
Inflammatory arthritis, erosive arthropathy
Myopathy, myositis
Gastrointestinal
Gastroesophageal reflux
Esophageal dysmotility, aperistaltic esophagus
Esophageal stricture
Watermelon stomach 
Decreased peristalsis throughout the GI tract
Bacterial overgrowth and malabsorptive diarrhea, alternating 
diarrhea and constipation
Megacolon
Colonic wide-mouth diverticuli
Pneumatosis cystoides intestinales
Primary biliary cirrhosis
Anal incontinence
Endocrine Hypothyroidism
Neurologic Carpal tunnel syndromeTrigeminal neuralgia
Pulmonary complications may present as dyspnea and nonproductive cough. 
Especially shortness of breath, fatigue, chest pain, and occasionally syncope are 
warning signs of pulmonary arterial hypertension, the most feared complication of 
SSc. Pulmonary arterial  hypertension develops in about 20% to 30% of lcSSc 
patients. Patients with dcSSc, most often develop interstitial lung disease, the 
pulmonary manifestations might be more severe in dcSSc patients who are ATA 
positive or have rapidly progressing skin disease. (17, 23) Renal involvement, or 
scleroderma renal crisis, is characterized by the development of severe 
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hypertension, renal failure, and microangiopathic hemolytic anemia. The 
development of renal crisis only occurs in patients with dcSSc (16,17). Cardiac 
complications are rare, but myocardial  fibrosis may develop in patients with dcSSc 
(24). 
Depending on the development of complications, the survival rate of SSc patients 
drops. Patients with lcSSc  have a 10 year survival of 75-79%, only 53%-62% of 
patients with dcSSc  survive the first 10 years after diagnosis. However, when a 
patient with lcSSc develops PAH, 5 year survival drops to 10% (25-28).
Environmental factors
Exposure to some chemicals seems to result in symptoms that mimic SSc  such as 
polyvinyl chloride intoxication or the toxic oil  syndrome (29). An Australian study 
found that SSc patients more frequently had an occupation involving retail, 
wholesale, construction, manufacturing and rural activities compared to healthy 
persons (6). These jobs place an individual at risk for exposure to hydrocarbons 
and silica dust. A recent meta-analysis addressing the effect of silica exposure on 
SSc development by analyzing all  reports up to 2007 was severely hampered by 
significant heterogeneity among the studies included (30). Although multiple 
substances have been investigated, up till now none of them was implicated in SSc 
susceptibility in a convincing and reproducible matter. 
Genetics and epigenetics in Systemic Sclerosis
The observations of environment independent ethnic  clustering, the strong 
predominance of disease in females and the lack of a clear general environmental 
factor involved in SSc  pathogenesis have inspired several researchers to decipher 
the genetic  background for SSc susceptibility. Genetic research has been 
performed on the level  of heritability studies in families, chromosomal, genome 
wide and candidate gene studies. The next paragraphs discuss the findings coming 
forth from these efforts. An overview is provided in figure 2.
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Figure	  2.	  Mul,level	  overview	  of	  gene,c	  involvement	  in	  SSc	  suscep,bility	  (116)
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Family studies
Family studies are the first logical step to investigate heritability. These studies 
have shown that indeed genetic factors play a role in SSc pathogenesis. Two 
studies investigated whether having a positive family history contributed to the risk 
of developing SSc, an Australian study found the relative risk (RR) to be increased 
in first degree relatives (RR 14.3) and siblings (RR 19.3) (31). An American study 
that included 703 families, eleven of which had multiple members affected reported 
similar results. The relative risk was found to increase from 13 in first-degree 
relatives to 15 for siblings (32). To date, this remains the highest risk factor for SSc 
development ever reported. However, it has to be noted that the absolute risk 
remains rather low (~1%). Based on these findings one may hypothesize that 
environmental  factors play a role as well, but there seemed to be no 
socioeconomic or geographic  clustering present in these populations. The genetic 
background of SSc patients is to some extent similar to the background underlying 
other autoimmune diseases (AID), which was recently illustrated by a study 
investigating the occurrence of autoimmune disease in first degree relatives of SSc 
patients. Of 719 SSc patients, 260 (36%) patients had first-degree relatives with at 
least one autoimmune disease, most notably RA (18%) and autoimmune thyroid 
disease (9%). No significant differences in the type and frequency of familial 
autoimmunity were observed between the diffuse and limited cutaneous subsets of 
disease (33). It has to be noted that, next to the age of the twins used in this study, 
other factors might play a role in the discrepancy between risks in twins and first-
degree relatives. The most obvious explanation is probably that some 
environmental  factors might play a role, but that they require a certain genetic 
background to act on, which unfortunately makes these factors hard to identify 
without adjusting for the genetic context of these individuals. Another explanation is 
that epigenetics play a role on determining the final clinical phenotype of having 
SSc, another AID or being healthy. For example, investigating methylation patterns 
in SSc  patients, and especially in discordant twins might be very useful to 
determine which parts of the genome are important for determining the final 
phenotype. Methylation is influenced by environmental factors, and therefore 
elucidating methylation patterns in SSc  and comparing them to explorations of the 
epigenome in other diseases might be helpful  in determining the environmental 
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factors contributing to SSc.  
Several  case reports describing twins concordant for SSc have been published 
over the past decades, but it was not before 2003 that a large twin study was 
published (34,35). This study included 42 twin pairs (24 monozygotic and 18 
dizygotic) of which at least one twin was suffering from SSc. Of the total 42 twin 
pairs only two pairs, both female-female, were concordant for SSc. One pair was 
dizygotic  (DZ) and suffered from the limited cutaneous subform of the disease 
(lcSSc), the other pair was monozygotic  (MZ) and one twin had lcSSc  whereas the 
other had dcSSc. These data did not show a significant difference in concordance 
rate between MZ twins (4.2%) and dizygotic twins (5.6%). The overall cross-
sectional concordance rate was 4.7%. (36). This is in contrast to the family studies 
from which it was clearly indicated that genetic  factors play a role in the 
development of the disease. Interestingly, there was a significantly higher 
concordance for anti nuclear antibody (ANA) positive titers (≥1:40) in the MZ twins 
(90%) compared to the DZ twins (40%). MZ twins had a higher concordance rate 
for the presence of either ANAs or anticytoplasmic autoantibodies (ACA) compared 
to the DZ twins, respectively 95% and 60%. The mean age of the participants in 
this study was 48.5 years, ranging from 28 to 69 years. The most common age of 
onset for SSc is somewhere around 50 years of age, and for that reason a longer 
follow-up period might have been more appropriate to investigate the concordance 
rates in these twin pairs, the real concordance might thus be underestimated (7). 
ANA and ACA antibody titers are often present before onset of clinical disease in 
SSc, but clinical disease does not always develop when they are present (37). 
These observations might explain the markedly increased concordance for 
antibody titers but not for SSc. Zhou et al collected total  RNA from dermal 
fibroblasts of 15 discordant twin pairs (10 MZ and 5 DZ) and healthy controls. This 
RNA was used in a microarray expression analysis. SSc fibroblasts had RNA 
expression profiles that were significantly different from those of unaffected DZ 
twins and normal  controls. Of interest, unaffected MZ twins were not significantly 
different from SSc  patients. Moreover, normal fibroblasts incubated with serum 
from a SSc patient or with serum from her unaffected MZ twin sister developed an 
expression pattern very similar to that observed in SSc fibroblasts. Based on these 
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observations the authors draw the conclusion that a genetic  predisposition to SSc 
seems to be apparent at the molecular level in skin fibroblasts (38). This finding 
illustrates that, in respect to studying fibroblasts in SSc, it has to be taken into 
account that the genetic  background of the fibroblast seems to be less important in 
determining disease compared to the molecules present in the serum of genetically 
similar individuals. This positions the fibroblasts downstream in the chain of events 
causing disease. On the other hand, it remains enigmatic why the fibroblasts of the 
healthy part of the MZ twin have similar RNA expression levels, without having 
SSc. This merely indicates that there needs to be an additional, possible 
environmental, factor leading to full blown disease and rather justifies the existence 
of the genetically “susceptible fibroblast”. These interesting findings need further 
investigations and a second large twin study would be of high interest in the field of 
SSc research.
Chromosomal studies in systemic sclerosis
Chromosomal instability seems to be present in a proportion of SSc patients, for 
instance findings of fragmented, dicentric and ring chromosomes have been 
reported, and more rarely, translocation and deletion of chromosome fragments, 
microchromosomes and double minute chromosomes (39-42). These findings are 
not only present in full blown SSc, but already in patients that have Raynaud’s 
phenomenon and will proceed to SSc later on (42). The current search for 
chromosomal aberrances in SSc is segregated in three directions. The first field of 
interest is telomere biology, provoked by observations of chromosomal aberrances 
in SSc. The second field focuses on the role of the X chromosome, prompted by 
the observation that SSc is far more frequently present in females. The third field 
focuses on physical aberrances that might trigger ANA (e.g. in centromeres). The 
latter will  not be discussed since it leaves the realm of genetics and enters the field 
of functional research. 
Telomeres are nucleoprotein complexes at the 5’and 3’end of the chromosome that 
play a pivotal role in DNA and, hence, chromosomal damage signalling and repair. 
The fundamental  component of the telomere is a nucleotide repeat stretch that 
22
shortens with cell division. An initial  study investigating telomeres in systemic 
sclerosis took off from the observation of chromosomal instability in SSc and 
hypothesized that this instability resulted from a shortened telomeric repeat. The 
study investigated telomere lengths of peripheral blood leukocytes (PBLs) from 43 
SSc patients, 182 SSc family and 96 age-matched controls. They found the 
average loss of telomeric  DNA in SSc patients and their family members to be 3 kb 
compared to the controls. This loss occurred independent of age and disease 
duration. Of interest, this difference was not observed in fibroblasts from SSc 
patients, family and controls. The authors concluded that these results might reflect 
a genetic  predisposition for shorter telomeres in these families, or exposure to a 
common environmental agent (43). A second study scrutinizing telomere 
shortening in SSc focused on the lcSSc phenotype only. This study investigated 43 
lcSSc  patients with age ranging from 37 to 80 years. The authors found telomere 
lengths in PBLs from lcSSc patients to be significantly longer than controls. In 
addition, shortening was not age-related and differed significantly from age-
matched controls only after 50 years of age (44). Until now, literature addressing 
the role of telomeres in SSc is conflicting, but this may come forth from the different 
clinical  subsets of SSc investigated by these studies. Noteworthy, a study 
investigating telomerase activity, which facilitates the maintenance of the telomere 
by adding repeat sequences to chromosomal ends, found a low telomerase activity 
in SSc compared to other autoimmune diseases and healthy controls (45). Taken 
these observations together, it is likely that aberrances in telomere biology are 
present in SSc, Chapter 11 of this thesis provides a further in depth study on the 
role of telomere shortening in SSc.
To level differences between males and females in X chromosomal gene 
expression, several species including mammals, evolved dosage compensation 
mechanisms. For instance, females randomly inactivate one of the two X 
chromosomes by methylation (46). As a consequence of this, females even-
handedly inactivate the paternal  and maternal X-chromosome throughout their 
cells (47). Although inactivation of the X chromosome is permanent for all 
descendants of a cell, the X chromosome inactivation (XCI) pattern alters with age. 
The frequency of skewed XCI, in other words a misbalance between the proportion 
of cells that inactivate the paternal X and the proportion that inactivate the maternal 
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X, increases in elderly compared to younger healthy females (48). Intriguingly, 
women with SSc comprise a significantly higher frequency of peripheral  blood cells 
with a skewed XCI pattern compared to healthy women. Two overlapping studies 
from the same Turkish research group showed that in 195 female SSc patients and 
160 female controls skewed XCI patterns were significantly more present; 44.9% of 
149 informative patients and in 8% of 124 healthy controls. In addition, they found 
extremely skewed patterns to be more frequent in the SSc population (49, 50). The 
study presented in Chapter 10 of this thesis validates these results and describes 
the role of XCI in multiple immune cell  subsets of SSc patients and its effects on 
forkhead box P3 (Foxp3) expression, which is located on the X chromosome. (51). 
X chromosome monosomy is another model  proposed to play a role in the 
increased prevalence of SSc  in females. It is a well-known fact that females with 
Turner’s syndrome, harbouring only one X chromosome, have a vastly increased 
risk for developing autoimmune disease. A study investigating the presence of X 
monosomy in peripheral  blood leukocytes from 44 females with SSc and 73 age-
matched healthy women found that the monosomy rates in SSc were significantly 
higher compared with healthy women. No significant difference in monosomy rates 
was observed in patients with different types of SSc. Monosomy rates seemed to 
increase with age and were higher in B and T cells compared to monocytes/
macrophages, polymorphonuclear, or natural killer cells. The authors excluded the 
possibility of male cell  microchimerism by ruling out the presence of the Y 
chromosome (52). Taken these observations together, there is cumulative evidence 
for a role of the X chromosome in SSc, which might bring more insights in the 
clustering of this disease in females.
The Human Leukocyte Antigen (HLA) region in systemic sclerosis
Many autoimmune diseases have been associated with variants in the HLA region 
and have inspired researchers to investigate this region in SSc. The HLA region 
remains an extremely polymorphic region in the genome, vastly influenced by 
ethnic  origin, and might therefore play a role in the differences of SSc prevalence in 
diverse ethnic  populations. The first endeavors to implement the HLA region in SSc 
susceptibility resulted in weak associations of SSc with a number of HLA alleles or 
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haplotypes. These concerned HLA-DR5 haplotypes (DRB1*1101 and 1104, 
DQA1*0501, DQB1*0301) and DR3 (DRB1*0301, DQA1*0501, DQB1*0201) in 
American and European white populations and HLA-DR2 (DRB1*1502, 
DQB1*0601) in Japanese (53-55). In the Choctaw Native Americans, the variants 
in HLA-DR2 (DRB1*1602, DQA1*0501, DQB1*0301) were found to pose an 
increased risk (56). A study of 98 patients with SSc from Greece, found HLA-
DRB1*1104, in linkage disequilibrium with DQA1*0501, DQB1*0301, associated 
with SSc susceptibility and ATA but not ACA antibodies (57). The significance levels 
of HLA associations, however, increase when SSc patients are subcategorized 
according to their specific autoantibody subsets. These included associations with 
the characteristic  SSc auto-antibodies. (55, 56, 58). In 2010 two large studies were 
published with complementary findings. The first investigated 1300 SSc  cases (961 
white, 178 black and 161 Hispanic) with extensive autoantibody characterization 
(ACA, ATA, anti-RNA polymerase III (ARA), and fibrillarin) to investigate 
predisposing effects of the HLA alleles. They found the strongest associations with 
SSc in white and Hispanic  SSc  patients (DRB1*1104, DQA1*0501, DQB1*0301 
haplotype and DQB1 alleles) and a protective effect for both lcSSC and dcSSc  of 
DRB1*0701, DQA1*0201, DQB1*0202 haplotype and DRB1*1501 haplotype, 
subsequently in a dominant and recessive model. SSc in black subjects was 
associated with DRB1*0804, DQA1*0501 and DQB1*0301 alleles. Anti-
topoisomerase antibodies were associated with DPB1*1301. Associations with 
ACA (DQB1*0501 and DQB1*26) and ARA (Caucasian and Hispanic: DRB1*0404, 
DRB1*11 and DQB1*03, Black patients: DRB1*08) were also described (59). A 
Spanish study in 100 patients postulated very similar findings and found the HLA-
DRB1*11 to be associated with SSc  susceptibility and the HLA-DRB1*0701 being 
protective as well  (60). In the American cohort described above, a novel strategy to 
identify variation in the HLA region was applied (61). This sequence feature variant 
type approach replicated the previous association between SSc and HLA-
DRB1*1104  in Caucasians and Hispanics. The most interesting part of this study is 
that they found a common amino-acid make up of DRB1*1104 and HLA-
DRB1*0804, associated in Caucasians and Hispanics. This finding might help 
explain why two different DRB1 alleles are both associated with SSc but in different 
races. 
More recently, two small-scale studies appeared that implicated HLA alleles in 
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development of complications during disease course. The first described a 3-factor 
model comprising two single nucleotide polymorphisms (SNPs), IL-6 174C>G and 
the IL2 330G>T, and the HLA-B*3501 allele that was predictive for the occurrence 
of digital ulcers in 200 Italian SSc patients (62). The second study describes 90 
patients, derived from a cohort of 1,519 SSc patients that developed scleroderma 
renal crisis. This study found that DRB1*0407 and *1304 are risk factors for the 
development of scleroderma renal  crisis, independent of previously postulated risk 
factors (63).
Candidate gene studies
Several  studies investigate genes that seem to play a role in SSc susceptibility. 
Selection of candidates is often based on either the functional implication of the 
gene in pathogenesis, or coming forth from studies in similar diseases. In SSc both 
have been done, although most targets for candidate gene or variant studies are 
derived from reports of associations in other AID. Association studies most often 
make use of the presence of variants or polymorphisms in genes. In the studies 
described below, single nucleotide polymorphisms were investigated. These are 
best described as single basepair transitions (e.g. a change from nucleotide A to G 
at a certain genomic locus). Based on their position in or around a gene they can 
have different impact on gene function. When the SNP is present in an exon, it 
might cause an amino-acid change or transcription stop at that position. Presence 
in a splice region might confer to alternative splicing and presence in the promoter 
or 3’UTR region to a change of gene expression. SNPs can also be used as 
indicator for the genomic region nearby their own locus; this principle is based on 
linkage disequilibrium. Therefore, when a SNP is found associated with a certain 
disease, the conclusion cannot unequivocally be that this SNP itself is contributing 
to disease susceptibility, but it is likely that a real causative variant can be found in 
linkage with this SNP. Both features of SNPs described above are used for 
association studies in SSc. Some studies have selected variants ultimately causing 
a change in protein function for their candidate gene studies. Other studies have 
selected those SNPs that provide information of a large part of the gene of interest 
based on linkage disequilibrium. Chapters 2 to 8 describe polymorphisms that are 
investigated for a possible role in SSc susceptibility and pathogenesis. Next to this, 
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polymorphisms investigated in Chapters 6 to 8 are assessed for a possible 
functional  impact on gene expression or inflammatory potential. Polymorphisms 
described in this section are best regarded as risk factors for developing SSc  or 
related clinical complications, not as diagnostic  tools. Below an overview of studies 
with sufficient patients and power to be reproducible and, hence, able to ascertain 
or exclude involvement of the selected candidate variants in SSc. The last 
paragraphs of this section will  discuss current unclear and conflicting findings. 
Table 4 provides an overview of all large genetic  association studies performed in 
SSc so far.
Table 4. Established non-HLA susceptibility genes for SSc and its clinical phenotypes
Gene
SNP 
(associated 
allele)
With Population
Size (tested 
phenotype/
HC)
OR (95%CI) Reference
STAT4 rs7574865 (T allele) lcSSc European 1317/3113
1.54 
(1.36-1.74) 65
lcSSc Japanese 282/590 1.35 (1.10-1.66) 66
ACA+ Japanese 87/590 1.62 (1.17-2.22) 66
SSc French 885/970 1.29 (1.11-1.51) 67
 
rs11889341 
(dominant A 
allele)
SSc North-American 902/4745 1.29 (1.20-1.50) 68
IRF5 rs2004640 (TT genotype) SSc French 881/760
1.58 
(1.18-2.11) 72
ANA+ French 608/760 1.59 (1.16-2.17) 72
Fibrosin
g 
alveoliti
s
French 280/760 2.07 (1.38-3.11) 72
SSc Japanese 281/477 1.23 (0.91-1.65) 73
dcSSc Japanese 142/477 1.27 (0.87-1.85) 73
ATA+ Japanese 87/477 1.56 (0.98-2.49) 73
rs10954213 
(AA genotype) SSc Japanese 281/477
1.41 
(1.0.1-1.96) 73
dcSSc Japanese 142/477 1.38 (0.90-2.10) 73
rs2280714 
(AA genotype) SSc Japanese 281/477
1.72 
(1.18-2.50) 73
dcSSc Japanese 142/477 2.05 (1.23-3.41) 73
  ATA+ Japanese 87/477 2.10 (1.12-3.95) 73
TBX21 rs11650354 (TT genotype) SSc North-American 902/4745
3.37 
(2.40-4.60) 79
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Gene
SNP 
(associated 
allele)
With Population
Size (tested 
phenotype/
HC)
OR (95%CI) Reference
Bank1 rs10516487 (G allele) SSc
European and North 
American 2362/3248
1.12 
(1.03-1.22) 83
dcSSc European and North American 770/3284
1.20 
(1.05-1.37) 83
ATA+ European and North American 435/3284
1.20 
(1.02-1.41) 83
rs10516487 
(T allele) dcSSc European 431/1118
0.77 
(0.64-0.93) 83
rs17266594 
(T allele) SSc
European and North 
American 2351/3231
1.14 
(1.05-1.25) 83
dcSSc European and North American 613/3231
1.23 
(1.08-1.41) 83
ATA+ European and North American 478/3231
1.24 
(1.05-1.46) 83
rs3733197 (G 
allele) dcSSc
European and North 
American 613/3143
1.15 
(1.02-1.31) 83
ATA+ European and North American 447/3143
1.26 
(1.07-1.47) 83
 rs3733197 (A allele) dcSSc European 431/1137
0.73 
(0.61-0.87) 84
BLK rs2736340 (TT genotype) SSc
European and North 
American 1639/1416 1.71 (1.2-2.4) 86
ACA+ European and North American 510/1416 2.27 (1.5-3.5) 86
rs2736340 
(CT genotype) SSc
European and North 
American 1639/1416 1.31 (1.1-1.5) 86
ACA+ European and North American 510/1416 1.6 (1.2-2.0) 86
rs13277113 
(AA genotype) SSc
European and North 
American 1639/1416
1.25 
(1.1.-1.4) 86
ACA+ European and North American 510/1416 1.42 (1.2-1.7) 86
 rs13277113 (A allele) SSc Japanese 309/769
1.45 
(1.17-1.79) 87
TNFSF4 rs2205960 (T allele) SSc North-American 1059/698 1.2 (1.1-1.5) 89
ATA+ North-American 174/698 1.4 (1.1-1.9) 89
rs1234314 (G 
allele) SSc North-American 1059/698 1.2 (1.04-1.4) 89
ACA+ North-American 300/698 1.3 (1.1-1.6) 89
ATA+ North-American 174/698 1.3 (1.02-1.7) 89
SSc European 2856/2920 1.15 (1.02-1.31) 90
lcSSc European 1608/2920 1.22 (1.07-1.38) 90
ACA+ European 828/2920 1.23 (1.10-1.37) 90
rs844648 (A 
allele) SSc North-American 1059/698 0.8 (0.7-0.97) 89
ARA+ North-American 193/698 1.4 (1.1-1.8) 89
lcSSc European 1673/2977 1.1 (1.01-1.20) 90
ACA+ European 860/2977 1.12 (1.01-1.25) 90
rs844644 (A 
allele) lcSSc European 1653/2946
0.91 
(0.83-0.99) 90
ACA+ European 856/2912 0.90 (0.80-1.00) 90
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Gene
SNP 
(associated 
allele)
With Population
Size (tested 
phenotype/
HC)
OR (95%CI) Reference
rs12039904 
(T allele) SSc European 2894/2991
1.18 
(1.08-1.29) 90
lcSSc European 1639/2991 1.20 (1.09-1.33) 90
  ACA+ European 840/2991 1.22 (1.07-1.38) 90
SSc:	  Systemic	  Sclerosis,	  lcSSc:	  limited	  cutaneous	  systemic	  sclerosis:	  dcSSc:	  diﬀuse	  cutaneous	  systemic	  sclerosis,	  
ACA:	  an6-­‐centromere	  an6bodies,	  ATA:	  an6-­‐topoisomerase	  an6bodies,	  ARA:	  an6-­‐RNA	  polymerase	  an6bodies.
Signal  transducer and activator of transcriptor 4 (STAT4) has been associated with 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (64). This 
prompted a study, described in Chapter 2 of this thesis, in five independent 
European cohorts totaling 1317 SSc  patients and 3113 healthy controls. This initial 
study found the STAT4 rs7574865 T allele associated with lcSSc but not with 
dcSSc (65). The very same association was later on confirmed in a Japanese 
cohort, which also added an association with ACA positivity (66). Subsequently, two 
reports replicated the association of STAT4 with SSc  susceptibility but in contrast, 
observed the association in both lcSSc and dcSSc  (67, 68). These studies together 
strongly implicated STAT4 in SSc  susceptibility. Interestingly, STAT4 plays a role in 
interleukin (IL)12 and IL23 receptor signalling and seems to be activated through 
interferon (IFN) type 1 receptors. STAT4 functions as a T helper cell  (Th) 1 
promoter (69). A recently developed murine model investigated the susceptibility 
for bleomycine-induced fibrosis in STAT4 knockout mice. This model  showed that 
mice deficient for STAT4 had decreased T cell activation, proliferation and cytokine 
release, which led to less fibrosis. Creating STAT4 knockout Tsk1 mice (which 
develop extensive fibrosis and tightening of the skin during life) however, did not 
ameliorate their fibrotic phenotype (70). 
 
Interferon regulatory factor 5 (IRF5) polymorphisms have been associated with 
SLE (71). In SSc this gene also seems to play a role. A French study investigated 
427 patients with SSc and 380 healthy controls and a replication set comprising 
454 patients with SSc  and 380 control subjects (72). This study found that the TT 
genotype of the functional polymorphism rs2004640 in IRF5 was significantly 
enriched in patients with SSc  compared to healthy controls. Analyses in all  SSc 
patients revealed a significant association between homozygosity for the T allele 
and the presence of ANA and fibrosing alveolitis. This study was confirmed by a 
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study in Japanese SSc  patients (73). Interestingly, a follow up on the French 
association study was published and showed that haplotypes of the IRF5 gene 
were more informative in predicting dcSSc  and fibrosing alveolitis (74). IRF5 is able 
to induce IFN alpha related genes (75), increased IFN alpha levels produced by 
plasmacytoid dendritic cells have previously been described in SSc, implicating the 
importance of this pathway on a functional level as well (76).
T-box expressed in T cells (T-bet, TBX21) knockout mice develop extensive fibrosis 
upon injection with bleomycin (77, 78). In addition, TBX21 is an important 
transcription factor involved in Th1 development and seems to play a role in B cell 
and dendritic  cell biology as well. Since this transcription factor appears to be 
intricately involved in the process of fibrosis, this gene was of interest to investigate 
in SSc. A study in American Caucasian patients and controls pointed out that the 
variant rs11650354 of TBX21 was involved in SSc  using a recessive model. The 
association was present regardless of clinical subtype or autoantibody pattern. 
Furthermore, this polymorphism seemed to be functional because SSc  patients 
homozygous for the rs11650354 TT variant expressed elevated Th2 cytokines, 
whereas carriers of the CC genotype were characterized by a type I interferon 
signature (79).
B-cell  scaffold protein with ankryn repeats (BANK1) is expressed in B cells and is 
tyrosine phosphorylated upon B-cell antigen receptor stimulation. Overexpression 
of BANK in B cells leads to enhancement of BCR-induced calcium mobilization 
(80). BANK1 polymorphisms have been previously associated with SLE and RA 
and have now been implicated in SSc susceptibility as well  (80-83). The initial large 
multi-centre study, encompassing 2380 white SSc patients and 3270 matched 
controls, found a strong association with the rs10516487 G and rs17266594 T 
alleles and the diffuse cutaneous subform of the disease. This observation was 
further strengthened by a combined French and German effort, which also found 
these alleles to be strongly associated with the dcSSc  subform (84). However, the 
functional implication of these polymorphisms still remains unclear.
B lymphoid kinase (Blk) is another susceptibility locus coming forth from genetic 
studies in SLE. More specifically it concerns the FAM167A-BLK region, previously 
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entitled C8orf13-BLK. BLK is a kinase that is expressed in thymocytes and 
involved in downstream signalling of the B cell receptor (85). Until now, two studies 
found an association of this region with both lcSSc and dcSSc. Both studies 
investigated two polymorphisms, rs13277113 and rs2736340. The T variant of 
rs2736340 was associated with SSc in both an U.S. and a Spanish case-control 
population. The A variant of rs13277113 was only associated with SSc in the U.S. 
cohort. Both variants demonstrated an association with ACA and lcSSc in a 
combined analysis. RNA expression profiling using peripheral blood pointed out 
different profiles of BCR related pathways when patients were clustered to their 
genotype (86). A Japanese study confirmed the association of rs13277113 with 
SSc, but did not investigate rs2736340 (87).
Tumor necrosis factor superfamily-4 (TNFSF4 or OX40 ligand (OX40L)) is the 
ligand for OX40 present on T  cells. OX40 ligation has been shown to enhance T-
cell  expansion and survival  and in addition, decreases the suppressive activity of 
regulatory T  cells (88). TNFSF4 polymorphisms have been associated with SLE 
susceptibility. A cohort consisting of 1059 Caucasian SSc  cases and 698 healthy 
controls revealed a significant association between susceptibility to SSc and the 
minor alleles of SNPs rs1234314, rs2205960 and rs844648. Additional analysis of 
clinical  phenotypes demonstrated significant associations of OX40L variants with 
lcSSc  and dcSSc as well as anti-topoisomerase (ATA), ACA and POL-positive 
patients (89). A replication study, displayed in Chapter 5, confirmed the influence of 
TNFSF4 polymorphisms in SSc  susceptibility, most marked in subsets of patients 
with lcSSc and ACA and this study also identified new risk haplotypes involved in 
SSc susceptibility (90).
Next to these confirmed, associated genes there are a number of genes that are 
very interesting but found ambivalently involved in SSc when searching the 
published literature. These ambivalent findings might be coming forth from 
environmental  differences, differences in ethnic background or might be caused by 
a type I or II error. These candidate genes are described below. 
Interleukin 23 (IL23) promotes proliferation of Th17 cells. It has been postulated 
that Th17 cells play a central role in SSc pathogenesis (91). In contrast to multiple 
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other autoimmune diseases, two studies showed that IL23R variants do not confer 
risk to SSc  susceptibility (92, 93). This was recently nuanced by an American 
study, which did not observe an association with SSc  susceptibility as well, but 
nevertheless found that the IL-23R variants rs11209026 and rs11465804 were 
associated with ATA and pulmonary arterial hypertension (94). Although apparent 
discrepancies between the studies might be coming forth from differences in 
subgroup analysis strategy, further investigations are necessary before IL23R can 
be added to the list of SSc susceptibility genes.
The FAS gene has been described as an “autogene”, because its dysregulated 
functioning contributes to various autoimmune diseases. One of the main 
activators of apoptosis in T  cells is soluble FAS; which has been found elevated in 
SSc serum (95, 96). A recessive model of the FAS -670 GG genotype revealed a 
strong association with SSc, lcSSc and ACA+ lcSSc in a multinational cohort 
consisting of 2900 SSc and 3186 healthy controls (97). These findings, displayed in 
Chapter 3, are in contradiction with conclusions previously reported. In an Italian 
study, encompassing 350 SSc  patients and 232 healthy controls, the other allele of 
FAS -670 was found to be associated with SSc  susceptibility. As an underlying 
factor for this apparent contradiction it is noteworthy to mention that the minor 
allele frequency in the Italian control  group differs from the allele frequency 
reported by the international HAPMAP project (www.hapmap.org) and other Italian 
studies investigating the FAS -670 A>G polymorphism (98).
Connective tissue growth factor (CTGF) has been implicated in SSc on a functional 
level. Several studies show CTGF up regulated in SSc skin and CTGF is able to 
promote fibrosis by enhancing extracellular matrix deposition and proliferation of 
mesenchymal cells. These observations put forward the hypothesis that CTGF 
polymorphisms might play a role in SSc (99). The first study describing an 
association of the homozygous GG genotype of a variant in CTGF (-945G>C) was 
performed in 500 SSc patients and 500 controls. This report also shows that the 
substitution of cytosine for guanine creates a binding site for the transcription 
factors Sp1 and Sp3. The CTGF-945 C allele has high affinity for Sp3 and reduces 
transcriptional activity. This was functionally confirmed with an immunoprecipitation 
assay (100). A Japanese report substantiated these findings, but two large studies 
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in European and North-American cohort were not able to replicate the findings 
(101-103). Of relevance is that nearly 50% of the Japanese cohort were dcSSc 
patients, with typical clinical hallmarks as ATA and interstitial lung disease. These 
were exactly the SSc patients subsets that had a higher frequency of the 
homozygous GG genotype in CTGF. On the other hand, a later author reply of the 
first UK study indicates that they used the nomenclature for the CTGF 
polymorphism as it was first described, stating that the CTGF-945GG genotype in 
their study is the same as the CTGF-945CC variant in the other studies and vice 
versa, because nomenclature was based on the complementary DNA strand. The 
Japanese study does not indicate which nomenclature was used, depending on 
this, the results might indeed be substantiated or in fact be the total  opposite. 
Interestingly, a more recent French study describes a transcription altering CTGF 
polymorphism (rs9399005), located in the 3’UTR region of CTGF having an 
protective effect for SSc development. Taken these observations together, the 
exact role of CTGF polymorphisms in SSc remains a matter of debate and still 
warrants more research (104).
In the past few months three additional reports have been published, giving new 
insights in the genetic  background of SSc. These are PTPN22, UPAR (CD87), 
CD226  and NLRP1. Although these genes seem to be related to the pathogenesis 
of SSc and its subtypes, future replication studies are necessary to establish these 
genes as risk factors implicated in SSc susceptibility (105-108).
Genome-wide association studies
To date, only a few studies have investigated the genetic  make-up of SSc  utilizing 
a genome-wide approach. Although their non-hypothesis based approach is the 
same, marked differences in robustness of the methodology used resulted in 
deviating results.
The first study appeared in 2003 and described a genome-wide microsatellite 
screen at 10 cM resolution, including 400 markers in 20 Choctaw patients with SSc 
and 76 matched controls. Based on the results of the initial screen, fine- mapping 
at < or =1 cM resolution was performed. From the genome-wide screen, 17 
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markers were associated with SSc in this population. The novel regions linked to 
SSc susceptibility were 1p32-31, 7q35, 8q24.12, 19p13.2, 22q13.1 and Xq21-23. 
These included loci close to the SPARC, MHC, FBN1, and TOPOI genes (109). 
A second genome-wide association study was performed in 137 Korean SSc 
patients and 564 controls using 500,568 SNP markers. This genome scan showed 
a significant peak located in the region of HLA–DPB1  and DPB2 on chromosome 
6p. The peak included the SNPs rs3128930, rs7763822, rs7764491, rs3117230, 
and rs3128965. Fine-mapping of this region revealed that rs3128930, rs7763822, 
rs7764491, rs3117230, and rs3128965 were the SNPs associated with SSc. The 
association was stronger in patients with ATA. These SNPs also showed an 
association with dcSSc, but not with lcSSc. After fine mapping, the results were 
validated in 1,107 Caucasian US SSc  patients and 2,747 controls. In this 
replication cohort two pairs of SNPs, rs7763822/rs7764491 and rs3117230/
rs3128965, showed an association with SSc in patients who had either circulating 
ATA or ACA, but the association with SSc susceptibility overall was not replicated. 
Interestingly, SNPs corresponding to genes that have previously been associated 
with SSc, such as PTPN22 and CTGF showed low p-values (10−5–10−6) but failed 
to reach genome-wide significance (110).
In 2010 however, a large and robust genome-wide association study was 
published. This study included 2296 SSc  patients and 5171 healthy controls 
originating from The Netherlands, Germany, Spain and the United States. Different 
sets of markers were used that ranged in density from 308,349 to 488,793 SNPs. 
This study adjusted for multiple testing by regarding the genome-wide significance 
threshold (P≤ 5×10−7) as their significance threshold. The strongest association 
was observed at the 6p21 locus in the midst of the MHC region. At this region, 
rs6457617, situated in HLA*DQB1, showed the strongest association. In addition, 
five non-HLA loci showed genome-wide significance; TNPO3/IRF5 region in 7q32, 
STAT4 in 2q32, CD247 in 1q22-23, CDH7 in 18q22 and EXOC2/IRF4 near 6p25. 
These results further establish STAT4 and IRF5 as genetic risk factors for SSc. To 
verify the novel  findings, a case-control set comprising 2753 SSc  patients and 
4569 controls were genotyped for the three, not previously described variants. Two 
SNPs identified in the discovery cohort in the EXOC2/IRF4 and CDH7 regions 
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were not replicated in the validation cohort. However, the initial  association with 
rs2056626 in the CD247 gene was replicated (111). CD247 is of particular interest, 
considering it has an important role in the immune system by encoding the T-cell 
receptor zeta subunit, which is a component of the T cell receptor complex, this 
gene has also been associated with susceptibility to SLE previously (112). The 
association of CD247 was recently independently replicated in a French Caucasian 
population consisting of 1031 SSc patients and 1014 healthy controls (113).
A follow up study, exploiting the above mentioned GWAS data, focused on 
determining genetic  components contributing to lcSSc, dcSSc, ACA+ and ATA+. To 
this purpose, a meta-analysis was performed in four cohorts, comprising 2,296 SSc 
patients and 5,171 healthy controls. Subsequently, 18 polymorphisms with a P 
value lower than 1x10-5, seven in the lcSSc subtype, five in the dcSSc subtype, two 
in ACA positives and four in ATA positives were further tested in nine independent 
cohorts composed of an additional  3,175 SSc patients and 4,971 controls. Overall 
analysis revealed one variant in the interferon regulatory factor 8 (IRF8) gene 
(rs11642873) to be associated with lcSSc at genome wide significance. Variants in 
the GRB10 growth factor receptor-bound protein 10 (GRB10) and sex determining 
region Y-box 5 (SOX5) were just below the genome wide significance threshold 
associated with, respectively, lcSSc and ACA+ subgroups. Intriguingly the authors 
propose a model of IRF8 and SOX5 affecting the formation of extra-cellular matrix 
through collagen, type II, alpha 1 in the skin and other organs of SSc patients. 
Furthermore this study revealed genome wide significant results in the HLA-DQB1 
locus for ACA+ patients (OR = 2.48), in the HLA-DPA1/B1 loci for ATA+ patients 
(OR = 8.84) and in NOTCH4 for ACA+ patients (OR = 0.55) and ATA+ (OR = 0.54). 
This study is of particular interest since it indicates that the heterogeneity of SSc 
phenotypes is likely to be the reflection of a different genetic foundation. (114)
Very recently, the fourth GWAS was published which used a high-resolution marker 
set comparable to the previous study (approximately 500,000 markers). The study 
used a two-step approach; the first step consisted of a GWAS and was conducted 
in a French cohort consisting of 564 cases and 1,776 controls. Although only one 
SNP showed genome wide significance, which was again in the HLA*DQB1  region, 
the authors validated 20 SNPs (the 17 top significant SNPs and 3 previously 
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associated SNPs) in a replication cohort of 1,682 SSc cases and 3,926 controls. 
Follow-up of the 17 top SNPs revealed associations at PSORS1C1 (HLA region), 
TNFAIP3 interacting protein 1 (TNIP1) and ras homolog gene family, member B 
(RHOB) loci. Furthermore, the associations of previously identified candidate loci 
STAT4, IRF5 and CD247 were substantiated. This study furthermore addressed 
the functional relevance of their findings by investigating TNIP1 gene and protein 
expression. TNIP1 was expressed at a lower level  in both SSc  lesional  skin tissue 
and cultured dermal fibroblasts from SSc patients based on genotype. Intriguingly, 
TNIP1 showed in vitro inhibitory effects on cytokine-induced collagen production. 
Although this study presents novel  and interesting candidate loci, it has to be noted 
that only one locus reached genome wide significance initially. The other loci 
become highly significant after pooling of the first and second step, but are strictly 
speaking not significant yet in the initial  French GWAS. These loci  not being 
identified from the first step may be a power problem coming forth from the 
relatively low number of patients included in the GWA step. In addition, the study 
does not describe if there is an overlap between cohorts used for previous studies 
identifying SSc susceptibility genes STAT4, IRF5 and CD247  and the ones used in 
this study for replication, which would be welcome to place these results in the 
correct perspective (115). 
Gene-gene interaction studies
As discussed in the previous sections, a large number of genetic  variants seems to 
be involved in SSc susceptibility and pathogenesis. These associated genes all 
have a very modest, but reproducible effect on susceptibility throughout 
populations. In line with the paradigm of multifactorial  diseases, one would expect 
to be at higher risk for SSc when harboring more susceptibility variants. Not until 
recently, genetic research in the field of SSc started to combine genetic  data to see 
whether some variants together formed an additive risk for SSc susceptibility. An 
additional  thought that justifies these attempts is the fact that many SSc candidate 
genes map to the same biological pathways (116). 
The first successful attempt showed that STAT4 (rs7574865) and IRF5 (rs2004640) 
variants form an additive risk for development of SSc and interstitial  lung disease 
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(67). After this first study, this research group repeated the analysis including the 
BANK1 polymorphisms and could display an additive effect with regard to diffuse 
SSc  susceptibility (84). In a subsequent analysis they added a NLRP1 
polymorphism to the list of variants interacting with STAT4 and IRF5 (117). In 
contrast, the SSc-associated BLK region had an additive effect with BANK1 in the 
dcSSc subset (84). An American study showed that the STAT4 polymorphism was 
predominantly enriched in SSc  patients who carried the ‘CC’ genotype at TBX21 
rs11650354 (68). Next to this, an interesting study was published last year, 
describing a 3-factor model comprising two single nucleotide polymorphisms 
(SNPs): IL6 -174C>G and the IL2 -330G>T, and the HLA-B*3501 allele that was 
predictive for the occurrence of digital ulcers in 200 Italian SSc patients (62).
These initial studies on interactions of susceptibility genes look promising, but they 
still display only a small  proportion of the risk for development of SSc. Chapter 9 
provides a novel method to investigate epistatic interactions between genes in 
SSc. The most promising findings of gene-gene interactions playing a role will 
probably come forward from genome wide interaction analysis. However, this kind 
of analysis is currently hampered by a lack of both computational power and robust 
statistical methods. It is intriguing, however, that most polymorphisms associated 
with SSc map to pathways involved in T cell  function and cell-cell  interaction, as 
displayed in figure 3. Underscoring the role of the immune system in SSc and the 
need to look at immune cell subsets when investigating the functional  impact of 
polymorphisms (116).
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Figure 3. Graphical representation of current confirmed SSc candidate genes and 
their involvement in immunological processes (116). APC: antigen presenting cell; VEC; 
vascular endothelial cell, TLR: Toll like receptor, TYK: Tyrosine kinase, BCR: B cell receptor, TCR: T cell 
receptor JAK:  Janus Kinase
Aim and outline of this thesis
The aim of this thesis is to decipher a part of the genetic background of systemic 
sclerosis and its clinical  phenotypes. Genetic  research in multifactorial  disease has 
been criticized due to the uncertainty of its clinical  and functional relevance, 
therefore this thesis targets at investigating the impact of polymorphisms on 
functioning of the immune system. When possible, the investigated polymorphisms 
will  be reviewed in the light of development of clinical complications in time. This 
makes them relevant not only for determining susceptibility, but also as predictors 
of symptom development. The aim of the last chapter is to bring epigenetic  and 
ageing related phenomena closer to immunological changes observed in SSc.
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Part I (Chapters 2-5)
The first part focusses on candidate genes that are likely to be involved in SSc 
susceptibility, based on their associations with other autoimmune diseases or 
possible impact on disease pathogenesis. It comprehends a study describing a 
strong association of a STAT4 polymorphism on SSc susceptibility, a variant 
previously associated with multiple AID. In addition, evidence is provided that a 
functional  polymorphism in the apoptosis regulating gene FAS is implicated in the 
susceptibility for ACA+ lcSSc. Chapter 5 consists of a large replication study, firmly 
establishing TNFSF4 polymorphisms in SSc  susceptibility. On the other hand, 
Chapter 4 shows that a polymorphism in the CD89 gene, previously associated 
with SLE, is not a common risk factor for SSc and RA.
Part II (Chapters 6-9)
The second part aims to combine both functional and genetic  research to unveil 
the role of polymorphisms in the (dys)function of immune cells in SSc and 
development of clinical  complications. It has been suggested that Interleukins 4 
and 13 play a role in SSc. In Chapter 6 we investigated functional  polymorphisms 
of these genes for their role in SSc  and related clinical  complications. In addition, 
we investigated whether these polymorphisms affected the expression of IL4 and 
IL13 in various cells of the immune system. Overall, these polymorphisms do not 
seem to play a major role in SSc. Chapter 7 consists of a study on the role of 
functional  TLR variants in SSc. The study involves three steps, in the first, various 
TLR polymorphisms are investigated in a discovery cohort. A polymorphism in the 
TLR2 gene is found to be associated with the diffuse subform of SSc, which is 
replicated in a large validation cohort. On a cellular level this polymorphism 
augments the immune response of dendritic  cells and clinically it seems to play a 
role in pulmonary complication development in the 15 years after disease onset. 
Chapter 8 illustrates the observation that PBEF/Visfatin levels are increased in SSc 
patients with PAH. We investigate whether two expression regulating 
polymorphisms are playing a role in the increased expression and subsequently in 
PAH development. The final  chapter of Part 2 describes a method for investigating 
epistatic  interactions, using a cohort of SSc patients as a proof of principle for a 
functional interaction.
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Part III (Chapters 10 and 11)
The final part expands on genomic foundations towards epigenetic  phenomena 
observed in SSc, enhanced telomere shortening and an increased frequency of X 
chromosomal inactivation in SSc females. Both are in healthy persons related to 
biological ageing. Intriguingly, telomere shortening in SSc seems to be immune cell 
subset specific  and X chromosomal inactivation seems to lose its relation with 
ageing in SSc.
Taken together, the parts and chapters of this thesis are interconnected by their 
common goal to investigate the genetic  background of SSc with hypotheses based 
on emerging clinical and immunological  findings in SSc and AID. This thesis 
therefore closely follows changing opinions on the genetics research and 
pathogenesis of SSc. As a consequence of this, the focus in this thesis shifts from 
basic SNP association studies, to evaluating functional and clinical  relevance of 
polymorphisms. After publication of a genome wide scan in SSc  it became clear 
that changes at the DNA level do not fully explain the risk for developing SSc, 
Therefore the final  focus of this thesis is aimed at epigenetics research. In total, 
these chapters converge in a common aim to decipher those genetic  processes 
likely to influence SSc pathogenesis based on contemporary scientific views on 
SSc.
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Chapter 2
The STAT4 gene influences the 
genetic predisposition to systemic 
sclerosis phenotype.
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Abstract
The aim of this study was to investigate the possible role of STAT4 gene in the 
genetic  predisposition to systemic sclerosis (SSc) susceptibility or clinical 
phenotype. A total  of 1317 SSc patients [896 with limited cutaneous SSc (lcSSc) 
and 421 with diffuse cutaneous SSc (dcSSc)] and 3113 healthy controls, from an 
initial  case–control  set of Spanish Caucasian ancestry and five independent 
cohorts of European ancestry (The Netherlands, Germany, Sweden, Italy and 
North-America), were included in the study. The rs7574865 polymorphism was 
selected as STAT4 genetic  marker. We observed that the rs7574865 T allele was 
significantly associated with susceptibility to lcSSc in the Spanish population (p = 
1.9 × 10−5 odds ratio (OR) 1.61 95% confidence intervals (CI) 1.29–1.99), but not 
with dcSSc  (p = 0.41 OR 0.84 95% CI 0.59–1.21). Additionally, a dosage effect was 
observed showing individuals with rs7574865 TT genotype higher risk for lcSSc 
(OR 3.34, p = 1.02 × 10−7 95% CI 2.11–5.31). The association of the rs7574865 T 
allele with lcSSc was confirmed in all the replication cohorts with different effect 
sizes (OR ranging between 1.15 and 1.86), as well  as the lack of association of 
STAT4 with dcSSc. A meta-analysis to test the overall effect of the rs7574865 
polymorphism showed a strong risk effect of the T  allele for lcSSc susceptibility 
(pooled OR 1.54 95% CI 1.36–1.74; P < 0.0001). Our data show a strong and 
reproducible association of the STAT4 gene with the genetic predisposition to 
lcSSc  suggesting that this gene seems to be one of the genetic markers 
influencing SSc phenotype.
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Introduction
Systemic  sclerosis (SSc) is one of the most disabling autoimmune conditions 
characterized by an extensive fibrotic process that affects multiple organs and 
tissues (1). Although the etiology of SSc is still  poorly understood, it is widely 
accepted that the interaction of environmental  factors with different individual 
genetic factors leads to SSc development (2).
To date, our knowledge of genetic factors contributing to SSc susceptibility or 
clinical  phenotypes is very limited. Only genes within the major histocompatibility 
complex have been associated with SSc genetic predisposition or clinical 
manifestations in a consistent and reproducible fashion (2). Similar to other 
complex genetic disorders, several  loci  are expected to contribute to SSc genetic 
predisposition each with only moderate magnitude (3).
Genes implicated in the main pathogenic mechanisms of SSc are interesting 
candidates. One of central  events responsible of the SSc  development is the 
dysregulation of the immune system. The altered immune response in SSc is 
marked by an increased T cell  activation and the secretion of pro-inflammatory 
mediators that contribute to the generation of fibrosis and endothelial alterations, 
hallmarks of SSc (4).
Several  mechanisms regulate T cell activation and differentiation, being one of the 
most important the specific activation of gene transcription after cytokine 
stimulation (5). Signal transducers and activators of transcription (STAT) are a 
family of transcription factors that have been demonstrated to exert a fundamental 
role in driving T cell differentiation and signaling (6,7). Among the six described 
STAT proteins, STAT4 has acquired great interest. STAT4 is implicated in the 
differentiation of Th1 and also in the recently described Th17 cells, two of the T  cell 
subsets that are implicated in SSc pathogenesis (4,8–10). In addition, the STAT4 
gene has been associated with genetic  predisposition to different autoimmune 
diseases (AIDs), such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), type 1 diabetes, inflammatory bowel  disease and Sjögren's syndrome. A tag 
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single nucleotide polymorphism (SNP) of STAT4 intron 3 (rs7574865) showed the 
strongest effect (11–17).
In view of these findings, we considered the STAT4  gene as an excellent candidate 
gene and aimed to investigate its possible implication in the genetic predisposition 
to SSc susceptibility or clinical phenotype.
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Results
STAT4 is associated with limited cutaneous SSc in the Spanish population
First we conducted an association study in a case–control set of Spanish 
Caucasian ancestry. The distribution of the STAT4 rs7574865 genotypes and 
alleles in the Spanish controls was very similar to that reported previously in 
Caucasian populations [minor allele frequency (MAF) 0.21] and were observed to 
be in Hardy–Weinberg equilibrium (HWE) (Table 1) (11). After comparing the 
genotypes and alleles of the rs7574865 polymorphism between SSc patients with 
limited disease and healthy controls, we observed that the rs7574865 T allele was 
strongly associated with lcSSc (p = 1.9 × 10–5 odds ratio (OR) 1.61 95% 
confidence intervals (CI) 1.29–1.99) (Table 1). In addition, the TT genotype was 
significantly increased in lcSSc patients compared with controls (P = 1.02 × 10−7 
OR 3.34 95% CI 2.11–5.31) (Table 1). Nevertheless, no evidence of association 
was observed when the distribution of STAT4 rs7574865 genotypes or alleles 
between patients with diffuse disease and healthy controls was compared (Table 
1).
The increased frequency of the rs7574865 T allele and genotype among lcSSc 
patients was observed also when they were compared with dcSSc patients (T 
allele in lcSSc 29.5% versus 23.3% in dcSSc), although the differences did not 
reach statistical significance (Table 1).
Table 1. Distribution of STAT4 rs7574865 genetic variant in the Spanish population
rs7574865
Controls 
n= 1296
lcSSc
n= 242
P OR 95% CI
dcSSc
n= 90
P OR 95% CI
Genotype
GG 813 (62.7) 130 (53.7) 0.008 0.68 (0.50–0.77) 54 (60.0) 0.61 0.88 (0.57–1.36)
GT 428 (33.0) 81 (33.5) 0.89 1.02 (0.76–1.37) 30 (33.3) 0.95 1.03 (0.65–1.62)
TT 55 (4.2) 31 (12.8) 1.02 × 10−7 3.34 (2.11–5.31) 6 (6.7) 0.29 1.82 (0.78–4.24)
Allele
G 2054 (79.2) 341 (70.5) 1.9 × 10−5 0.62 (0.50–0.77) 138 (76.7) 0.41 0.84 (0.59–1.21)
T 538 (20.8) 143 (29.5) 1.61 (1.29–1.99) 42 (23.3) 1.18 (0.82–1.68)
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A replication study in five independent Caucasian populations and a meta-analysis 
confirm that STAT4 is strongly associated with limited SSc
In view of the interesting findings observed in our Spanish population and in order 
to confirm the association of STAT4 with lcSSc, we conducted a large replication 
study including five independent populations with Caucasian ancestry. All analyzed 
control  populations were in HWE for the STAT4 rs7574865 genetic  variant. The 
frequency for the rs7574865 T allele in the control populations ranged between 
0.21 and 0.25 as expected from previous studies (11).
Interestingly, we confirmed the significant association of the rs7574865 T allele with 
susceptibility to lcSSc in all  cohorts tested including patients from the Netherlands 
(OR 1.8 95% CI 1.32–2.47), Germany (OR 1.6 95% CI 1.15–2.21), North America 
(OR 1.4 95% CI 1.04–3.66) and Italy (OR 2.0 95% CI 1.05–1.78) (Table 2). 
Although not statistical  significant, we observed the same trend in the Swedish 
population (rs7574865 T allele OR 1.3). Probably, this was due to the lower 
frequency for both rs7574865 TT genotype and T allele observed in the Swedish 
lcSSc  patients compared with that observed in the other populations analyzed. 
Furthermore, the lack of association of STAT4 rs7574865 polymorphism with the 
diffuse cutaneous SSc subtype was confirmed in all five independent case–control 
sets (Table 2).
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Table 2. Distribution of STAT4 rs7574865 genetic variant in five replication cohorts
Population rs7574865 Controls lcSSc P dcSSc P
Dutch n = 893 n = 101 n = 30
GG 552 (61.8) 49 (48.5) 0.009 18 (60.0) 0.84
GT 295 (33.0) 37 (36.6) 0.46 10 (33.3) 0.97
TT 46 (5.2) 15 (14.9) 1.2 × 10−4 2 (6.7) 0.71
G 1399 (78.3) 135 (66.8) 2.2 × 10−4 46 (76.7) 0.76
T 387 (21.7) 67 (33.2) 14 (23.3)
German n = 227 n = 153 n = 117
GG 138 (60.8) 77 (50.3) 0.04 63 (53.8) 0.22
GT 78 (34.4) 57 (37.3) 0.56 46 (39.3) 0.36
TT 11 (4.8) 19 (12.4) 0.007 8 (6.8) 0.44
G 354 (78.0) 211 (69.0) 0.005 134 (74.4) 0.19
T 100 (22.0) 95 (31.0) 46 (25.6)
North-
American
n = 77 n = 30 n = 53
GG 44 (57.1) 9 (30.0) 0.012 23 (43.4) 0.12
GT 27 (35.1) 18 (60.0) 0.019 25 (47.2) 0.16
TT 6 (7.8) 3 (10.0) 0.71 5 (9.4) 0.74
G 115 (74.7) 36 (60.0) 0.034 71 (67.0) 0.17
T 39 (25.3) 24 (40.0) 35 (33.0)
Italian n = 362 n = 259 n = 92
GG 222 (61.3) 140 (54.1) 0.07 48 (52.2) 0.11
GT 127 (35.1) 99 (38.2) 0.42 39 (42.4) 0.19
TT 13 (3.6) 20 (7.7) 0.024 5 (5.4) 0.42
G 571 (78.9) 379 (73.2) 0.019 135 (73.4) 0.11
T 153 (21.1) 139 (26.8) 49 (26.6)
Swedish n = 285 n = 111 n = 39
GG 169 (59.3) 58 (52.3) 0.20 24 (61.5) 0.79
GT 100 (35.1) 44 (39.6) 0.39 12 (30.8) 0.59
TT 16 (5.6) 9 (8.1) 0.36 3 (7.7) 0.60
G 438 (76.8) 160 (72.1) 0.16 60 (76.9) 0.99
T 132 (23.2) 62 (27.9) 18 (23.1)
Additionally, we conducted a meta-analysis to test the overall effect of the 
rs7574865 T  allele on lcSSc susceptibility. The estimation of the homogeneity 
between the Spanish, Dutch, German, North American, Italian and Swedish 
populations did not reveal significant differences between them. In consequence, 
we performed a combined analysis considering the data from the six case–control 
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series using the Mantel–Haenszel test under fixed effects that again showed the 
strong risk effect of the STAT4 rs7574865 T allele for lcSSc  genetic predisposition 
(pooled OR 1.54 95% CI 1.36–1.74; p < 0.0001) (Fig. 1A). Furthermore, in the 
pooled analysis, individuals carrying the TT  genotype showed an increased risk for 
lcSSc  susceptibility (pooled OR of 2.55 95% CI 1.93–3.36, p < 0.0001). The same 
trend was observed for the comparison of lcSSc with dcSSc  that showed a 
significant increased frequency of the STAT4 rs7574865 T allele and TT genotype 
in the lcSSc patients group (pooled OR for the T allele 1.27 95% CI 1.04–1.54, p = 
0.019 (Fig. 1B); pooled OR for the TT genotype 1.7 95% CI 1.10–2.60, p = 0.02).
In addition, we performed a pooled analysis to further investigate the overall  effect 
of the rs7574865 T allele on dcSSc susceptibility. The meta-analysis reached a 
pooled OR of 1.23 95% CI 1.01–1.46 (p = 0.03) showing a trend for association of 
the rs7574865 T allele with dcSSc when compared with controls, but with a lower 
effect than in lcSSc. However, the pooled analysis for the TT genotype reached no 
statistically significant association with dcSSc (pooled OR 1.44 95% CI 0.93–2.26; 
p = 0.12).
STAT4 is not implicated in SSc clinical manifestations
The possible implication of STAT4 in SSc  clinical manifestations was further 
investigated. First, we analyzed the Spanish cohort individuals in whom data 
regarding selective auto-antibodies status (306 SSc patients for anti-Scl-70 and 
294 for ACA) were available. Data related to pulmonary function were available in 
281 SSc  patients for pulmonary fibrosis, 233 for DLCO and 279 for forced vital 
capacity (FVC). We observed no significant association between the rs7574865 
genetic variant and the presence of SSc specific  antibodies (Scl70 or ACA) or 
pulmonary involvement (Table 3). This lack of association of STAT4 and SSc 
clinical features was confirmed in the five replication cohorts (data not shown).
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Figure 1. Effect of the STAT4 rs7574865 T allele in lcSSc in Caucasian populations. (A) 
lcSSc versus controls. Mantel–Haenszel test for overall association of rs7574865 T allele with lcSSc 
susceptibility p < 0.0001. (B) lcSSc versus dcSSc. Mantel–Haenszel test for overall association of 
rs7574865 T allele in lcSSc susceptibility p = 0.019.
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Table 3.  Distribution of STAT4 rs7574865 genetic variant according to SSc  clinical features in the 
Spanish population
Genotype Allele
rs7574865 GG GT TT G T
ACA+ n = 151 (%) 81 (53.6) 53 (35.1) 17 (11.3) 215 (71.2) 87 (28.8)
ACA− n = 155 (%) 82 (52.9) 55 (35.5) 18 (11.6) 219 (70.6) 91 (29.4)
Anti-Scl70+ n = 55 (%) 30 (54.5) 21 (38.2) 4 (7.3) 81 (73.6) 29 (26.4)
Anti-Scl70− n = 239 (%) 130 (54.4) 81 (33.9) 28 (11.7) 341 (71.3) 137 (28.7)
Pulmonary fibrosis+ n = 90 (%) 47 (52.2) 28 (31.1) 15 (16.7) 122 (67.8) 58 (32.2)
Pulmonary fibrosis− n = 191 (%) 109 (57.1) 66 (34.6) 16 (8.4) 284 (74.3) 98 (25.7)
Predicted DLCO >75% n = 129 (%) 74 (54.7) 39 (30.2) 16 (12.4) 187 (72.5) 71 (27.5)
Predicted DLCO <75% n = 104 (%) 57 (54.8) 37 (35.6) 10 (9.6) 151 (72.6) 57 (27.4)
Predicted FVC >75% n = 201 (%) 112 (55.7) 66 (32.8) 23 (11.4) 290 (72.1) 112 (27.9)
Predicted FVC <75% n = 78 (%) 40 (51.3) 29 (37.2) 9 (11.5) 109 (69.9) 47 (30.1)
62
Discussion
SSc is characterized by skin fibrosis, vascular damage and immune system 
activation leading to a very heterogeneous pattern of clinical symptoms. Although, 
these three key events affect all  SSc patients, there is a broad range of variability 
in the extent and severity of skin and internal  organ involvement between 
individuals. In the clinical practice, SSc patients are divided in two groups 
characterized based upon the distribution of skin involvement (18).
One of the possible explanations for the existence of these two markedly different 
forms of disease could reside in the presence of differences in the genetic 
background between individuals. The results from the present study are in line with 
this hypothesis and support a role of the STAT4 gene as a genetic determinant of 
SSc phenotype. Through a large association study that included six independent 
populations of Caucasian ancestry, we demonstrate that the STAT4  rs7574865 
genetic variant confers susceptibility to lcSSc, but not to dcSSc. The rs7574865 T 
allele was significantly increased in the group of lcSSc  patients compared with 
healthy controls or dcSSc patients. In addition, a dosage effect was observed 
showing that individuals with the rs7574865 TT genotype have a 2-fold increased 
risk for lcSSc susceptibility.
To our knowledge, this is the strongest genetic association with lcSSc  described so 
far, being reproducible in different independent populations. This fact, together with 
the high statistical  power of our study design, strongly suggests that the STAT4 
gene may be considered as a novel susceptibility gene for lcSSc.
Nevertheless, our data does not support evidence that the STAT4 gene exerts such 
a strong effect in dcSSc genetic  predisposition. Certainly, the independent 
analyses of rs7574865 T allele and TT genotype and the meta-analysis of 
rs7574865 TT genotype in dcSSc compared with the healthy population point that 
this polymorphism has a negligible effect on dcSSc susceptibility. Only the meta-
analysis of the rs7574865 T allele showed a trend for association with dcSSc. In 
this regard, considering that there is still no consensus on the levels of statistical 
significance for meta-analysis (19), the p value (0.03) and the 95% intervals close 
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to the null obtained for the meta-analysis of the rs7574865 T allele found in our 
study do not allow us to conclude an association of this SNP with dcSSc. In 
addition, the comparison of the overall distribution of rs7574865 T and TT  genotype 
between lcSSc and dcSSc patients showed that this genetic  marker confers a 
significant increased risk for SSc limited phenotype susceptibility. However, due to 
the lower proportion of dcSSc in European populations, the total number of dcSSc 
included in our study (n = 421) may not be enough to reach a high statistical power. 
On the other hand, it has been empirically demonstrated that meta-analyses with 
P-values between 0.01 and 0.05, similar to that obtained in our analyses for the 
dcSSc phenotype, do not have strong reliability (20). On this basis, the results from 
the present study suggest that the STAT4 gene does not seem to play a major role 
in dcSS; however, further independent studies are needed to confirm this 
hypothesis.
STAT4 is an essential transcription factor for the regulation of the immune 
response. Upon the stimulation of cytokines such as IL-12, IL-23 or IL-17 STAT4 is 
activated and drives the expression of several pro-inflammatory mediators 
implicated in the differentiation and proliferation of Th1 and Th17 T cell subsets 
(8,21). Therefore, it is plausible that the elevated levels of IL-12, IL-23 and IL-17 
observed in SSc patients lead to the activation of the STAT4 pathway (22,23). 
Then, a prolonged STAT4 increased activity due to different genetic  variation in this 
gene might cause a sustained inflammatory response together with the expansion 
and infiltration of pro-inflammatory T cell  subpopulations in skin and internal  organs 
of SSc patients. However, further functional studies are necessary to elucidate the 
exact molecular mechanisms by which STAT4 is implicated in the pathogenesis of 
SSc and more precisely, how this transcription factor can lead to the development 
of the lcSSc.
In the past few years, using both genome-wide association studies and candidate 
gene association studies, genes such as PTPN22, CTLA4 or IL23R have been 
associated with genetic susceptibility to various autoimmune conditions, leading to 
the hypothesis that different AIDs may share common genetic factors and 
pathways (24–27).
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The association of STAT4 with SSc  reported here, together with previous findings 
that have shown recently the association of STAT4 with susceptibility to RA, SLE 
and Sjögren syndrome support the notion that this gene seems to be another 
common genetic factor for autoimmunity. Nevertheless, to understand how STAT4 
influences the development of AIDs the next step is to conduct functional studies in 
order to identify which is/are the real  causing variants that may influence STAT4 
activity or expression.
In summary, in this study we described for the first time a strong and reproducible 
association of the STAT4 gene with the genetic  susceptibility to lcSSc. Our data 
shed light on the pathogenic  mechanisms that may underlie SSc development and 
open a new opportunity for the treatment of this debilitating disease.
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Methods
Patients
A total of 1317 SSc  patients and 3113 controls were included in the study. First we 
analyzed an initial case–control set of 332 SSc patients (242 with lcSSc and 90 
with dcSSc) and 1296 healthy controls of Spanish Caucasian ancestry. Additionally, 
five independent replication cohorts were analyzed (Dutch: 101 lcSSc, 30 dcSSc 
and 893 controls; German: 153 lcSSc, 117 dcSSc and 227 controls; North 
American: 30 lcSSc, 53 dcSSc and 77 controls; Italian: 259 lcSSc, 92 dcSSc and 
362 controls; Swedish: 111 lcSSc, 39 dcSSc and 285 controls).
All  the patients fulfilled the 1980 American College of Rheumatology (ACR) 
classification criteria for SSc  (28). In addition, patients were classified as having 
limited or diffuse SSc. When patients with SSc have cutaneous involvement distal 
from elbows, and knees they fulfilled definitions for limited scleroderma (29). Those 
SSc patients with cutaneous changes proximal from elbows and knees were 
classified as having diffuse SSc (30).
In addition, the following clinical  data were collected for ascertainment of SSc 
clinical  phenotype; age, gender, disease duration and presence of SSc specific 
auto-antibodies, anti-topoisomerase (Anti-Scl70) and anti-centromere (ACA). Lung 
involvement was assessed according to the international guidelines (31). 
Pulmonary fibrosis was assessed by a computed tomography scan. Restrictive 
syndrome and diffusion capacity of the lungs was defined as a FVC < 75% of the 
predicted value and a diffusion capacity for carbon monoxide (DLCO) of less than 
75% of predicted (based on age, sex, height and ethnic origin). The main clinical 
features of the SSc patients from all  the analyzed case sets are summarized in 
table 4.
The control population consisted in unrelated healthy individuals recruited in the 
same geographical region as SSc patients and matched by age, sex and ethnicity 
with the SSc patients groups.
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The study was approved by local ethical  committees from all  the participating 
centers. Both patients and controls were included in the study after written 
informed consent.
Table 4. Main clinical features of  SSc patients from the Spanish and the five replication 
cohorts
Phenotype Spanish Dutch German American Swedish Italian
Female (%) 87 72 87 100 77 95
Limited phenotype (%) 73 65 56.7 34 66 73
ACA positivity (%) 49 26 40 17 20 40
Anti-Scl70 positivity (%) 19 21 23 29 14.5 24
Pulmonary fibrosis on CT scan (%) 32 40 36 – 45 36.2
Low FVC (<75% predicted) (%) 28 24 18 – 35 18
Low DLCO (<75% predicted) (%) 45 20 50 – 24 50
STAT4 genotyping
DNA from patients and controls was obtained using standard methods. As STAT4 
genetic marker, we selected the rs7574865 polymorphisms, since this is the tagger 
SNP of the haplotype block of STAT4  intron 3 associated with autoimmunity, and at 
the same time the genetic variant showing the strongest association with AIDs. 
Samples were genotyped for the rs7574865 polymorphism by Taqman 5′-allelic 
discrimination assay technology using a Pre-designed SNP Genotyping 
Assaysprovided by Applied Biosystems (Part number: C__29882391_10, Foster 
City, CA, USA). The PCR reaction was performed in a total volume of 5 µl with the 
following amplification protocol: denaturation at 92°C for 10 min, followed by 40 
cycles of denaturation at 92°C for 15 s and annealing and extension at 60°C for 
1:00 min. Post-PCR, the genotype of each sample was automatically attributed by 
measuring the allele-specific fluorescence in the ABI Prism 7900 Sequence 
Detection System, using the SDS 2.3 software for allele discrimination (Applied 
Biosystems, Foster City, CA, USA).
All  samples were genotyped in the same center to avoid genotyping 
inconsistencies and to verify the genotyping consistency, alleatory samples were 
genotyped twice showing 99% identical genotypes.
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Statistical analysis
We tested HWE for each case–control set by using the program FINETI. 
Significance was calculated by 2x2 contingency tables and Fisher's exact test, to 
obtain p values, OR and 95% CI by using Statcalc  software (Epi Info 2002; Centers 
for Disease Control  and Prevention, Atlanta, GA, USA). P-values below 0.05 were 
considered as statistically significant. The analysis of the combined data from all 
populations was performed using the Stats Direct software. First, homogeneity of 
OR among cohorts was calculated using Breslow-Day and Woolf Q methods. We 
then performed a calculation of the pooled OR under a fixed-effects model 
(Mantel–Haenszel meta-analysis) or random effects (DerSimonian-Laird) when 
necessary.
The estimation of the power of the study was performed using the Quanto v 0.5 
software (Department of Preventive Medicine, University of Southern California, 
CA, USA). For the pooled analysis of lcSSc  (n = 841) and considering a medium 
MAF of 0.25, our study reach a 93% power to detect the effect of a polymorphism 
at an OR of 1.3 similar to that observed for the rs7574865 T allele in previous 
studies (11,12). Under the same conditions, the estimation of the power for the 
pooled analysis of dcSSc that included a total of 421 patients was 67%.
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Abstract
Objective: To investigate the possible role of the FAS −670A>G functional 
polymorphism in the genetic predisposition to systemic sclerosis (SSc) 
susceptibility or clinical phenotype.
Methods: A total  of 2,900 SSc patients and 3,186 healthy controls were included in 
this study. We analyzed the genotype and allele frequencies of the FAS −670A>G 
polymorphism in 9 distinct ethnic cohorts, including 6 cohorts of European ancestry 
(a Spanish cohort of 228 SSc  patients and 265 controls, a Dutch cohort of 203 SSc 
patients and 277 controls, a German cohort of 313 SSc patients and 247 controls, 
an Italian cohort of 323 SSc cases and 89 controls, a British cohort of 269 SSc 
patients, and a Swedish cohort of 182 patients) and 3 distinct ethnic  cohorts from 
the US (a cohort of 1,047 white patients and 692 controls, a cohort of 159 Hispanic 
patients and 137 controls, and a cohort of 176 black SSc patients and 194 
controls). Genotyping was performed using a TaqMan 5′ allelic discrimination 
assay.
Results: In the British, Italian, and American white cohorts we observed an 
association of the FAS −670G allele with limited cutaneous SSc (lcSSc) (odds 
ratios [ORs] 1.25, 1.43, and 1.18, respectively). A meta-analysis comprising all  9 
cohorts revealed an association of both the FAS −670G allele (OR 1.10) and the 
FAS −670GG genotype (OR 1.13) with the lcSSc phenotype. In a meta-analysis 
including only white subjects, both the FAS −670G allele and the FAS −670GG 
genotype remained associated with lcSSc  (allele OR 1.12; genotype OR 1.16). In 
addition, a recessive model of the −670GG genotype exhibited a strong association 
with SSc, lcSSc, and anticentromere antibody–positive lcSSc (OR 1.23, OR 1.33, 
and OR 1.45, respectively).
Conclusion: Our data show that the FAS −670A>G polymorphism plays a role in 
lcSSc  susceptibility. A similar trend has been observed in other autoimmune 
diseases.
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Introduction
Systemic  sclerosis (SSc; scleroderma) is a connective tissue disease in which 
patients develop extensive fibrosis of the skin and internal organs. Based on the 
extent of skin involvement, the disease can be classified as limited cutaneous SSc 
(lcSSc) or diffuse cutaneous SSc (dcSSc) (1). In the early stage of SSc, 
perivascular infiltrations of immune cells are observed, among which T  cells and 
antigen-presenting cells are key players (2).
Intriguingly, some T cell  subsets in patients with SSc exhibit a decreased response 
to activation-induced cell  death and apoptosis compared with healthy controls (3). 
One of the main activators of apoptosis in T cells is soluble Fas, which has been 
found to be elevated in SSc serum (4). The FAS gene has been described as an 
“autogene,” because its dysregulated function contributes to various autoimmune 
diseases. A common single-nucleotide polymorphism (SNP), FAS −670A>G 
(rs1800682), occurring at the binding sequence of the interferon-γ activation site, 
has been reported to confer susceptibility to systemic  lupus erythematosus, 
multiple sclerosis, sarcoidosis, and autoimmune hepatitis (5–8). Recently, the FAS 
−670A allele was found to be significantly more frequent in a cohort of 350 Italian 
SSc patients compared with healthy controls; additionally, the FAS −670AA 
genotype influenced the predisposition to SSc  in general and to both lcSSc  and 
dcSSc (9). Insight into the potential  role of Fas in SSc  pathogenesis would greatly 
facilitate our understanding of the disease. Therefore, we studied the FAS 
−670A>G polymorphism in 9 large independent SSc case–control series 
comprising 2,900 SSc patients and 3,186 controls of multiple races.
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Methods
Patients and controls.
DNA samples from European subjects were provided by the European Consortium 
on Systemic Sclerosis Genetics (acknowledgements). The study population was 
composed of 2,900 SSc patients and 3,186 healthy controls matched by 
geographic region, age, and sex. Six case–control sets were of European ancestry 
(a Spanish cohort of 228 SSc  patients and 265 controls, a Dutch cohort of 203 SSc 
patients and 277 controls, a German cohort of 313 SSc patients and 247 controls, 
an Italian cohort of 323 SSc cases and 89 controls, a British cohort of 269 SSc 
patients, and a Swedish cohort of 182 patients). The genotype frequency in the 351 
Swedish and 934 British controls was derived from literature reports (10, 11). 
Additionally, 3 distinct ethnic cohorts resident in the US were considered in the 
−670A>G genotyping (1,047 American white SSc patients and 692 matched 
controls, 159 American Hispanic  SSc  patients and 137 matched controls, and 176 
American black SSc  patients and 194 controls). All patients fulfilled the American 
College of Rheumatology (formerly, the American Rheumatism Association) 1980 
classification criteria for SSc (12). The local ethics committee from each center 
approved the study. Patients and controls provided written informed consent before 
enrollment in the study. All patients included in this study were classified as having 
lcSSc  or dcSSc, using the criteria proposed by LeRoy et al (1). In addition, the 
presence or absence of antibodies (anti–topoisomerase I (ATA) and anti-
centromere (ACA)) was recorded (table 1).
Genotyping of the FAS −670A>G polymorphism.
DNA samples from patients and controls were genotyped for the FAS −670A>G 
polymorphism (rs1800682) with a TaqMan SNP genotyping assay using the ABI 
7500/7900HT real time thermocycler according to the protocol recommended by 
the manufacturer (Applied Biosystems, Foster City, CA). Automated allele calling 
was performed using SDS 2.3 software from Applied Biosystems. Multiple positive 
Centre d'Etude du Polymorphisme Humain DNA samples from Coriell Institute for 
Medical Research (Camden, NJ) and negative controls were used in each 
genotyping assay.
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Table 1. Demographic and clinical characteristics of the 9 SSc cohorts included in the present study
 Phenotype
Population
The 
Netherlan
ds
Spain Germany Sweden Italy UK
American 
white
American 
Hispanic
American 
black
n 203 228 313 182 323 269 1,047 159 176
Female, % 71.7 83.8 87.4 76.9 95.5 81.3 73.9 74.4 78.2
Age, mean ± 
SD years
56 ± 13 58 ± 13 56 ± 12 56 ± 15 55 ± 13 59 ± 12 NA NA NA
Disease 
duration, 
mean ± SD 
months
133 ± 87 144 ± 90 110 ± 109 81 ± 73 141 ± 138 154 ± 91 NA NA NA
lcSSc, % 77.5 70.0 52.5 82.1 70.7 74.6 60.8 41.1 32.5
ATA positive, 
%
20.3 18.4 24.7 16.7 46.9 6.3 16.5 22.0 23.0
ACA positive, 
%
26.8 46.7 40.4 26.1 48.1 38.5 29.0 7.0 16.0
Statistical analysis.
Hardy-Weinberg equilibrium was tested with the program FINETI. Significance 
levels were calculated with 2 × 2 contingency tables and Fisher's exact test, using 
SPSS 16.0. P values less than 0.05 were considered significant. Homogeneity of 
odds ratios (ORs) among cohorts was calculated using the Breslow-Day and Woolf 
Q methods, and pooled ORs were calculated under a fixed-effects model (Mantel-
Haenszel meta-analysis). Ninety-five percent confidence intervals (95% CIs) were 
calculated. The statistical power of the study was estimated using Quanto software, 
version 0.5. For the power calculation in the pooled analysis of white lcSSc 
patients (n = 1,552), we considered a minor allele frequency of 0.46, as reported in 
the HapMap data. The study reaches a power of 80% to detect the effect of a 
polymorphism at an OR of 1.26 in a recessive model and 1.25 in a dominant 
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model. Under the same conditions, the estimation of the power for the pooled 
analysis of dcSSc  (n = 811) is 80% to detect an OR of 1.37 in a recessive model 
and 1.36 in a dominant model. Although the clinical  features tested are not truly 
independent, we applied the Bonferroni correction for multiple testing. Corrected p 
values less than 0.02 were considered significant.
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Results
The FAS −670G allele is associated with lcSSc in 3 cohorts.
The FAS −670G allele frequencies in the controls enrolled in the study cohorts 
were consistent with frequencies reported in the HapMap project. To evaluate the 
effect of the FAS −670A>G polymorphism on SSc  susceptibility, we compared 
genotype and allele frequencies in the healthy controls with those in the total SSc 
group and the lcSSc and dcSSc  subgroups. Presence of the FAS −670G allele was 
found to be associated with lcSSc in 3 cohorts: the British cohort (OR 1.25 [95% CI 
1.00–1.60], p = 0.049), the Italian cohort (OR 1.43 [95% CI 1.00–2.07], p = 0.045), 
and the American white cohort (OR 1.18, [95% CI 1.01-1.39], p = 0.036). In 
addition, in the American white cohort, an association of the FAS −670GG 
genotype was observed for lcSSc (OR 1.26 [95% CI 1.02–1.55], p  = 0.017) and 
SSc overall (OR 1.18 [95% CI 0.98–1.41], p = 0.022) (table 2).
A meta-analysis with the 9 distinct ethnic populations confirms that the FAS −670G 
allele and FAS −670GG genotype are more frequent in patients with lcSSc.
To validate the associations observed in the 3 independent populations (table 2), 
we performed a meta-analysis under a fixed-effects model  (Mantel-Haenszel) for 
both the total SSc cohort and the SSc  subtypes. No statistically significant 
deviation in heterogeneity between cohorts was observed (p = 0.575, p = 0.280, 
and p = 0.385, controls versus all SSc, lcSSc, and dcSSc, respectively). The FAS 
−670G allele and the FAS −670GG genotype were found to be associated with 
lcSSc  (Table 3) (allele OR 1.10 [95% CI 1.01–1.21], p  = 0.036; genotype OR 1.13 
[95% CI 1.01–1.27], p = 0.036).
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Table 2. Genotype and allele distributions of the FAS −670A>G polymorphism
Phenotype n AA AG GG P vs. controls
Allele, P vs. 
controls
−670GG 
recessive, P vs. 
controls
Italy        
 SSc 323 0.27 0.46 0.27 0.196 0.078 0.084
 lcSSc 213 0.26 0.44 0.30 0.105 0.045 0.156
 ACA+ lcSSc 102 0.27 0.45 0.28 0.223 0.106 0.089
 dcSSc 84 0.26 0.52 0.21 0.627 0.358 0.568
 Control 89 0.33 0.49 0.18 – – –
Sweden        
 SSc 182 0.32 0.47 0.20 0.413 0.366 0.899
 lcSSc 117 0.33 0.46 0.21 0.463 0.52 0.896
 ACA+ lcSSc 41 0.32 0.42 0.27 0.421 0.905 0.373
 dcSSc 50 0.34 0.48 0.18 0.587 0.361 0.646
 Control† 351 0.27 0.53 0.21 – – –
Spain        
 SSc 228 0.31 0.42 0.27 0.046 0.652 0.290
 lcSSc 154 0.33 0.41 0.27 0.046 0.545 0.358
 ACA+ lcSSc 78 0.32 0.42 0.26 0.213 0.59 0.582
 dcSSc 58 0.22 0.48 0.29 0.557 0.412 0.280
 Control 265 0.24 0.53 0.23 – – –
Germany        
 SSc 313 0.32 0.45 0.24 0.106 0.446 0.072
 lcSSc 163 0.33 0.42 0.25 0.073 0.465 0.057
 ACA+ lcSSc 118 0.32 0.42 0.26 0.073 0.400 0.049
 dcSSc 121 0.31 0.48 0.21 0.647 0.817 0.450
 Control 247 0.30 0.53 0.17 – – –
UK        
 SSc 269 0.28 0.49 0.23 0.731 0.465 0.702
 lcSSc 172 0.22 0.52 0.26 0.104 0.049 0.295
 ACA+ lcSSc 78 0.27 0.47 0.26 0.714 0.417 0.451
 dcSSc 59 0.31 0.56 0.14 0.282 0.346 0.128
 Control‡ 934 0.30 0.48 0.22 – – –
The Netherlands        
 SSc 203 0.28 0.50 0.23 0.89 0.713 0.631
 lcSSc 130 0.28 0.49 0.24 0.985 0.861 0.878
 ACA+ lcSSc  0.15 0.50 0.35 0.175 0.060 0.158
 dcSSc 50 0.36 0.52 0.12 0.120 0.048 0.051
 Control 277 0.27 0.48 0.25 – – –
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Phenotype n AA AG GG P vs. controls
Allele, P vs. 
controls
−670GG 
recessive, P vs. 
controls
American white        
 SSc 1,047 0.29 0.49 0.23 0.022 0.086 0.007
 lcSSc 603 0.27 0.49 0.24 0.017 0.032 0.004
 ACA+ lcSSc 341 0.28 0.49 0.24 0.07 0.124 0.023
 dcSSc 389 0.32 0.47 0.21 0.091 0.819 0.120
 Control 692 0.29 0.54 0.18 – – –
American 
Hispanic
       
 SSc 159 0.21 0.50 0.29 0.863 0.669 0.851
 lcSSc 62 0.21 0.48 0.31 0.873 0.852 0.919
 ACA+ lcSSc 46 0.24 0.48 0.28 0.704 0.541 0.830
 dcSSc 89 0.20 0.51 0.29 0.934 0.779 0.909
 Control 137 0.18 0.52 0.30 – – –
American black        
 SSc 176 0.09 0.39 0.53 0.718 0.699 0.519
 lcSSc 53 0.11 0.43 0.45 0.675 0.438 0.588
 ACA+ lcSSc 44 0.14 0.41 0.46 0.457 0.359 0.629
 dcSSc 110 0.07 0.36 0.57 0.412 0.275 0.191
 Control 194 0.08 0.43 0.50 – – –
*Patients with an undifferentiated skin phenotype were excluded from phenotype analysis. 
† Control frequencies derived from ref.10. ‡ Control frequencies derived from reference11.
The effect of the FAS −670G allele on lcSSc is most prominent in white ACA-
positive lcSSc patients.
Although we observed no significant deviation in heterogeneity between the 9 
cohorts, it was clear that there was a large difference in the frequency of the FAS 
−670G allele in the total group of white subjects compared with the black American 
and Hispanic American subjects. In contrast to the white population, in both the 
black and Hispanic Americans the FAS −670G allele was the major allele. For this 
reason we performed an additional  meta-analysis solely on the 7 white study 
populations. We found that both the FAS −670G allele and the FAS −670GG 
genotype were associated with lcSSc (allele OR 1.12 [95% CI 1.02–1.24], p = 0.02; 
genotype OR 1.16 [95% CI 1.03–1.31], p = 0.017). In addition, we analyzed the 
subgroup of lcSSc patients who were positive for ACA. In all  white populations we 
observed that the frequency of the FAS −670GG genotype was higher in this 
subgroup than in controls. Although the difference did not reach significance in any 
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single population, the meta-analysis revealed a significant effect of both the minor 
allele (OR 1.16 [95% CI 1.03–1.31], p = 0.01) and the −670GG genotype (OR 1.21 
[95% CI 1.03–1.41], p = 0.017) (table 3).
Implementation of the FAS −670GG genotype in a recessive model  reveals a 
strong association with SSc and lcSSc in whites.
When evaluating the frequencies of the FAS genotypes in cases and controls, we 
observed a higher frequency of the −670GG in the lcSSc  patients, whereas the 
−670AG genotype was more frequent in controls. This finding, taken together with 
reports of a strong effect of the FAS −670GG genotype on FAS expression levels 
(9, 13), led us to hypothesize that a recessive effect of the FAS −670GG genotype 
in SSc susceptibility should be considered. To investigate this, we compared the 
proportion of white study subjects with the FAS −670GG genotype versus the 
proportion with the FAS −670AG or the FAS −670AA genotype (grouped together). 
In the meta-analysis we observed a strong association of the FAS −670GG 
genotype with SSc  overall (OR 1.23 [95% CI 1.07–1.41], p = 0.004), lcSSc (OR 
1.33 [95% CI 1.14–1.56], p = 0.0003), and ACA-positive lcSSc (OR 1.45 [95% CI 
1.19–1.76], p = 0.0002) (table 3).
Table 3. Overall genotype frequencies and Mantel-Haenszel meta-analysis under a fixed-effects model
Phenotype n
Genotype
P vs. 
controls
−670GG 
recessive, 
P vs. 
controls
Allele
P vs. 
controlsAA AG GG A G
All          
 SSc 2,900 0.27 0.47 0.26 0.173 0.005 0.51 0.49 0.172
 lcSSc 1,667 0.27 0.47 0.26 0.036 0.001 0.51 0.49 0.036
 ACA+ 
lcSSc
770 0.28 0.46 0.26 0.032 0.0017 0.50 0.50 0.056
 dcSSc 1,010 0.27 0.47 0.25 0.925 0.322 0.51 0.49 0.862
 Control 3,186 0.27 0.50 0.23 – – 0.52 0.48 –
Caucasians
         
 SSc 2,565 0.29 0.47 0.24 0.147 0.004 0.53 0.47 0.145
 lcSSc 1,552 0.28 0.47 0.25 0.02 0.0003 0.51 0.49 0.017
 ACA+ 
lcSSc
686 0.29 0.46 0.25 0.017 0.0002 0.51 0.49 0.01
 dcSSc 811 0.31 0.49 0.20 0.714 0.548 0.55 0.45 0.718
 Control 2,855 0.29 0.51 0.21 – – 0.54 0.46 –
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Discussion
The aim of this study was to validate the results of a previous study depicting FAS 
−670A>G as a novel underlying genetic variant influencing SSc susceptibility (9). In 
the present investigation, we showed that the FAS −670A>G variant plays a 
significant role in susceptibility to SSc, lcSSc, and ACA-positive lcSSc in white 
populations. After Bonferroni correction for multiple comparisons, most 
associations remained statistically significant, underscoring their soundness.
The −670 variant in the FAS promoter influences gene expression, with the G 
variant disrupting the interferon-γ binding site for the transcription factor STAT1. It 
has been shown that healthy subjects who are homozygous for the −670A major 
allele have higher levels of FAS expression than those who are homozygous for 
the −670G variant (13). It is tempting to speculate that the up-regulation of soluble 
FAS observed in SSc patients is an endeavor of the immune system to diminish 
the autoreactive immune processes observed in SSc. From this standpoint, FAS 
levels would be less able to increase through the STAT1 signaling cascade in 
individuals carrying the −670GG genotype, and these individuals would be 
exposed to autoreactive T cell  clones at an increased rate. However, we did not 
observe a significant effect of the FAS −670G allele on dcSSc. This is consistent 
with a previous report describing a strong effect of a STAT4 polymorphism on 
lcSSc  susceptibility but not on dcSSc (14). It suggests that there are marked 
differences in the genetic background underlying these disease subtypes.
It should be noted that our findings contradict results previously reported by 
Liakouli  et al, from a study of Italian subjects (9). In that study, the FAS −670A 
allele was found to be associated with SSc susceptibility. We suggest that an 
underlying factor contributing to this apparent discrepancy might be that the 
frequency of the minor G allele in Liakouli and colleagues' Italian control group 
(0.52) differs from the allele frequency reported in the International HapMap 
project, as well as that found in other Italian studies investigating the FAS 
−670A>G polymorphism (15, 16) and that observed in the present study. The 
frequency observed by Liakouli  et al may thus not be representative of the general 
Italian population. On the other hand, conflicting results in rheumatoid arthritis and 
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primary Sjögren's syndrome have been described as well. Considering the power 
of the study, it is unlikely that our findings were biased by a type I error.
Associations of the FAS −670A>G polymorphism with other autoimmune diseases 
have already been documented. Therefore, it is conceivable that this 
polymorphism, together with others, is part of a genetic  framework that renders an 
individual susceptible to a breach of immune tolerance. On this framework, 
additional  genetic and environmental factors determine the characteristics of the 
full-blown autoimmune disease. Fortunately, we are in an era in which genetic 
research is evolving at an astonishing pace, and with the use of whole-genome 
association studies and subsequent meta-analyses, more of the genetic  factors 
underlying SSc etiology will certainly be illuminated.
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Abstract
Objective: To investigate the role of the FCAR1 844A>G functional polymorphism 
in the genetic predisposition to rheumatoid arthritis (RA) and systemic sclerosis 
(SSc) susceptibility.
Methods: The study population was composed of 1401 SSc patients, 642 RA 
patients and 1317 healthy controls. The FCAR1 (CD89) SNP rs16986050 was 
genotyped by Pyrosequencing. 
Results: We observed no significant deviation of the genotype and allele 
frequencies in RA and SSc  compared to controls. A meta-analysis, a recessive and 
dominant model yielded similar negative results. 
Conclusion: Our data show that the FCAR1 844A>G polymorphism is not 
associated with SSc or RA susceptibility.
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Introduction
Fc-receptors (FcR) play a pivotal role in linking humoral  and cellular components of 
immunity by effectuating the recognition of antigens bound to immunoglobulins (Ig). 
Interestingly, there is a large body of evidence describing genetic variations in FcR 
that were found associated with a wide range of autoimmune pathologies, such as 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (1). Although 
disease specific  IgA is present in auto-immune disease, its impact remains to be 
the least scrutinized. IgA exhibits its immunoregulatory functions mainly by 
triggering cellular effector functions through the FC alpha receptor (FCAR) on the 
cell  surface. FCAR1 (CD89) is the functionally most important IgA receptor and is 
expressed on various cells of the immune system (2). Serum IgA regulates 
secretion of IL1β, IL10, TNF-α, IL6 and IL1RA. To mediate these effects, the FcR-
associated signal-transducing transmembrane gamma-chain (FCGR) needs to be 
present in complex with FCAR1 (3). Intriguingly, a polymorphism (844A>G, 
rs16986050) in the coding region of FCAR1 leads to an amino-acid change of 
Serine 248 to Glycine (S248G) which potentates IL6 production and is able to 
induce cytokine release in the absence of the FCGR chain. (4). This variant was 
found to be enriched in two SLE populations compared to healthy controls (5). In 
other auto-immune diseases specific IgA antibodies are also present. For instance, 
anti-topoisomerase IgA and rheumatoid factor (RF) IgA and anti-CCP IgA are 
present in systemic  sclerosis (SSc) and RA (6;7). Although the exact role of IgA in 
these diseases remains to be elucidated, we hypothesized that an increased 
inflammatory response upon disease specific  IgA binding caused by this 
polymorphism could contribute to these diseases. For this reason we investigated 
the frequency of this variant in SSc and RA patients.
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Methods
Study population
The study population was composed of 1401 SSc patients, 642 Dutch RA patients 
and 1317 healthy controls derived from healthy blood donors, demographically, age 
and gender matched. Since SSc is a rare disease we composed a cohort of five 
case–control sets of European (Table 1). All patients fulfilled the American College 
of Rheumatology (ACR) 1980 classification criteria for SSc  (8). The local  ethics 
committee from each center approved the study. Patients and controls provided 
written informed consent. All  patients included in this study were classified as 
having limited cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc), using the 
criteria proposed by LeRoy et al. (9) Further information on clinical phenotype was 
recorded as well. Autoantibody testing was performed in every center separately 
using either ELISA or immunofluorescence microscopy (table 1). The study 
included RA patients who met the ACR 1987 revised criteria for RA (10) (table 2).
Table 1. Clinical characteristics of the SSc patients and controls included in this study
Population Netherlands Spain Germany Sweden Italy
Number 143 231 422 161 444
Age (years, SD) 56 (13) 55 (13) 57(12) 53 (15) 54(13)
Disease duration 
(months,SD) 132 (87) 143 (90) 112 (109) 83 (73) 146 (138)
Female % 73.2 83.8 83.2 78.8 89.0
Limited phenotype% 74.8 73.7 61.2 72.0 74.4
Positivity ANA% 73.2 85.4 83.2 75.1 81.6
Positivity anti-topo% 22 N.A. 24.8 16.7 25.2
Positivity ACA% 26.8 46.7 41.3 26.1 47.1
Healthy Control 
Age  (years, SD) 45 (12) 56 (14) 48 (9) 52 (11) 52 (14)
Healthy Control
Female % 69.3 85.1 82.4 80.2 85.0 
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Genotyping
The FCAR1 844A>G variant was genotyped by pyrosequencing, congruent with 
previously published reports from our group, pyrosequencing reactions were 
performed according to the manufacturer's instructions on a PSQ-HS96A system 
(Biotage)  (5, 11).
Table 2. Clinical characteristics of the rheumatoid arthritis patients included in this study
Number 642
Age (years, SD) 65 (13)
Female % 66.5
Positivity RF% 78
Positivity Anti-CCP%* 65
*status available in 155 patients
Statistical analysis 
Significance levels were calculated with Fisher’s exact test, P values below 0.05 
were considered significant after Bonferroni adjustment. Homogeneity of odds 
ratios (ORs) was assessed with Breslow-Day statistics, pooled ORs were 
calculated under a fixed-effects model  (Mantel-Haenszel). In the SSc population 
(n=1401), this study reaches a power of 80% to detect an OR of 1.21. The 
estimation of the power for the RA population (n=645) is 80% to detect an OR of 
1.31.
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Results
After genotyping no divergence in HWE was observed. We observed no significant 
deviation in genotype and allele frequencies of the FCAR1 844A>G polymorphism 
in Dutch RA patients compared to Dutch controls and when comparing ACPA+/- 
and RF+/- RA patients. No significant heterogeneity was detected between the five 
European populations, justifying a meta-analysis. Initially, we observed a 
divergence in genotype distribution in the Swedish (p =0.034) and Spanish (p 
=0.019) SSc populations. The same was observed for lcSSc  susceptibility in both 
the Swedish (p =0.016) and Spanish (p =0.022) SSc population. The FCAR1 844G 
allele was associated with an increased risk to SSc, lcSSc  and ACA+ SSc in the 
Swedish cohort (respectively; p =0.019, 0.030 and 0.032). The 844G allele was 
found less frequent in the Italian ACA+ SSc patients (p =0.042). However, after 
correction for multiple testing, no result remained significant. In addition, a meta-
analysis, recessive and dominant models yielded similar negative results (table 3 
and data not shown).
Table 3. Genotype frequencies of the FCAR1 844A>G polymorphism in five European systemic 
sclerosis populations and a Dutch rheumatoid arthritis population.
Origin Subtype n total AA% AG% GG% P vs HC A% G% P vs HC
Italy SSc 444 0.76 0.22 0.02 0.484 0.87 0.13 0.277
lcSSc 327 0.75 0.24 0.01 0.253 0.87 0.13 0.211
dcSSc 112 0.74 0.21 0.05 0.409 0.85 0.15 0.903
ACA+ 144 0.80 0.19 0.01 0.123 0.90 0.10 0.042
Anti-Topo+ 146 0.71 0.27 0.01 0.631 0.85 0.15 0.923
Control 362 0.73 0.25 0.02 0.85 0.15
Sweden SSc 161 0.58 0.30 0.12 0.034 0.73 0.27 0.019
lcSSc 116 0.60 0.26 0.14 0.016 0.73 0.27 0.030
dcSSc 45 0.53 0.40 0.07 0.252 0.73 0.27 0.107
ACA+ 44 0.55 0.32 0.13 0.055 0.70 0.30 0.039
Anti-Topo+ 25 0.64 0.28 0.08 0.712 0.78 0.22 0.591
Control 165 0.67 0.29 0.04 0.81 0.19
Spain SSc 231 0.66 0.26 0.08 0.019 0.79 0.21 0.639
lcSSc 157 0.66 0.25 0.09 0.022 0.79 0.21 0.794
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Origin Subtype n total AA% AG% GG% P vs HC A% G% P vs HC
dcSSc 56 0.62 0.29 0.09 0.274 0.76 0.24 0.900
ACA+ 89 0.66 0.28 0.06 0.388 0.80 0.20 0.525
Anti-Topo+ N.A. N.A. N.A. N.A. N.A. N.A.
Control 250 0.60 0.36 0.04 0.78 0.22
Germany SSc 422 0.64 0.31 0.05 0.564 0.79 0.21 0.680
lcSSc 261 0.68 0.29 0.03 0.532 0.82 0.18 0.612
dcSSc 160 0.63 0.32 0.05 0.642 0.79 0.21 0.722
ACA+ 78 0.69 0.25 0.06 0.936 0.81 0.19 0.825
Anti-Topo+ 50 0.58 0.34 0.08 0.616 0.75 0.25 0.507
Control 266 0.66 0.28 0.06 0.80 0.20
Netherlands SSc 143 0.69 0.28 0.03 0.434 0.83 0.17 0.769
lcSSc 98 0.72 0.24 0.04 0.983 0.84 0.16 0.999
dcSSc 33 0.61 0.39 0.00 0.09 0.80 0.20 0.484
ACA+ 34 0.76 0.24 0.00 0.455 0.88 0.12 0.383
Anti-Topo+ 33 0.70 0.27 0.03 0.860 0.83 0.17 0.862
RA 642 0.71 0.26 0.03 0.593 0.84 0.16 0.582
Control 274 0.72 0.24 0.04 0.84 0.16
          
Total SSc 1401 0.68 0.27 0.05 0.662 0.82 0.18 0.675
Mantel-
Haenszel lcSSc 959 0.68 0.26 0.06 0.842 0.81 0.19 0.825
dcSSc 406 0.63 0.32 0.05 0.102 0.79 0.21 0.192
ACA+ 389 0.72 0.24 0.04 0.278 0.84 0.16 0.287
Anti-Topo+ 254 0.68 0.28 0.04 0.394 0.82 0.18 0.547
Control 1317 0.68 0.28 0.04 0.82 0.18
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Discussion
In this study we show that a common polymorphism in the coding region of FCAR1 
is not associated with RA or SSc susceptibility in two large cohorts. Considering 
the power of our study to detect significant deviations in allele frequencies of the 
FCAR1 844G variant between cases and controls, it is unlikely that the lack of 
association is due to a type 2 error. This indicates that the FCAR1 844A>G 
polymorphism does not play a role in the susceptibility to RA and SSc and neither 
influences clinical phenotype. This is in contrast to the previous association of the 
FCAR1 844A>G polymorphism with SLE susceptibility (5). A number of 
polymorphisms have been found to influence susceptibility to RA as well as SSc 
and SLE (12, 13). These polymorphisms form therefore merely a genetic 
foundation for autoimmunity in general. Intriguingly, the polymorphism investigated 
in this study seems to be specific for SLE. An explanation for this can perhaps be 
found in the properties of IgA in these three conditions. In contrast to RA and SSc, 
mean total IgA has been found significantly elevated in SLE compared to controls, 
and IgA mediated inflammation may thus play a proportional  larger role in SLE 
(14;15). IgA anti-CCP antibodies are present in 29% of the overall  RA patients and 
in 47% of the RA patients with IgG anti-CCP antibodies. In SSc, IgA anti-
topoisomerase antibodies have been described in 26.6% in a study containing 45 
patients (15,16). However, this implies that in a subgroup of SSc  and RA patients 
with high IgA antibody titers, which has been described in smoking RA patients, an 
effect of this variant may still  be present (15). This data was not available from the 
cohorts described in this study In addition, autoantibody measurements have been 
performed in separate centers with either ELISA or immunofluorescence 
microscopy, recently has been described that caution is warranted when comparing 
outcomes from both techniques with each other (17). Future investigations into the 
role of IgA and the FCAR1 gene might therefore benefit from taking this 
observation into account and focussing on subgroups with high IgA titers. 
Altogether, we could not demonstrate a role for the FCAR1 844A>G variant in SSc 
and RA.
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Abstract
Objectives: The aim of this study was to confirm the influence of TNFSF4 
polymorphisms on systemic sclerosis (SSc) susceptibility and phenotypic features.
Methods: A total of 8 European populations of Caucasian ancestry were included, 
comprising 3014 patients with SSc and 3125 healthy controls. Four genetic 
variants of TNFSF4 gene promoter (rs1234314, rs844644, rs844648 and 
rs12039904) were selected as genetic markers.
Results: A pooled analysis revealed the association of rs1234314 and rs12039904 
polymorphisms with SSc (OR 1.15, 95% CI 1.02 to 1.31; OR 1.18, 95% CI 1.08 to 
1.29, respectively). Significant association of the four tested variants with patients 
with limited cutaneous SSc (lcSSc) was revealed (rs1234314 OR 1.22, 95% CI 
1.07 to 1.38; rs844644 OR 0.91, 95% CI 0.83 to 0.99; rs844648 OR 1.10, 95% CI 
1.01 to 1.20 and rs12039904 OR 1.20, 95% CI 1.09 to 1.33). Association of 
rs1234314, rs844648 and rs12039904 minor alleles with patients positive for anti-
centromere antibodies (ACA) remained significant (OR 1.23, 95% CI 1.10 to 1.37; 
OR 1.12, 95% CI 1.01 to 1.25; OR 1.22, 95% CI 1.07 to 1.38, respectively). 
Haplotype analysis confirmed a protective haplotype associated with SSc, lcSSc 
and ACA positive subgroups (OR 0.88, 95% CI 0.82 to 0.96; OR 0.88, 95% CI 0.80 
to 0.96; OR 0.86, 95% CI 0.77 to 0.97, respectively) and revealed a new risk 
haplotype associated with the same groups of patients (OR 1.14, 95% CI 1.03 to 
1.26; OR 1.20, 95% CI 1.08 to 1.35; OR 1.23, 95% CI 1.07 to 1.42, respectively).
Conclusions: The data confirm the influence of TNFSF4 polymorphisms in SSc 
genetic susceptibility, especially in subsets of patients positive for lcSSc and ACA.
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Introduction
Systemic  sclerosis (SSc) is a connective tissue disorder characterized by fibrosis, 
vascular damage and immune imbalance. This pathology has a complex polygenic 
etiology and variable clinical  manifestations. Patients with SSc  are commonly 
classified in two major subgroups: limited cutaneous systemic sclerosis (lcSSc) and 
diffuse cutaneous systemic  sclerosis (dcSSc) (1). Autoantibody status, especially 
anti-centromere antibodies (ACA) and anti-topoisomerase antibodies (ATA), is 
clinically used as prognostic bookmaker (1).
Familial clustering and ethnic  influences support the genetic component of this 
disease (2). Initially, only major histocompatibility complex (MHC) genes were 
firmly associated with SSc. Nevertheless, recently a number of candidate genes 
such as STAT4, BANK1 or IRF5, have been related to SSc genetic predisposition 
in independent populations by well powered studies (3). Hypothesis free 
approaches such as genome-wide association studies, have lately confirmed the 
role of MHC, IRF5 and STAT4 and uncovered new SSc susceptibility loci, such as 
CD247 (4-5).
In this line of research, four TNFSF4 promoter single nucleotide polymorphisms 
(SNPs) rs1234314, rs844644, rs844648 and rs12039904 were recently implicated 
in susceptibility to SSc in a Caucasian American population (composed of 1059 
patients with SSc and 698 healthy controls) (6). Interestingly, the TNFSF4 gene, 
which encodes OX40L, is considered as a potential autoimmunity candidate gene. 
OX40L is expressed on activated antigen presenting cells and endothelial cells in 
acute inflammation. Furthermore, it enhances B cell proliferation and differentiation 
and its binding to OX40 (CD134) promotes proliferation and survival of T  cells 
(7,8). All  these processes could play an important role in loss of immune tolerance 
and pathology as observed in SSc.
On this basis, the aim of this study was to replicate the association of TNFSF4 
gene promoter polymorphisms with SSc through a large association study in eight 
independent European populations of Caucasian ancestry, in order to confirm the 
implication of TNFSF4 gene in SSc genetic susceptibility and phenotypic features.
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Methods
Patients
A total of 3014 cases and 3125 controls from 8 European Caucasian cohorts 
(Spain, Germany, The Netherlands, Belgium, Italy, Sweden, Norway and UK) were 
included in this study. Patients with SSc were diagnosed accordingly with the 1980 
American College of Rheumatology classification criteria for SSc (9). and were 
subdivided into those with lcSSc and dcSSc as defined by LeRoy et al. (10).
The following clinical  data was collected for ascertainment of clinical phenotype of 
patients with SSc: age, gender, disease duration and presence of SSc specific 
autoantibodies, ATA and ACA. Clinical  subtype information was available for 82% 
of the patients, and autoantibody status was available for 74% of the patients. The 
control  population consisted of unrelated healthy individuals recruited in the same 
geographical regions as patients with SSc, matched by age, sex and ethnicity. The 
local ethical  committees at all  participating centres approved the study. Patients 
and controls were included in the study after written informed consent was 
obtained.
TNFSF4 polymorphisms genotyping
SNPs rs1234314, rs844644, rs844648 and rs12039904 (tag-SNP of rs2205960 
SNP) were genotyped using TaqMan SNP genotyping assays in a 7900HT Real-
Time PCR System from Applied Biosystems (Foster City, California, USA). The 
genotyping call rate was over 93% in all cases and controls included.
Statistical analysis
Association was calculated by 2×2 contingency tables and Fisher's exact test or χ2 
when necessary, obtaining p values, OR and 95% CI using PLINK (V.1.06; http://
pngu.mgh.harvard.edu/purcell/plink/). P values below 0.05 after Benjamini  and 
Hochberg False Discovery Rate Method correction were considered as statistically 
significant. Hardy–Weinberg equilibrium (HWE) was tested for all SNPs at 
significance level=0.01.
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Haplotypes were constructed using PLINK (V.1.06) and Haploview V.4.2 (http://
www.broadinstitute.org/haploview/haploview). Haplotypes having a frequency <5% 
in control groups were excluded for the analysis. Haplotype p values were 
corrected using Bonferroni correction. Meta-analysis was carried out by PLINK (V.
1.06) and StatsDirect (V.2.6.6; StatsDirect, Altrincham, UK) in the case of 
haplotypes. Homogeneity among cohorts was calculated using the Breslow–Day 
method, and OR calculation was performed under fixed effects model  (Mantel–
Haenszel) or random effects (DerSimonian–Laird) when necessary.
The power of the study for the whole set of patients and controls reached over 98% 
(Power Calculator for Genetic Studies 2006 (11)).
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Results
Analysis of TNFSF4 promoter polymorphisms
The allelic frequencies of the four SNPs tested were similar to those reported for 
Caucasian populations in previous studies and the international  HapMap Project 
(http://hapmap.ncbi.nlm.nih.gov/) (6,12,13). In addition, the genotypic distribution of 
healthy controls and SSc cases was in HWE for all SNPs.
Table 1 describes allelic  distribution of the four SNPs in the pooled analysis, and 
supplementary tables 1–4 contain detailed data for each population. Pooled 
analysis of rs1234314 SNP showed statistically significant association of the G 
allele with SSc (p =0.03, OR 1.15, 95% CI 1.02 to 1.31), with the subset of patients 
with lcSSc  (p =0.003, OR 1.22, 95% CI 1.07 to 1.38) and with patients positive for 
ACA (p =2.51E-04, OR 1.23, 95% CI 1.10 to 1.37) (table 1 and supplementary 
figure 1). The association of this genetic marker with lcSSc remained significant 
after the comparison of this subgroup of patients with those having dcSSc (p =0.01, 
OR 0.85, 95% CI 0.75 to 0.96, data not shown). Pooled analysis revealed a 
significant protective association of rs844644 minor allele with lcSSc (p =0.03, OR 
0.91, 95% CI 0.83 to 0.99) (table 1, supplementary figure 2). Similarly, the 
rs844648 A allele showed a significant association with susceptibility to lcSSc and 
ACA positive subgroups (p =0.04, OR 1.10, 95% CI 1.01 to 1.20; p =0.04, OR 1.12, 
95% CI 1.01 to 1.25, respectively) (table 1, supplementary figure 3). Pooled 
analysis revealed a strong association of rs12039904 T  allele with patients with 
SSc (p =1.53E-04, OR 1.18, 95% CI 1.08 to 1.29), with patients in the lcSSc 
subgroup (p =2.81E-04, OR 1.20, 95% CI 1.09 to 1.33) and patients in the ACA-
positive subgroup (p =2.09E-03, OR 1.22, 95% CI 1.07 to 1.38) (table 1, 
supplementary figure 4).
TNFSF4 haplotype analysis
Haplotypes represented in over 5% of the healthy controls in any of the eight 
populations considered, were selected for pooled analysis (table 2 and 
supplementary table 5). Linkage disequilibrium patterns were tested in each of 
the eight cohorts analysed (supplementary table 6). Only two haplotypes reached 
significant association with SSc, CAGC (p =2.30E-03, OR 0.88, 95% CI 0.82 to 
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0.96) and GCAT (p =9.10E-03, OR 1.14, 95% CI 1.03 to 1.26) (supplementary 
table 5) (the order of the SNPs is rs1234314-rs844644-rs844648-rs12039904). 
Interestingly, the CAGC haplotype is composed by the protective alleles of all  the 
tested SNPs while the GCAT haplotype harbours all the risk alleles. The 
association of CAGC and GCAT haplotypes with SSc clinical features remained 
significant for patients in the lcSSc (p =6.8E-03, OR 0.88, 95% CI 0.80 to 0.96; 
p=1.3E-03, OR 1.20, 95% CI 1.08 to 1.35, respectively, data not shown) and ACA-
positive subsets (p =0.01, OR 0.86, 95% CI 0.77 to 0.97; p=3.7E-03, OR 1.23, 95% 
CI 1.07 to 1.42, respectively, data not shown).
Table 1. Pooled analysis of TNFSF4 promoter genetic variants
SNP (minor/major 
alleles), 
chromosome 
position (bp)
N MAF PMH PFDR OR (95% CI)
rs1234314 (G/C), 
171444015
Controls 2920 0.41
SSc 2856 0.44 0.03*† – 1.15 (1.02 to 1.31)
lcSSc 1608 0.46 0.003*‡ – 1.22 (1.07 to 1.38)
dcSSc 724 0.42 0.75§ 0.84 1.02 (0.91 to 1.15)
ACA+ 828 0.46 2.51E-04¶ 0.001 1.23 (1.10 to 1.37)
ATA+ 519 0.42 0.23** 0.43 1.08 (0.95 to 1.24)
rs844644 (A/C), 
171476118
Controls 2946 0.47
SSc 2912 0.45 0.049† 0.07 0.93 (0.86 to 1.00)
lcSSc 1653 0.45 0.03‡ 0.04 0.91 (0.83 to 0.99)
dcSSc 743 0.46 0.84§ 0.84 0.99 (0.88 to 1.11)
ACA+ 856 0.44 0.049¶ 0.049 0.90 (0.80 to 1.00)
ATA+ 533 0.46 0.33** 0.43 0.94 (0.82 to 1.07)
rs844648 (A/G), 
171490486
Controls 2977 0.43
SSc 2940 0.44 0.07† 0.07 1.07 (1.00 to 1.15)
lcSSc 1673 0.45 0.04‡ 0.04 1.1 (1.01 to 1.20)
dcSSc 742 0.42 0.69§ 0.84 0.98 (0.87 to 1.10)
ACA+ 860 0.45 0.04¶ 0.049 1.12 (1.01 to 1.25)
ATA+ 529 0.42 0.74** 0.74 1.02 (0.89 to 1.17)
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rs12039904 (T/C), 
171478896
Controls 2991 0.23
SSc 2894 0.26 1.53E-04† 6.12E-04 1.18 (1.08 to 1.29)
lcSSc 1639 0.26 2.81E-04‡ 5.61E-04 1.20 (1.09 to 1.33)
dcSSc 735 0.24 0.3§ 0.84 1.07 (0.94 to 1.23)
ACA+ 840 0.26 2.09E-03¶ 4.17E-03 1.22 (1.07 to 1.38)
ATA+ 523 0.24 0.15** 0.43 1.12 (0.96 to 1.31)
Controls are used as reference for all comparisons. * DerSimonian–Laird random effects model p value. 
† Breslow–Day rs1234314 p=0.01; rs844644 p=0.23; rs844648 p=0.52; rs12039904 p=0.50. ‡ Breslow–
Day rs1234314 p=0.08; rs844644 p=0.52; rs844648 p=0.33; rs12039904 p=0.48. § Breslow–Day 
rs1234314 p=0.61; rs844644 p=0.49; rs844648 p=1.00; rs12039904 p=0.38. ¶ Breslow–Day rs1234314 
p=0.29; rs844644 p=0.79; rs844648 p=0.94; rs12039904 p=0.74. ** Breslow–Day rs1234314 p=0.41; 
rs844644 p=0.73; rs844648 p=0.71; rs12039904 p=0.56.
Table 2. Pooled analysis of TNFSF4 haplotypes in patients with systemic sclerosis and controls
(2n cases/2n controls) Haplotype Cases (%) Controls (%) PMH OR (95% CI)
Pooled (5222/5296) CAGC 40.49 43.19 2.30E-03* 0.88 (0.82 to 0.96)
CCGC 10.23 10.04 0.47†‡ 1.09 (0.86 to 1.39)
GAGC 4.43 3.75 0.08§ 1.20 (0.98 to 1.47)
GCAC 16.71 16.68 0.53¶ 0.97 (0.87 to 1.07)
GCAT 21.54 19.33 9.10E-03** 1.14 (1.03 to 1.26)
Others 6.60 7.01 0.67*†† 0.94 (0.73 to 1.23)
The order of the SNPs is rs1234314-rs844644-rs844648-rs12039904.* Breslow–Day p=0.22. † 
DerSimonian–Laird random effects model p value. ‡ Breslow–Day p=0.004. § Breslow–Day p=0.62. ¶ 
Breslow–Day p=0.16. ** Breslow–Day p=0.24. †† Breslow–Day p=0.01. PMH, allelic Mantel–Haenszel 
fixed effects model p value.
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Discussion
TNFSF4 polymorphisms have been related to susceptibility for different 
autoimmune diseases including SSc. (6, 14) With the aim of validating the initially 
reported association of TNFSF4 gene in SSc, we conducted a large case-control 
study and a pooled analysis in eight independent European populations of 
Caucasian ancestry.
In accordance with the report by Gourh et al, our study supports the implication of 
TNFSF4  gene promoter polymorphisms in SSc  genetic predisposition (6). 
Stratification by SSc clinical  subtype or autoantibody status confirmed the 
significant association of the TNFSF4 variants with the patients in the lcSSc subset 
and ACA-positive subgroup but not with patients in the dcSSc or ATA-positive 
subsets. Nevertheless, the risk or protective directions in the associations were 
consistent with those reported by Gourh et al. (6).
Similarly, haplotype pooled analysis results obtained in the present study keep in 
with the findings from Gourh et al. (6). The most represented haplotype in both 
reports are equivalent, appear in similar frequency and have a protective effect. 
Nevertheless, in our study the opposite haplotype GCAT, which could not be 
observed in the previous study, showed a significant risk association with SSc.
Interestingly, previous findings in systemic  lupus erythematosus revealed the 
existence of equivalent protective and risk haplotypes to the ones reported in this 
study. Moreover, functional  data showed that the risk haplotype produced an 
increased level  of TNFSF4 transcript (compared to the protective haplotype), and a 
higher surface expression of OX40L in lymphoblastoid cell  lines and peripheral 
blood lymphocytes after activation. This overexpression seems to be related to the 
destruction of the DNA binding site for the transcriptional  repressor E4BP4 (with a 
role in the survival of early B cell progenitors) (12). Thus, the TNFSF4 risk 
haplotype associated with SSc  and producing higher levels of OX40L might be 
implicated in the pathogenic mechanisms of SSc, by the alteration of regulatory 
processes controlling B and T cell  proliferation and differentiation, leading to 
autoantibody production and tissue damage  (7 8 14–16). Further studies are 
necessary to elucidate the exact molecular mechanisms by which OX40L is 
implicated in SSc pathogenesis and more precisely how it can lead to the 
development of lcSSc and ACA production.
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In summary, our results confirm the implication of TNFSF4 promoter 
polymorphisms in SSc susceptibility, especially in patients in the lcSSc and ACA-
positive subgroups. These findings together with previous genetic and functional 
studies suggest TNFSF4  as an interesting and consistent genetic  factor for SSc 
and other autoimmune diseases and may open new opportunities for SSc 
treatment.
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Supplementary data
Supplementary Table 1. Distribution of  TNFSF4 rs1234314 genetic variant in eight 
replication cohorts.
Population N MAF Pu PFDR OR (95% CI)
Spain Controls 905 0.44
SSc 853 0.44 0.91 0.91 0.99 (0.87-1.13)
lcSSc 491 0.45 0.53 0.64 1.05 (0.90-1.23)
dcSSc 236 0.42 0.53 0.98 0.94 (0.76-1.15)
ACA+ 327 0.45 0.57 0.57 1.05 (0.88-1.26)
ATA+ 169 0.41 0.33 0.66 0.89( 0.70-1.13)
Germany Controls 245 0.41
SSc 308 0.46 0.26 0.53 1.15 (0.90-1.46)
lcSSc 146 0.46 0.14 0.31 1.25 (0.93-1.62)
dcSSc 126 0.45 0.29 0.56 1.18 (0.87-1.60)
ACA+ 73 0.45 0.43 0.94 1.16 (0.80-1.69)
ATA+ 46 0.48 0.21 0.79 1.33 (0.85-2.08)
The Netherlands Controls 187 0.41
SSc 329 0.49 0.03 0.1 1.34 (1.04-1.73)
lcSSc 101 0.5 0.06 0.13 1.39 (0.98-1.95)
dcSSc 30 0.38 0.65 0.99 0.88 (0.50-1.54)
ACA+ 35 0.54 0.05 0.12 1.68 (1.00-2.80)
ATA+ 27 0.48 0.35 0.62 1.31 (0.74-2.33)
Belgium Controls 251 0.42
SSc 174 0.5 0.02 0.03 1.37 (1.04-1.81)
lcSSc 111 0.53 0.01 0.02 1.51 (1.10-2.08)
dcSSc 52 0.44 0.74 0.74 1.08 (0.7-1.65)
ACA+ 38 0.51 0.15 0.56 1.43 (0.88-2.32)
ATA+ 29 0.55 0.06 0.09 1.67 (0.97-2.89)
Italy Controls 465 0.36
SSc 483 0.42 0.02 0.07 1.25 (1.04-1.50)
lcSSc 302 0.43 0.01 0.04 1.31 (1.07-1.62)
dcSSc 103 0.35 0.83 0.9 0.97 (0.71-1.32)
ACA+ 159 0.46 2.92E-03 0.01 1.48 (1.14-1.91)
ATA+ 171 0.4 0.25 0.49 1.16 (0.90-1.50)
Sweden Controls 246 0.41
SSc 179 0.36 0.13 0.53 0.81 (0.61-1.07)
107
Population N MAF Pu PFDR OR (95% CI)
lcSSc 78 0.37 0.34 0.66 0.83 (0.57-1.21)
dcSSc 36 0.33 0.22 0.59 0.72 (0.43-1.22)
ACA+ 27 0.39 0.78 0.98 0.92 (0.52-1.64)
ATA+ 19 0.37 0.63 0.77 0.84 (0.43-1.67)
Norway Controls 264 0.41
SSc 83 0.42 0.81 0.81 1.04 (0.73-1.49)
lcSSc 49 0.41 0.96 0.96 1.01 (0.65-1.57)
dcSSc 28 0.45 0.55 0.97 1.18 (0.68-2.06)
ACA+ 40 0.45 0.45 0.45 1.20 (0.75-1.93)
ATA+ 11 0.41 0.97 0.97 1.02 (0.43-2.42)
United Kingdom Controls 357 0.4
SSc 447 0.47 0.002 0.008 1.37 (1.12-1.67)
lcSSc 330 0.48 1.72E-03 0.007 1.41 (1.14-1.74)
dcSSc 113 0.45 0.18 0.7 1.23 (0.91-1.67)
ACA+ 129 0.48 0.02 0.07 1.41 (1.06-1.88)
ATA+ 47 0.43 0.59 0.9 1.13 (0.73-1.74)
Nucleotide change: G/C. Position in chromosome 1: 171444015bp. Controls are used as reference for 
all comparisons. MAF: Minor allele (G) frequency; Pu: Allelic chi-square uncorrected p-value; PFDR: 
Corrected p-value using Benjamini & Hochberg False Discovery Rate
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Supplementary Table 2. Distribution of TNFSF4 rs844644 genetic variant in eight 
replication cohorts.
Population N MAF Pu PFDR OR (95% CI)
Spain Controls 902 0.45
SSc 880 0.44 0.56 0.91 0.96 (0.84-1.10)
lcSSc 511 0.43 0.32 0.64 0.93 (0.79-1.08)
dcSSc 240 0.45 0.98 0.98 1 (0.81-1.22)
ACA+ 335 0.42 0.16 0.33 0.88 (0.74-1.05)
ATA+ 171 0.46 0.7 0.73 1.05 (0.83-1.32)
Germany Controls 265 0.42
SSc 341 0.46 0.18 0.53 1.17 (0.93-1.47)
lcSSc 159 0.47 0.15 0.31 1.22 (0.93-1.62)
dcSSc 141 0.45 0.42 0.56 1.13 (0.84-1.51)
ACA+ 81 0.46 0.47 0.94 1.14 (0.80-1.62)
ATA+ 52 0.43 0.88 0.88 1.03 (0.68-1.58)
The Netherlands Controls 171 0.48
SSc 326 0.43 0.17 0.17 0.83 (0.64-1.08)
lcSSc 96 0.46 0.64 0.64 0.92 (0.64-1.31)
dcSSc 29 0.45 0.66 0.99 0.88 (0.50-1.54)
ACA+ 32 0.41 0.28 0.28 0.74 (0.43-1.28)
ATA+ 26 0.44 0.62 0.62 0.86 (0.48-1.55)
Belgium Controls 238 0.45
SSc 170 0.38 0.06 0.06 0.76 (0.58-1.01)
lcSSc 109 0.4 0.21 0.22 0.81 (0.59-1.13)
dcSSc 51 0.35 0.06 0.24 0.66 (0.42-1.02)
ACA+ 37 0.46 0.93 0.93 1.02 (0.63-1.67)
ATA+ 30 0.33 0.08 0.09 0.6 (0.34-1.06)
Italy Controls 478 0.51
SSc 469 0.47 0.11 0.21 0.86 (0.72-1.03)
lcSSc 306 0.47 0.13 0.25 0.85 (0.70-1.05)
dcSSc 102 0.52 0.71 0.9 1.06 (0.78-1.43)
ACA+ 167 0.47 0.27 0.31 0.87 (0.68-1.12)
ATA+ 169 0.46 0.2 0.49 0.85 (0.66-1.09)
Sweden Controls 269 0.48
SSc 179 0.5 0.53 0.73 1.09 (0.83-1.42)
lcSSc 80 0.46 0.66 0.66 0.92 (0.65-1.32)
dcSSc 36 0.54 0.29 0.59 1.3 (0.79-2.13)
109
Population N MAF Pu PFDR OR (95% CI)
ACA+ 28 0.46 0.87 0.98 0.95 (0.55-1.66)
ATA+ 20 0.5 0.77 0.77 1.1 (0.58-2.09)
Norway Controls 265 0.48
SSc 94 0.45 0.42 0.7 0.87 (0.62-1.22)
lcSSc 58 0.41 0.19 0.37 0.76 (0.51-1.14)
dcSSc 30 0.5 0.78 0.97 1.08 (0.63-1.84)
ACA+ 46 0.39 0.11 0.24 0.69 (0.44-1.09)
ATA+ 13 0.46 0.85 0.97 0.92 (0.42-2.04)
United Kingdom Controls 358 0.49
SSc 453 0.45 0.16 0.32 0.87 (0.71-1.06)
lcSSc 334 0.45 0.21 0.38 0.87 (0.71-1.08)
dcSSc 114 0.45 0.35 0.7 0.87 (0.64-1.17)
ACA+ 130 0.47 0.54 0.72 0.92 (0.69-1.22)
ATA+ 52 0.48 0.9 0.9 0.97 (0.65-1.47)
Nucleotide change: A/C. Position in chromosome 1: 171476118bp. Controls are used as reference for 
all comparisons. MAF: Minor allele (A) frequency; Pu: Allelic chi-square uncorrected p-value; PFDR: 
Corrected p-value using Benjamini & Hochberg False Discovery Rate
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Supplementary Table 3. Distribution of TNFSF4 rs844648 genetic variant in eight 
replication cohorts.
Population N MAF Pu PFDR OR (95% CI)
Spain Controls 865 0.45
SSc 887 0.44 0.8 0.91 1.02 (0.87-1.16)
lcSSc 510 0.45 0.64 0.64 1.04 (0.89-1.21)
dcSSc 240 0.44 0.77 0.98 0.97 (0.79-1.19)
ACA+ 336 0.46 0.38 0.5 1.08 (0.91-1.30)
ATA+ 171 0.43 0.73 0.73 0.96 (0.76-1.21)
Germany Controls 271 0.44
SSc 342 0.43 0.82 0.82 0.97 (0.78-1.22)
lcSSc 160 0.45 0.82 0.82 1.03 (0.78-1.36)
dcSSc 140 0.42 0.56 0.56 0.92 (0.68-1.23)
ACA+ 77 0.44 0.96 0.98 1.01 (0.70-1.45)
ATA+ 50 0.41 0.59 0.79 0.89 (0.58-1.37)
The Netherlands Controls 199 0.43
SSc 327 0.48 0.13 0.17 1.22 (0.95-1.56)
lcSSc 104 0.48 0.28 0.37 1.20 (0.86-1.69)
dcSSc 31 0.44 0.99 0.99 1.00 (0.58-1.72)
ACA+ 35 0.51 0.22 0.28 1.38 (0.83-2.29)
ATA+ 28 0.48 0.5 0.62 1.21 (0.69-2.12)
Belgium Controls 278 0.43
SSc 176 0.5 0.02 0.03 1.37 (1.04-1.79)
lcSSc 113 0.53 0.01 0.02 1.5 (1.10-2.06)
dcSSc 52 0.45 0.61 0.74 1.12 (0.73-1.70)
ACA+ 38 0.47 0.42 0.56 1.22 (0.75-1.97)
ATA+ 29 0.55 0.06 0.09 1.67 (0.97-2.87)
Italy Controls 469 0.37
SSc 479 0.39 0.36 0.36 1.09 (0.91-1.31)
lcSSc 311 0.4 0.27 0.36 1.13 (0.91-1.39)
dcSSc 106 0.36 0.9 0.9 0.98 (0.72-1.34)
ACA+ 169 0.41 0.19 0.31 1.19 (0.92-1.53)
ATA+ 172 0.37 0.96 0.96 1.01 (0.78-1.30)
Sweden Controls 266 0.43
SSc 185 0.42 0.73 0.73 0.95 (0.73-1.25)
lcSSc 79 0.38 0.26 0.66 0.81 (0.56-1.17)
dcSSc 36 0.42 0.82 0.93 0.95 (0.57-1.56)
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Population N MAF Pu PFDR OR (95% CI)
ACA+ 27 0.43 0.95 0.98 0.98 (0.56-1.73)
ATA+ 20 0.4 0.71 0.77 0.88 (0.46-1.70)
Norway Controls 277 0.44
SSc 94 0.46 0.52 0.7 1.12 (0.80-1.56)
lcSSc 58 0.49 0.27 0.37 1.25 (0.84-1.87)
dcSSc 30 0.43 0.97 0.97 0.99 (0.58-1.70)
ACA+ 46 0.51 0.18 0.24 1.35 (0.87-2.10)
ATA+ 13 0.42 0.9 0.97 0.95 (0.43-2.10)
United Kingdom Controls 352 0.43
SSc 450 0.45 0.45 0.45 1.08 (0.88-1.32)
lcSSc 338 0.45 0.38 0.38 1.1 (0.89-1.36)
dcSSc 107 0.43 0.92 0.92 0.98 (0.72-1.34)
ACA+ 132 0.45 0.61 0.72 1.08 (0.81-1.43)
ATA+ 46 0.46 0.62 0.9 1.12 (0.72-1.73)
Nucleotide change: A/G. Position in chromosome 1: 171490486bp. Controls are used as reference for 
all comparisons. MAF: Minor allele frequency; Pu: Allelic chi-square uncorrected p-value; PFDR: 
Corrected p-value using Benjamini & Hochberg False Discovery Rate
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Supplementary Table 4. Distribution of TNFSF4 rs12039904 genetic variant in eight 
replication cohorts.
Population N MAF Pu PFDR OR (95% CI)
Spain Controls 902 0.22
SSc 863 0.26 0.01 0.06 1.21 (1.04-1.42)
lcSSc 499 0.26 0.01 0.05 1.25 (1.05-1.50)
dcSSc 238 0.25 0.22 0.86 1.16 (0.92-1.47)
ACA+ 329 0.27 0.02 0.07 1.29 (1.05-1.58)
ATA+ 171 0.26 0.09 0.36 1.26 (0.96-1.64)
Germany Controls 272 0.26
SSc 312 0.25 0.67 0.82 0.94 (0.73-1.23)
lcSSc 149 0.28 0.54 0.73 1.10 (0.80-1.52)
dcSSc 132 0.2 0.09 0.35 0.74 (0.52-1.05)
ACA+ 73 0.26 0.98 0.98 1.01 (0.66-1.53)
ATA+ 45 0.22 0.46 0.79 0.82 (0.48-1.39)
The Netherlands Controls 167 0.19
SSc 338 0.26 0.06 0.11 1.36 (0.99-1.86)
lcSSc 102 0.28 0.048 0.13 1.50 (1.00-2.24)
dcSSc 31 0.19 0.77 0.99 0.91 (0.46-1.79)
ACA+ 35 0.31 0.06 0.12 1.72 (0.98-3.05)
ATA+ 27 0.28 0.26 0.62 1.45 (0.76-2.78)
Belgium Controls 262 0.23
SSc 175 0.31 0.009 0.03 1.5 (1.10-2.04)
lcSSc 112 0.31 0.01 0.02 1.55 (1.09-2.19)
dcSSc 52 0.3 0.12 0.24 1.45 (0.91-2.31)
ACA+ 37 0.28 0.28 0.56 1.35 (0.78-2.33)
ATA+ 29 0.33 0.08 0.09 1.66 (0.92-2.98)
Italy Controls 493 0.21
SSc 473 0.23 0.17 0.23 1.16 (0.94-1.44)
lcSSc 307 0.22 0.51 0.51 1.09 (0.85-1.39)
dcSSc 105 0.24 0.23 0.9 1.24 (0.87-1.76)
ACA+ 168 0.23 0.31 0.31 1.17 (0.87-1.57)
ATA+ 168 0.22 0.66 0.88 1.07 (0.79-1.45)
Sweden Controls 264 0.26
SSc 186 0.28 0.54 0.73 1.1 (0.81-1.48)
lcSSc 76 0.24 0.66 0.66 0.91 (0.60-1.38)
dcSSc 37 0.26 0.93 0.93 0.98 (0.56-1.70)
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Population N MAF Pu PFDR OR (95% CI)
ACA+ 25 0.26 0.98 0.98 0.99 (0.51-1.92)
ATA+ 20 0.23 0.61 0.77 0.82 (0.38-1.77)
Norway Controls 274 0.25
SSc 93 0.28 0.43 0.7 1.16 (0.80-1.69)
lcSSc 58 0.31 0.18 0.37 1.35 (0.87-2.09)
dcSSc 27 0.24 0.89 0.97 0.95 (0.51-1.80)
ACA+ 46 0.33 0.12 0.24 1.45 (0.90-2.34)
ATA+ 13 0.23 0.82 0.97 0.9 (0.35-2.29)
United Kingdom Controls 357 0.24
SSc 454 0.27 0.26 0.35 1.14 (0.91-1.43)
lcSSc 336 0.26 0.3 0.38 1.14 (0.89,1.45)
dcSSc 113 0.26 0.54 0.72 1.11 (0.79-1.57)
ACA+ 127 0.25 0.72 0.72 1.06 (0.76-1.48)
ATA+ 50 0.23 0.81 0.9 0.94 (0.57-1.55)
Nucleotide change: T/C. Position in chromosome 1: 171478896bp. Controls are used as reference for 
all comparisons. MAF: Minor allele frequency; Pu: Allelic chi-square uncorrected p-value; PFDR: 
Corrected p-value using Benjamini & Hochberg False Discovery Rate
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Supplementary Table 5. Distribution of TNFSF4 haplotypes in SSc patients and controls in 
eight replication cohorts.
Population 
(2n cases/2n controls) Cases (%) Controls (%) PBf OR (95% CI)
Spain
(1650/1666) CAGC 40.77 41.43 NS 0.97 (0.85-1.12)
CCGC 9.66 11.37 0.55 0.83 (0.67-1.04)
GAGC 3.14 2.77 NS 1.14 (0.76-1.70)
GCAC 17.16 19.42 NS 0.98 (0.88-1.08)
GCAT 21.59 19.67 0.88 1.12 (0.95-1.33)
Others 7.69 5.35 0.03 1.47 (1.11-1.95)
Germany CAGC 41.80 39.30 NS 1.11 (0.86-1.43)
(534/468) CCGC 9.96 13.32 0.51 0.72 (0.49-1.07)
GAGC 5.86 3.28 0.28 1.78 (0.95-3.33)
GCAC 17.77 16.16 NS 1.02 (0.85-1.22)
GCAT 19.53 20.96 NS 0.92 (0.67-1.25)
Others 5.08 6.99 NS 0.72 (0.42-1.22)
The Netherlands CAGC 39.01 45.56 0.40 0.76 (0.57-1.03)
(574/248) CCGC 6.56 6.05 NS 1.05 (0.57-1.94)
GAGC 4.79 3.63 NS 1.25 (0.59-2.65)
GCAC 19.15 18.95 NS 1.01 (0.82-1.26)
GCAT 22.52 16.53 0.26 1.45 (0.98-2.13)
Others 7.98 9.27 NS 0.83 (0.49-1.40)
Belgium CAGC 34.89 40.23 0.68 0.8 (0.59-1.08)
(328/438) CCGC 9.03 9.77 NS 0.93 (0.57-1.52)
GAGC 4.05 5.35 NS 0.77 (0.39-1.53)
GCAC 19.63 16.51 NS 1.01 (0.82-1.24)
GCAT 25.23 20.23 0.52 1.33 (0.94-1.88)
Others 7.17 7.91 NS 0.91 (0.53-1.57)
Italy CAGC 41.57 48.14 0.03 0.77 (0.63-0.93)
(866/878) CCGC 13.00 10.44 0.50 1.28 (0.95-1.72)
GAGC 5.27 3.83 0.76 1.39 (0.88-2.19)
GCAC 14.87 14.04 NS 1.02 (0.89-1.17)
GCAT 20.14 16.71 0.33 1.26 (0.98-1.60)
Others 5.15 6.84 0.70 0.74 (0.5-1.11)
Sweden CAGC 39.27 42.40 NS 0.88 (0.65-1.18)
(310/450) CCGC 18.48 9.52 1.93E-03 2.14 (1.39-3.28)
GAGC 3.30 4.08 NS 0.83 (0.39-1.81)
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Population 
(2n cases/2n controls) Cases (%) Controls (%) PBf OR (95% CI)
GCAC 8.25 13.83 NS 0.95 (0.77-1.18)
GCAT 17.16 20.86 NS 0.79 (0.54-1.15)
Others 13.53 9.30 0.35 1.52 (0.96-2.41)
Norway CAGC 40.49 42.37 NS 0.93 (0.65-1.33)
(164/472) CCGC 10.43 8.39 NS 1.31 (0.72-2.37)
GAGC 5.52 5.59 NS 1.05 (0.49-2.26)
GCAC 10.43 13.12 NS 1.01 (0.78-1.31)
GCAT 25.15 21.29 NS 1.25 (0.83-1.9)
Others 7.98 9.25 NS 0.89 (0.47-1.69)
United Kingdom CAGC 40.29 45.18 0.31 0.82 (0.66-1.01)
(796/676) CCGC 8.74 7.83 NS 1.12 (0.77-1.64)
GAGC 5.35 4.07 NS 1.32 (0.80-2.16)
GCAC 18.38 16.42 NS 1.02 (0.88-1.19)
GCAT 22.03 19.28 1.00 1.18 (0.91-1.53)
Others 5.22 7.23 0.57 0.71 (0.46-1.09)
The order of the SNPs is rs1234314-rs844644-rs844648-rs12039904. PBf: Corrected p-value using 
Bonferroni multiple test correction; NS: non-significant; OR: odds ratio.
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Supplementary Table 6. Linkage disequilibrium of TNFSF4 polymorphisms in eight European cohorts.
Population
R2 
rs1234314-
rs844644
R2 
rs1234314-
rs844648
R2 
rs1234314-
rs12039904
R2 
rs844644-
rs844648
R2 
rs844644-
rs12039904
R2 
rs844648-
rs12039904
Spain 0.44 0.68 0.24 0.55 0.24 0.33
Germany 0.31 0.63 0.22 0.51 0.28 0.42
The 
Netherlands 0.48 0.56 0.13 0.72 0.23 0.29
Belgium 0.38 0.52 0.27 0.61 0.28 0.36
Italy 0.39 0.55 0.26 0.58 0.25 0.35
Sweden 0.37 0.45 0.22 0.66 0.39 0.41
United 
Kingdom 0.41 0.58 0.18 0.68 0.27 0.34
Norway 0.31 0.44 0.22 0.66 0.27 0.35
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Supplementary figure 1.A) Forest plot of the TNFSF4 rs1234314 polymorphism in SSc versus 
controls in eight cohorts,  B) in lcSSc patients versus controls and C) ACA positive patients versus 
controls.
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Supplementary figure 2. Forest plot for the meta-analysis of the TNFSF4 rs844644 polymorphism in 
lcSSc patients versus controls in eight Caucasian cohorts. 
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Supplementary Figure 3.A) Forest plot for the meta-analysis of the TNFSF4 rs844648 polymorphism 
in lcSSc patients versus controls in eight Caucasian cohorts. B) Forest plot for the meta-analysis of 
the TNFSF4 rs844648 polymorphism in ACA positive patients versus controls in eight Caucasian 
cohorts. 
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Supplementary figure 4.A) Forest plot of the TNFSF4 rs12039904 polymorphism in lSSc patients 
versus controls  B) lcSSc patients versus controls and C) ACA positive patients versus controls.
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Supplementary figure 5.A) Forest plot for the meta-analysis of the in CAGC haplotype in SSc patients 
versus controls in eight Caucasian cohorts. B) Forest plot for the meta-analysis of GCAT haplotype in 
SSc patients versus controls in eight Caucasian cohorts.
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Abstract
Aim: Polymorphisms in the genes encoding interleukin 4 (IL4), interleukin 13 (IL13) 
and their corresponding receptors have previously been associated with multiple 
immune mediated diseases. In this study we aim to validate these previous 
observations in systemic sclerosis (SSc) patients and scrutinize the effect of the 
polymorphisms on gene expression in various populations of peripheral blood 
leukocytes.
Patients and Methods: We genotyped a cohort of 2488 SSc patients and 2246 
healthy controls from The Netherlands, Spain, United Kingdom, Italy, Germany and 
France. Taqman assays were used to genotype single nucleotide polymorphisms 
(SNP)s in the following genes: 1) IL4 (−590C>T/rs2243250), 2) IL4 receptor alpha 
(IL4RA) (Q576R/rs1801275) 3) IL13  (R130Q/rs20541 and  -1112C>T rs1800925) 
and 4) IL13 receptor alpha 1 (IL13RA1) (43163G>A/rs6646259). In addition, the 
effect of these polymorphisms on expression of the corresponding genes was 
assessed using quantitative RT-PCR on RNA derived from peripheral blood B-cells, 
T-cells, plasmacytoid dendritic cells, monocytes and myeloid dendritic cells. 
Moreover, we investigated whether these polymorphisms influence development of 
pulmonary complications in SSc patients over 15 years.
Results: None of the investigated polymorphisms were associated with SSc  or any 
SSc clinical subtype. In addition, we did not observe any effect on transcript levels 
in the cell subtypes or on development of pulmonary complications.
Conclusions: Our data show that several polymorphisms in IL4, IL13 and their 
receptors do not play a role in SSc and do not influence the expression of their 
corresponding transcript in peripheral blood cells.
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Introduction
Systemic  Sclerosis (SSc) is a debilitating autoimmune disease featuring immune 
activation, vasculopathy and auto-antibody production. These processes eventually 
lead to fibrosis of skin and internal organs (1). The exact aetiology still needs to be 
unravelled, although it is generally accepted that multiple common genetic variants 
contribute to the risk of developing SSc (2). Traditionally, SSc has been regarded 
as a disease propelled by a T helper 2 (Th2) response (3). This view was mainly 
based on the increased expression of several signature molecules that are 
associated with Th2 response, such as Interleukin 4 (IL4), Interleukin 13 (IL13) and 
Interleukin 5 (IL5) in SSc  serum, skin and bronchoalveolar lavage (4,5). However, 
evidence is accumulating that other T-cell subsets including Th1, Th17 and T 
regulatory cells may also drive pathology observed in SSc (6,7). In parallel  with the 
important role of IL4 and IL13 in Th2 responses, both cytokines seem to exhibit a 
key role in tuning Th17 responses. For instance, both IL13 and IL4 are able to 
attenuate Th17 cytokine production (8,9). Adding to the complexity, cells of the 
innate immune system may also produce pathologically relevant quantities of IL13, 
especially in the context of fibrosing diseases (10, 11). In addition to being involved 
in the same biologic  processes, IL4 and IL13 display similar features in structure 
and signalling. Although they share only 25% homology at the amino acid level, 
their core structure is very similar. The genes are closely situated to each other on 
chromosome 5q31.1 and are often co-regulated. Both cytokines mediate their 
effects by interacting with the same receptor complex composed of two 
transmembrane proteins, IL4RA1 and IL13RA1 (12,13). A second IL13 receptor 
with a short cytoplasmic tail, IL13RA2, binds IL13 with high affinity and acts as a 
decoy receptor though a recent study suggests that it may mediate TGFβ induced 
fibrosis (14).
Polymorphisms of both IL4 and IL13  and their receptors have been implicated in 
susceptibility to asthma (15) and atopic  dermatitis and are believed to play a role in 
psoriasis as well  (16,17). In addition, IL13 variants have recently been implicated in 
susceptibility to psoriatic arthritis (18). To further elucidate the role of 
polymorphisms in the IL4, IL13, IL4R and IL13RA1 genes, we aimed to validate 
previous associations with immune mediated diseases, including SSc, in a large 
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multi-national SSc cohort (19-21). Lastly, we investigated the possible effect of 
these polymorphisms on IL13, IL13RA1 and IL4RA expression in B cells, T cells, 
myeloid dendritic  cells (MyDC), plasmacytoid dendritic cells (PDC) and monocytes 
from SSc patients.
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Methods
Patients and Controls
The study population was composed of 2488 SSc  patients and 2246 healthy 
controls matched by geographical  region and age. Six case-control sets were of 
European ancestry; a Spanish cohort: 231 SSc patients and 250 controls; a Dutch 
cohort: 143 SSc patients and 274 controls; a German cohort: 422 SSc patients and 
266 controls; a British cohort: 234 SSc patients and 98 controls: an Italian cohort 
444 SSc patients and 362 controls; and a French cohort: 1014 SSc patients and 
996 controls. All  the patients fulfilled the 1980 American College of Rheumatology 
(ACR) classification criteria for SSc (22). The local  ethical committee from each 
center approved the study. Both patients and controls were included in the study 
after written informed consent. All patients included in this study were classified as 
having limited cutaneous (lcSSc) or diffuse cutaneous SSc   (dcSSc) using the 
criteria postulated by LeRoy (23). Patients with scleroderma changes limited to the 
skin distal  to elbows and/or knees, regardless of facial involvement, fulfill  the 
definition for lcSSc. Those SSc  patients with more proximal scleroderma skin 
changes were classified as having dcSSc. The presence of pulmonary fibrosis was 
investigated by a high resolution computed tomography scan. Restrictive syndrome 
and diffusion capacity of the lungs was defined as a forced vital capacity (FVC) < 
70% of the predicted value and a diffusion capacity of the lung for carbon 
monoxide (DLCO) of less than 70% of predicted. Pulmonary artery hypertension 
was diagnosed by right heart catheterization and considered confirmed if the mean 
pulmonary artery pressure was greater than 25 mmHg at rest with a normal  left 
atrial wedge pressure. Furthermore, we used follow up data on FVC decline and 
PAH development from an inception cohort including 358 Dutch and Italian 
patients, starting inclusion after the onset of the first non-Raynauds symptom and 
ending at 15 years of follow-up. The patients were evaluated at least yearly for 
these complications (Table 1). 
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Table 1. Basic and clinical characteristics of the 6 SSc cohorts included in this study.
Population
The
Spain Germany France Italy United KingdomNetherlands
Number 143 231 422 1014 444 234
Age (years, (SD)) 58 (13) 58 (13) 57(12) 56 (13) 55 (13) 54 (12)
Disease duration (months, 
(SD)) 131 (82) 144 (90) 113 (109) 128 (98) 140 (138) 155 (92)
Female % 81 82 76 86 92 85
Limited phenotype % 69 68 51 63 52 79
Positivity anti-topo % 23 23 26 24 33 15
Positivity ACA % 58 39 46 37 32 71
Pulmonary fibrosis CT 
scan 32.3 30.7 37.2 39.0 32.1 43.2
Low FVC (<70% predicted) 
% 26.1 29.1 18.5 16.2 15.3 30.1
Low DLCO (<70% 
predicted) % 33 45.1 50.2 N.A. 67.2 11.5
Genotyping
Peripheral blood samples (10 ml) collected in EDTA tubes were obtained from each 
patient and stored at -80°C prior to DNA isolation. Genomic DNA was extracted 
from leucocytes in peripheral venous blood according to standard protocols. DNA 
was transferred to 96 wells plates. Each plate contained 3 negative controls (H2O) 
and 5 duplicate samples (3 within the plate and 2 between the plates). We chose 
SNPs that have previously been shown to influence susceptibility to immune 
mediated diseases and are protein altering, or associated with altered expression 
levels (19-21). In addition, the IL13RA1 SNP (rs6646259) covers the largest part of 
the IL13RA1 gene since it is situated in a large haplotype block.  Taqman assays 
were used for genotyping SNPs within IL4 (−590C>T/rs2243250/assay 
I D : C _ _ 1 6 1 7 6 2 1 6 _ 1 0 ) a n d t h e I L 4 R ( Q 5 7 6 R / r s 1 8 0 1 2 7 5 / a s s a y 
ID:C___2351160_20). In the IL13 gene two SNPs were genotyped R130Q 
(rs20541/assay ID:C___2259921_20) and -1112C>T (rs1800925/assay 
ID:C___8932056_10). In the IL13RA1 gene, the 43163G>A (rs6646259/assay 
ID:C__11770516_10) variant was genotyped. Taqman assays were performed 
according to the protocol from the manufacturer using the 7500 Fast Real-Time 
PCR system (Applied Biosystems, Foster City, California, USA). Results were 
analyzed using Sequence Detection Software version 1.4. A competitive allele 
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specific PCR system (Kaspar Genotyping, Kbioscience, Hoddeston, UK) was used 
to genotype these SNPs in the French sample as previously reported (24).
Isolation of cell subsets and expression analysis
From 25 SSc patients and 9 controls, derived from the Boston University Medical 
Center (Boston, MA, USA) we isolated PBMCs from heparinized venous blood by 
density-gradient centrifugation. Subsequently, BDCA4+ (PDC), CD3+ (T cell), 
CD19+ (B cell), CD1C+ (MyDC) and CD14+ (monocyte) cells were isolated by 
magnetic  cell separation techniques according to the manufacturer's protocol  and 
as described previously (25). RNA was purified by AllPrep DNA/RNA columns 
(Qiagen, Valencia, CA), and cDNA was synthesized by I-script (Bio-Rad, Hercules, 
CA). Quantitative real-time PCR (qRT-PCR) was performed on an Mx3005P QPCR 
System (Stratagene). Each primer set yielded a product with a dissociation curve 
composed of a single peak. Ct values for duplicate samples were averaged and 
the amount of cDNA relative to a housekeeping gene (GAPDH) was calculated with 
the ΔCt method. Primers are displayed in table 2 and have been derived from the 
Harvard primerbank or were created with Primer3 software (26,27). 
Table 2. Primer sequences used for RT-PCR
Gene Forward Primers (5’-3’) Reverse Primers (5’-3’) Primerbank ID
GAPDH ATGGGGAAGGTGAAGGTCG GGGGTCATTGATGGCAACAATA 7669492a1
IL13 GAAGGCTCCGCTCTGCAAT TCTGGGTCTTCTCGATGGCA 26787978a1
IL13RA1 ACTCCTGCTTTACCTAAAAAGGC GCACTACAGAGTCGGTTTCCT 4504647a1
IL4RA TCATGGATGACGTGGTCAGT CAGGTCAGCAGCAGAGTGTC *
*Primer was newly designed with Primer3 software; Rozen S, Skaletsky H.Primer3 on the 
WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-86.
Data analysis
Significance levels were calculated with 2x2 contingency tables and Fisher’s exact 
test by SPSS 16.0. To account for multiple testing the Bonferroni adjustment was 
applied (significance threshold p =0.002). Homogeneity of OR among cohorts was 
calculated using Breslow-Day and Woolf Q methods and the calculation of the 
pooled OR was performed under a fixed-effects model  (Mantel-Haenszel meta-
analysis). Power calculations using the pooled sample size (2488 SSc patients and 
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2246 controls) showed that  we reached a power of detecting a relative risk of 1.2 
of respectively 97% (both rs1801275 and rs20541), 95% (rs1800925), 92% 
(rs2243250). Since IL13RA1 is located on the X chromosome we performed an 
analysis in the female population only (SSc  n=2036, controls n=1035), doing this 
we still reached a power of 84% to detect a relative risk of 1.2 (rs6646259). 
Survival analysis was performed using Kaplan-Meier curves and significance levels 
were calculated with Log Rank (Mantel-Cox) statistics. Cox Proportional Hazards 
Survival Regression was used to determine relative risks. Capped lines represent 
standard error of the mean throughout the manuscript.
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Results
After genotyping, no divergence in Hardy Weinberg Equilibrium was observed. The 
minor allele frequencies (MAF) of the SNPs tested were all in line with the 
frequencies reported by the HAPMAP project (www.hapmap.org). The 6 SSc 
populations showed very little variation in the MAF. According to the Breslow-Day 
statistics, no significant heterogeneity affecting the six European populations was 
detected, justifying a meta-analysis. We observed no significant deviation in 
genotype and allele frequencies in any of the polymorphisms tested in SSc  patients 
compared to controls. Initially, we observed a divergence in allele distribution of the 
rs1800925 polymorphism in the French dcSSc (p =0.02) and anti-topoisomerase 
positive (p =0.03) population with SSc compared to controls (Supplementary 
Tables 1-5). However, after correction for multiple testing using the Bonferroni 
adjustment, no results remained significant. In addition, a meta-analysis taking into 
account all six European SSc populations did not reveal a significant effect for any 
of the investigated variants on SSc  susceptibility or clinical phenotypes (Table 3). 
When we corrected for gender in our analysis for the non X chromosome located 
SNPs, no significant differences were observed. Finally, we performed a recessive 
and dominant analysis which yielded similar negative results (data not shown). 
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Table 3. Combined analysis of the five investigated polymorphisms, using Mantel-Haenszel analyisis 
under a fixed model for estimation of combined effects.
SNP Subtype total n minor allele frequency M-H p
IL13 rs1800925 SSc 1832 0.19 0.15
lcSSc 1125 0.18 0.11
dcSSc 558 0.20 0.06
ACA 689 0.18 0.67
Anti-topo 426 0.20 0.07
Controls 1869 0.17
IL13 rs20541 SSc 2474 0.37 0.34
lcSSc 1520 0.35 0.14
dcSSc 723 0.41 0.97
ACA 1046 0.29 0.77
Anti-topo 563 0.41 0.75
Controls 2246 0.44
IL13RA1 rs6646259 SSc 2037 0.19 0.2
(Females only) lcSSc 1211 0.16 0.78
dcSSc 556 0.23 0.19
ACA 800 0.13 0.25
Anti-topo 413 0.22 0.85
Controls 1035 0.16
IL4 rs2243250 SSc 1829 0.16 0.46
lcSSc 1128 0.16 0.7
dcSSc 553 0.15 0.3
ACA 692 0.16 0.81
Anti-topo 422 0.14 0.26
Controls 1869 0.15
IL4R rs1801275 SSc 1819 0.20 0.11
lcSSc 1125 0.19 0.64
dcSSc 547 0.20 0.16
ACA 685 0.19 0.4
Anti-topo 419 0.20 0.19
Controls 1879 0.19
The implication of IL4 and IL13 in many immune mediated pulmonary diseases: 
(11, 14, 28-32) led us to further investigate the role of functional variants in the IL4 
and IL13 genes with special emphasis on pulmonary involvement. For this purpose 
we used follow up data on FVC decline and PAH development from 358 Dutch and 
Italian patients, starting at the date of onset of the first non-Raynaud’s symptom 
and ending at 15 years. Patients were evaluated at least once a year for these 
complications. None of the polymorphisms influenced development of these 
complications significantly in the follow-up period (Supplementary Figure 1). 
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Supplementary Figure 1.  Effect of investigated polymorphisms on pulmonary complication 
development. No significant effects of the polymorphisms on the development of either a deterioration of 
forced vital capacity (FVC) below 70% of predicted (A,C,E, G and I) or on the development of 
pulmonary arterial hypertension (PAH) (B,D,F,H and J) were observed. Both log-rank and hazard ratio’s 
were calculated in 358 patients for a period of 15 years starting at the onset of the first non-Raynaud’s 
symptom (A-J).
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To investigate whether polymorphisms in IL13, IL4RA and IL13RA1 affect gene 
expression, the levels of transcripts for these genes were determined by qRT-PCR 
in purified populations of monocytes, plasmacytoid dendritic  cells, myeloid dendritic 
cells and T cells from the peripheral blood of healthy controls and SSc patients. 
Overall expression levels of IL13 were low with either undetectable or very high Ct 
values in most samples, precluding a comparative analysis for this gene. No 
statistically significant differences in the expression of IL13RA1 or IL4RA were 
found in the cell subsets between SSc patients and healthy controls (Figure 1). In 
addition, neither the polymorphism in IL13RA1 nor the one in IL4RA influenced 
expression of their corresponding gene in any cell type tested (Figure 2).
Figure 1. mRNA expression levels of (A) IL13RA1 and (B) IL4RA in T cells, plasmacytoid dendritic 
cells (PDCs), myeloid dendritic cells (MyDC) and monocytes from healthy controls and SSc patients. No 
significant differences were observed between healthy controls and SSc patients for either transcript in 
any cell type. (RE: relative expression compared to GAPDH)
Figure 2. mRNA expression levels of (A) IL13RA1 and (B) IL4RA in T cells, plasmacytoid  dendritic 
cells (PDCs), myeloid dendritic cells (MyDC) segregated by genotype for rs6646259 and rs1801275, 
respectively. Neither polymorphism significantly influenced gene expression in both SSc patients and 
controls. 
139
Discussion
In this study we show that five common polymorphisms in the coding regions of 
IL4, IL13 or their corresponding receptors are not associated with SSc 
susceptibility in six European populations. The role for both IL4 and IL13 has been 
addressed in multiple autoimmune diseases including SSc (5, 10, 14-18, 29-36). 
The functional  genetic  variants included in this study have been previously 
associated with immune mediated diseases however they do not seem to 
contribute to SSc  pathogenesis. Furthermore, genetic  variation at the IL13RA1 and 
IL4RA loci did not influence gene expression across a variety of immune cells. 
However, differences in expression at the protein level or within immune cells of 
lesional  tissue cannot be excluded. On the other hand, a recent genome wide 
association study which covered these genes fully, did not reveal  a statistical 
significant association either (37). To fully exclude a role for these genes in the 
pathogenesis of SSc, resequencing would be necessary to cover rare variants as 
well. It has to be noted that this study did not address a variant in the IL13RA2 
gene previously associated with SSc in a small French cohort (n=107) (38). This 
variant was left out because a possible overlap between the French cohort in our 
study and the cohort in the previous report could not be excluded. Considering the 
size and power of our study to detect significant deviations of all  the five variants 
between cases and controls, the lack of association is improbable due to a type 2 
error. The patients included in this study are well-described and evaluated following 
conventional guidelines (22,23), making disease classification bias unlikely. The 
patients used in the follow-up cohort were included upon the first evaluation of a 
non-Raynaud’s SSc  symptom, flowing from this it may be that patients with 
extremely progressive disease and with high mortality are not included in this 
analysis. On the other hand, the time these patients were evaluated covers 15 
years and therefore reflects the vast majority of patients that develop pulmonary 
complications later in disease course, making these results relevant. In SSc  mouse 
models, fibrosis after Bleomycin administration is dependent on IL13 (10). In 
addition to this, both cytokines are able to drive collagen production by fibroblasts 
directly (39). However T-cells do not seem to be the key producers of these 
cytokines and other celltypes are likely to be the main producers of these cytokines 
in SSc (40). For instance, alveolar macropages have been found to produce this 
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profibrotic  cytokine in pulmonary fibrosis (32). In this study we do not observe 
statistical significant differences in immune cell  subtypes of SSc  and HC. However, 
it has been recently described that scleroderma patients display heterogeneity at 
the gene expression level that may not be reflected in clinical phenotype (41). We 
cannot exclude the possibility that a RNA expression level analysis similar to ours 
across molecular sub-types of SSc might reveal an association especially in 
patients that show an immune cell activation signature. In addition, genetic 
variation at the IL13RA1 and IL4RA loci did not influence gene expression across a 
variety of immune cells. Differences in expression at the protein level or within 
immune cells of lesional tissue cannot be excluded. Lastly, expression levels of 
resting cells were measured, whereas differences may become more apparent 
when placed in a pro-inflammatory environment. 
Our results make it likely that the higher levels of IL4 and IL13 observed in SSc 
patients are not caused by the common genetic  variations investigated in this study 
but may result from other polymorphisms or upstream immune activation 
mechanisms that promote Th2 maturation or the differentiation of innate immune 
cells that can also make these cytokines (3,4). For instance, recently aberrances in 
expression of genes upstream of IL4 and IL13 have been identified in SSc that 
may have an impact on expression of these genes, instead of polymorphisms in 
IL4 and IL13 (42). In conclusion, we could not replicate the previous association of 
the rs1800925 polymorphism in the IL13 gene with SSc, which is most likely due to 
the small population of SSc patients involved in the initial study (n=107) (43). In 
addition, we did not observe an association with functional genetic variants of IL4, 
IL4RA and IL13RA1 with SSc susceptibility and/or phenotype. Further studies are 
necessary to investigate the mechanisms involved in the up regulation of, and 
response to, IL4 and IL13 observed in SSc.
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Supplementary Tables.
Supplementary Table 1: Overview of the genotype and allele frequencies of IL13 
rs1800925 in the individual populations
IL13	  rs1800925 	  Phenotype n TT TC CC p MAF p
Netherlands SSc 143 0.69 0.27 0.03 0.21 0.17 0.78
lcSSc 98 0.67 0.30 0.03 0.51 0.18 0.99
dcSSc 33 0.68 0.30 0.02 0.76 0.17 0.87
ACA 84 0.68 0.29 0.04 0.38 0.18 0.99
An,-­‐topo 33 0.66 0.30 0.04 0.76 0.19 0.74
Controls 274 0.65 0.33 0.01 0.18
Spain SSc 231 0.62 0.33 0.04 0.015 0.21 0.12
lcSSc 157 0.64 0.34 0.02 0.31 0.19 0.45
dcSSc 56 0.64 0.32 0.04 0.092 0.2 0.49
ACA 89 0.66 0.33 0.02 0.28 0.18 0.82
An,-­‐topo N.A. N.A. N.A. N.A. N.A.
Controls 250 0.66 0.34 0.00 0.17
Italy SSc 444 0.59 0.41 0.01 0.08 0.21 0.05
lcSSc 231 0.64 0.35 0.02 0.15 0.19 0.39
dcSSc 154 0.67 0.32 0.01 0.36 0.17 0.99
ACA 144 0.67 0.32 0.01 0.76 0.17 0.99
An,-­‐topo 146 0.67 0.33 0.01 0.79 0.17 0.99
Controls 362 0.66 0.33 0.00 0.17
France SSc 1014 0.66 0.31 0.03 0.25 0.19 0.22
lcSSc 639 0.67 0.30 0.03 0.65 0.18 0.58
dcSSc 315 0.61 0.35 0.03 0.35 0.21 0.02
ACA 372 0.66 0.32 0.02 0.15 0.18 0.63
An,-­‐topo 247 0.61 0.35 0.04 0.06 0.21 0.03
	   Controls 983 0.69 0.28 0.03 	   0.17 	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Supplementary Table 2: Overview of the genotype and allele frequencies of IL13 rs20541 
in the individual populations
IL13 rs20541 Phenotype n CC CT TT p MAF p
Netherlands SSc 143 0.64 0.30 0.06 0.91 0.21 0.79
lcSSc 98 0.69 0.29 0.03 0.61 0.17 0.34
dcSSc 33 0.64 0.27 0.08 0.7 0.22 0.63
ACA 84 0.64 0.32 0.04 0.71 0.20 0.99
Anti-topo 33 0.64 0.27 0.08 0.7 0.22 0.63
Controls 274 0.65 0.29 0.05 0.20
Spain SSc 231 0.64 0.29 0.06 0.95 0.21 0.75
lcSSc 157 0.68 0.29 0.04 0.38 0.18 0.21
dcSSc 56 0.64 0.29 0.08 0.96 0.22 0.99
ACA 89 0.63 0.29 0.07 0.93 0.22 0.99
Anti-topo N.A. N.A. N.A. N.A. N.A.
Controls 250 0.63 0.30 0.07 0.22
Italy SSc 444 0.66 0.30 0.04 0.72 0.19 0.61
lcSSc 231 0.66 0.30 0.04 0.75 0.19 0.71
dcSSc 154 0.65 0.30 0.05 0.99 0.20 0.99
ACA 144 0.67 0.30 0.03 0.48 0.18 0.54
Anti-topo 146 0.66 0.29 0.06 0.98 0.20 0.99
Controls 362 0.65 0.30 0.05 0.20
UK SSc 234 0.64 0.29 0.06 0.7 0.21 0.60
lcSSc 186 0.67 0.29 0.03 0.92 0.18 0.82
dcSSc 41 0.62 0.32 0.06 0.68 0.22 0.62
ACA 167 0.66 0.29 0.04 0.99 0.19 0.99
Anti-topo 34 0.64 0.29 0.06 0.9 0.21 0.73
Controls 98 0.66 0.30 0.04 0.19
Germany SSc 422 0.66 0.29 0.04 0.99 0.19 0.37
lcSSc 215 0.63 0.30 0.07 0.6 0.22 0.69
dcSSc 132 0.65 0.30 0.05 0.97 0.20 0.78
ACA 196 0.64 0.31 0.06 0.82 0.21 0.99
Anti-topo 109 0.66 0.29 0.04 0.98 0.19 0.55
Controls 266 0.24 0.11 0.02 0.21
France SSc 1000 0.66 0.30 0.04 0.082 0.19 0.61
lcSSc 633 0.67 0.29 0.04 0.079 0.19 0.88
dcSSc 307 0.64 0.33 0.04 0.412 0.20 0.36
ACA 366 0.68 0.29 0.03 0.45 0.18 0.70
Anti-topo 241 0.63 0.34 0.03 0.71 0.20 0.42
 Controls 996 0.65 0.32 0.03  0.19  
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Supplementary Table 3: Overview of the genotype and allele frequencies of IL13RA1 
rs6646259 in the individual populations (females only)
IL13RA1 rs6646259 n GG GA AA p MAF p
Netherlands SSc 116 0.56 0.35 0.08 0.09 0.26 0.15
lcSSc 79 0.56 0.35 0.08 0.12 0.26 0.22
dcSSc 27 0.58 0.34 0.08 0.53 0.25 0.59
ACA 68 0.59 0.35 0.05 0.59 0.23 0.63
Anti-topo 27 0.57 0.37 0.05 0.95 0.24 0.60
Controls 222 0.61 0.36 0.03 0.21
Spain SSc 187 0.57 0.36 0.07 0.54 0.25 0.31
lcSSc 127 0.58 0.36 0.06 0.75 0.24 0.57
dcSSc 45 0.58 0.33 0.08 0.49 0.25 0.49
ACA 72 0.60 0.35 0.06 0.93 0.23 0.82
Anti-topo N.A. N.A. N.A. N.A.
Controls 203 0.60 0.36 0.04 0.22
Italy SSc 360 0.58 0.37 0.06 0.68 0.24 0.69
lcSSc 187 0.60 0.36 0.04 0.9 0.22 0.75
dcSSc 125 0.56 0.38 0.06 0.78 0.25 0.59
ACA 117 0.57 0.39 0.03 0.93 0.23 0.99
Anti-topo 118 0.56 0.41 0.04 0.84 0.24 0.78
Controls 293 0.58 0.38 0.04 0.23
UK SSc 190 0.58 0.36 0.06 0.8 0.24 0.66
lcSSc 151 0.59 0.37 0.05 0.09 0.23 0.91
dcSSc 33 0.57 0.36 0.07 0.87 0.25 0.61
ACA 135 0.56 0.40 0.04 0.89 0.24 0.72
Anti-topo 28 0.61 0.33 0.07 0.73 0.23 0.85
Controls 79 0.60 0.37 0.04 0.22
Germany SSc 342 0.60 0.37 0.04 0.89 0.22 0.71
lcSSc 93 0.59 0.38 0.03 0.97 0.22 0.83
dcSSc 83 0.56 0.40 0.04 0.97 0.24 0.83
ACA 63 0.57 0.38 0.05 0.93 0.24 0.90
Anti-topo 41 0.56 0.42 0.02 0.88 0.23 0.89
Controls 215 0.58 0.39 0.04 0.23
France SSc 843 0.52 0.40 0.09 0.75 0.28 0.62
lcSSc 574 0.53 0.39 0.08 0.77 0.27 0.48
dcSSc 243 0.50 0.40 0.10 0.69 0.30 0.86
ACA 345 0.52 0.40 0.08 0.746 0.28 0.63
Anti-topo 200 0.47 0.44 0.10 0.537 0.31 0.39
 Controls 22 0.59 0.32 0.09  0.25  
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Supplementary Table 4: Overview of the genotype and allele frequencies of IL4 rs2243250 
in the individual populations
IL4 rs2243250 Phenotype n CC CT TT p MAF p
Netherlands SSc 143 0.74 0.24 0.02 0.67 0.14 0.48
lcSSc 98 0.73 0.24 0.03 0.96 0.15 0.73
dcSSc 33 0.75 0.21 0.03 0.89 0.14 0.72
ACA 84 0.72 0.24 0.04 0.99 0.16 0.99
Anti-topo 33 0.75 0.21 0.03 0.9 0.14 0.72
Controls 274 0.72 0.24 0.04 0.16
Spain SSc 231 0.71 0.25 0.05 0.82 0.17 0.66
lcSSc 157 0.72 0.24 0.04 0.98 0.16 0.99
dcSSc 56 0.75 0.21 0.03 0.87 0.14 0.77
ACA 89 0.72 0.24 0.04 0.91 0.16 0.99
Anti-topo N.A. N.A. N.A. N.A. N.A.
Controls 250 0.72 0.25 0.04 0.16
Italy SSc 444 0.71 0.26 0.03 0.87 0.16 0.99
lcSSc 231 0.73 0.23 0.05 0.83 0.16 0.99
dcSSc 154 0.72 0.26 0.02 0.6 0.15 0.71
ACA 144 0.72 0.24 0.04 0.96 0.16 0.99
Anti-topo 146 0.73 0.25 0.03 0.89 0.15 0.78
Controls 362 0.72 0.25 0.04 0.16
France SSc 1011 0.72 0.25 0.03 0.9 0.15 0.84
lcSSc 642 0.71 0.26 0.02 0.75 0.15 0.67
dcSSc 310 0.72 0.26 0.02 0.47 0.15 0.87
ACA 375 0.71 0.26 0.03 0.86 0.16 0.67
Anti-topo 243 0.73 0.26 0.01 0.38 0.14 0.59
 Controls 983 0.73 0.24 0.03  0.15  
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Supplementary Table 5: Overview of the genotype and allele frequencies of IL4R 
rs1801275 in the individual populations
IL4R	  rs1801275 Phenotype n GG GA AA p MAF p
Netherlands SSc 143 0.67 0.29 0.05 0.96 0.19 0.71
lcSSc 98 0.66 0.30 0.04 0.91 0.19 0.75
dcSSc 33 0.66 0.27 0.06 0.94 0.2 0.99
ACA 84 0.67 0.30 0.03 0.84 0.18 0.58
An,-­‐topo 33 0.66 0.27 0.06 0.93 0.2 0.99
Controls 274 0.65 0.30 0.05 0.2
Spain SSc 231 0.64 0.29 0.06 0.14 0.21 0.12
lcSSc 157 0.66 0.29 0.04 0.65 0.19 0.45
dcSSc 56 0.67 0.27 0.07 0.28 0.2 0.49
ACA 89 0.69 0.26 0.05 0.43 0.18 0.82
An,-­‐topo N.A. N.A. N.A. N.A. N.A.
Controls 250 0.69 0.29 0.03 0.17
Italy SSc 444 0.65 0.29 0.07 0.36 0.21 0.38
lcSSc 231 0.67 0.29 0.03 0.85 0.18 0.65
dcSSc 154 0.64 0.28 0.08 0.3 0.22 0.27
ACA 144 0.67 0.28 0.05 0.97 0.19 0.99
An,-­‐topo 146 0.65 0.27 0.07 0.36 0.21 0.54
Controls 362 0.66 0.29 0.04 0.19
France SSc 1001 0.66 0.29 0.04 0.94 0.19 0.87
lcSSc 639 0.66 0.30 0.03 0.51 0.19 0.91
dcSSc 304 0.67 0.27 0.06 0.63 0.19 0.87
ACA 368 0.65 0.31 0.04 0.77 0.20 0.58
An,-­‐topo 240 0.65 0.30 0.05 0.88 0.20 0.61
	   Controls 993 0.67 0.29 0.04 	   0.19 	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 Chapter 7
A rare polymorphism in Toll Like Receptor 2 is 
associated with systemic sclerosis phenotype 
and increases production of inflammatory 
mediators.
Broen JCA, Bossini-Castillo L, Van Bon L, Vonk MC,  Knaapen H, 
Beretta L, Rueda B, Hesselstrand R, Herrick A, Worthington J, 
Hunzelman N, Denton C, Fonseca C, Riemekasten G, Kiener H, 
Scorza PhD, Simeon CP, Ortego-Centeno N (for the Spanish 
Systemic Sclerosis group), Gonzalez-Gay MA, Airo’ P, Coenen MJH, 
Martin J and Radstake TRDJ
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Abstract
Aim: To investigate whether polymorphisms in toll like receptor (TLR) genes, 
previously reported to be associated with immune mediated diseases are 
implicated in systemic sclerosis (SSc).
Methods: We genotyped 14 polymorphisms in the TLR 2, 4, 7, 8 and 9 genes in a 
discovery cohort comprising 452 SSc patients and 537 controls and a replication 
cohort consisting of 1170 SSc patients and 925 controls. Furthermore we analyzed 
15 year follow-up data from 964 patients to assess the potential association of TLR 
variants with the development of disease complications. Next to this, we analyzed 
the functional impact of the associated polymorphism on monocyte derived 
dendritic cells. 
Results: Exploiting the discovery cohort, we observed that a rare functional 
polymorphism in TLR2 (Pro631His), was associated with anti-topoisomerase 
positivity (p =0.003 OR 2.24 95%CI:1.24-4.04). This observation was validated in 
the replication cohort (p=0.0001 OR 2.73 95%CI:1.85-4.04). In addition, the 
replication cohort also revealed an association between the TLR2 variant with the 
diffuse subform of the disease and the development of pulmonary arterial 
hypertension, respectively (p=0.02, Log-Rank p=0.003, Cox proportional hazards 
ratio: 5.61 ((95%CI 1.53-20.58)). Functional  analysis revealed that monocyte 
derived dendritic cells carrying the Pro63His variant produce more inflammatory 
mediators (TNFalpha and IL-6) upon TLR2 mediated stimulation (both p<0.0001).
Conclusion: The rare TLR2 Pro631His variant is robustly associated with anti-
topoisomerase positivity, diffuse SSc and the development of PAH. Besides, this 
variant influences TLR2 mediated cell responses. Further research is necessary to 
reveal the precise role of TLR2 in the disease pathogenesis of SSc. 
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Introduction
Systemic  sclerosis (SSc) bares all the hallmarks of an autoimmune disease, which 
features vasculopathy, immune activation and ultimately extensive fibrosis of skin 
and internal organs. Although the research in the field of SSc is intensified over the 
last years, there is still  no clear view on the pathogenesis or a cure (1). It is 
generally accepted that genetic  factors play a role in this disease, which is 
supported by the observation of both familial and ethnic aggregation and the 
numerous reports describing an association between genetic variants and SSc (2). 
The family of pattern recognition receptors (PRPs), and more specifically the family 
of Toll Like Receptors (TLRs) are among the most scrutinized molecules in 
immunity and autoimmunity. TLRs provide a first line pathogen recognition system 
and are able to direct the innate immune system towards the appropriate immune 
responses (3). Although the main purpose of these receptors is to identify microbial 
antigens and subsequently mount a proper response, growing evidence points 
towards their direct implication in various autoimmune diseases (4). 
The role for several  TLRs has been shown in SSc. For instance, monocyte-derived 
and myeloid dendritic  cells (DCs) from SSc patients display an augmented 
response to various TLR specifc ligands, some of which have been show to be 
present in serum of SSc  patients (5,6). In addition, subcutaneous administration of 
TLR ligands in an experimental model provokes a marked inflammation in the skin 
that partly resembles SSc skin changes (7). However, the extent of the role of the 
different TLR subsets in SSc has not been investigated intensely. Genetic studies 
are able to shed light on this latter aspect. Therefore we investigated 14 
polymorphisms covering the TLR 2, 4, 7, 8 and 9 genes, previously associated with 
immune mediated disease, for their role in SSc  susceptibility and corresponding 
clinical  phenotypes. The selection of these SNPs was founded on a Pubmed based 
search for TLR polymorphisms associated with immune-mediated disease, most 
preferably with functional impact on the protein or cell function level as well.
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Methods
Patients and Controls
We used a discovery cohort composed of 452 SSc patients and 537 healthy 
controls matched by geographical region, age and gender. This population was 
composed of three case-control  sets of European ancestry; a Spanish cohort: 188 
SSc patients and 193 controls; a Dutch cohort: 85 SSc patients and 255 controls; 
and an Italian cohort: 179 SSc patients and 89 controls. As a replication cohort we 
exploited a second cohort comprising 1170 SSc patients and 925 controls. This 
cohort consisted of a Swedish cohort: 193 SSc patients and 167 controls: a 
German cohort of 312 SSc patients and 247 controls; a second Italian cohort of 
158 patients and 231 controls: a second Dutch cohort of 238 SSc patients and 196 
controls and an English cohort consisting of 269 SSc patients and 84 controls. 
Both the allele frequencies of the controls originating from the United Kingdom and 
Dutch replication cohort were derived from literature reports (8,9).
All patients fulfilled the 1980 American College of Rheumatology (ACR) 
classification criteria for SSc (10). The local ethical  committee from each centre 
approved the study. Both patients and controls were included in the study after 
written informed consent. All  patients included in this study were classified as 
having limited cutaneous (lcSSc) or diffuse cutaneous SSc (dcSSc) using the 
criteria postulated by LeRoy (11). Autoantibody testing was performed using either 
ELISA or immunofluorescence microscopy. The presence of pulmonary fibrosis 
was investigated by a high-resolution computed tomography scan. Restrictive 
syndrome and diffusion capacity of the lungs was defined as a forced vital  capacity 
(FVC) < 70% of the predicted value and a diffusion capacity of the lung for carbon 
monoxide (DLCO) of less than 70% of predicted. Pulmonary artery hypertension 
was diagnosed by right heart catheterization and considered confirmed if the mean 
pulmonary artery pressure was greater than 25 mmHg at rest with a normal  left 
atrial wedge pressure. Furthermore, we used follow up data on FVC and DLCO 
decline, development of pulmonary fibrosis, kidney involvement and pulmonary 
arterial hypertension (PAH) development from 964 patients, starting at the date of 
onset of the first non-Raynauds symptom and ending at 15 years or death. The 
155
patients were evaluated at least yearly for these complications (supplementary 
table 1). 
Genotyping
We assessed 14 functional polymorphisms in the TLR2 ,4, 7, 8 and 9 genes for 
their role in SSc susceptibility and clinical  phenotype. Genotyping was performed 
using 5' nuclease (Taqman) assays with predesigned primers and probes (Applied 
Biosystems, Foster City, CA). The polymorphisms investigated and their functional 
properties and previous associations are displayed in table 1.
Table 1. Overview of tested TLR polymorphisms
SNP Gene
Func,onal	  
change
AB	  Assay	  ID
Previous	  (immune	  system	  related)	  
associa,on
References
rs1898830 TLR2 -­‐15607A>G C__11853988_10 Bronchioli6s	  Obliterans 20
rs5743704 TLR2 Pro631His C__25607736_10
IBD,	  impaired	  membrane	  internaliza6on,	  
acute	  reac6ve	  arthri6s
14,21,22
rs4986790 TLR4 896A>G	  (D299G) C__11722238_20 Asthma	  and	  atopy 23
rs4986791 TLR4 1196C>T	  p.T399I C__11722237_20 Liver	  cirrosis 23
rs7873784 TLR4 16649G>C C__29292008_10 Mul6ple	  sclerosis 25
rs3853839 TLR7 3'UTR C___2259573_10 SLE,	  increased	  expression 26
rs179008 TLR7 Gln11Leu C___2259574_10 Asthma 27
rs2302267 TLR7 C__15757400_10 Chronic	  HCV	  infec6on 28
rs5743781 TLR7 A448V C__25643238_10 Newly	  found	  variant 29
rs3764879 TLR8 TLR8-­‐129G>C C___2183829_10 Fatal	  crimean	  congo	  hemorrhagic	  fever 30
rs3764880 TLR8 Met1Val C___2183830_10 Isoform	  regula6ng,	  tuberculosis 31,32
rs5741883 TLR8 C__29409072_10 Rheumatoid	  factor	  posi6vity 33
rs5744088 TLR8 C__32184097_10
rs187084 TLR9 C___2301952_10 Graves'	  ophthalmopathy 34
Cell isolation, stimulation and expression analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized 
venous blood by using density-gradient centrifugation over Ficoll-Paque 
(Amersham Bioscience). Monocytes were obtained using CD14 and BDCA1 
microbeads (Miltenyi Biotec Inc, CA, USA) for monocytes and myeloid DCs, 
respectively. Generation of monocyte-derived DCs (moDCs) has been extensively 
described by our group previously (5).
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Flowcytometric analysis of CD14, CD86 and MHC expression on moDCs
Phenotypical analysis of moDCs was performed using standardized flow cytometry 
protocols as described previously (17). DCs were characterized by staining with 
mAbs against human CD14 (Miltenyi Biotec  Inc., Ca, USA), CD86 (BD Bioscience, 
NJ, USA), MHC-II DR/DP (clone Q1514). Cells were analyzed with a fluorescence-
activated cell sorter (FACSCalibur; BD Biosciences) and analyzed with FlowJo 
8.7.3, (Treestar, OR, USA) for the proportion of positive cells and the mean 
fluorescence intensity relative to cells stained with the relevant IgG isotype 
controls. 
Stimulation of moDC with TLR ligands
At day 6 of culture moDCs were re-plated in a concentration of 0.5x106 DCs/ml and 
either transferred to 24 well (1 ml) or 96 well (100 µl) culture plates. The culture 
medium consisted of RPMI-1640 Dutch modification (Invitrogen Life Technologies) 
supplemented with 10% FCS and antibiotic-antimycotic  (Invitrogen Life 
Technologies) in the presence of IL4 (500 U/ml; Schering-Plough) and GM-CSF 
(800 U/ml; Schering-Plough). Cells were then stimulated with TLR2 agonists for 24 
hours, after which supernatants were collected. The concentration of TLR2 ligand 
Pam3Cys (TLR2, 5 µg/ml, EMC microcollections, Germany) was similar throughout 
the studies. 
Measurement of cytokines
Levels of tumour necrosis factor alpha (TNFa) and Interleukin 6 (IL6) were 
measured in the supernatants using commercially available kits (Bio-Rad) 
according to the manufacturer’s instructions. Cytokine levels were measured and 
analyzed with the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine assay 
was < 5 pg/ml for all cytokines measured.
Statistical analysis.
Statistical  analyses were performed using 2x2 contingency tables and Fisher’s 
exact test by using SPSS 16.0. Homogeneity of OR among cohorts was calculated 
using Breslow-Day and Woolf Q methods and the calculation of the pooled OR was 
performed under a fixed-effects model  (Mantel-Haenszel meta-analysis). 
Candidate loci themselves were used to test for population stratification, as 
described previously (12). For stratification tests, when more SNPs were in linkage 
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disequilibrium (LD), the SNP/LD block with the highest χ2 test value, that is the 
SNP that the contributes most to differences across ethnicities, was chosen for the 
analysis. The TLR7 and 8 polymorphisms were analyzed in the female population 
only, since both genes are situated on the X chromosome. Power analysis showed 
that his study reaches a power of 80% or more to detect the effect of all included 
polymorphisms at an OR of 1.3 in a log additive model. Survival  analysis was 
performed using Kaplan-Meier curves and significance levels were calculated with 
Log Rank (Mantel-Cox) statistics. Cox Proportional Hazards Survival Regression 
was used to determine relative risks. Capped lines represent standard error of the 
mean throughout the manuscript. For the cellular experiments, values are shown 
throughout the paper as mean ± sem. Statistical  analyses were applied using 
Students t-test or Mann-Whitney U-test were appropriate. Differences were 
considered significant for *p<0.05, **p<0.01 and ***p<0.001. We did not apply 
correction for multiple testing in the discovery cohort, to avoid increasing the risk of 
false negative results not being profoundly investigated in the replication cohort. 
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Results
Discovery cohort
All the 14 investigated variants were in Hardy-Weinberg equilibrium and 
frequencies in the control  population were very similar to those reported in the 
HAPMAP project. No significant evidence of population stratification was present. 
We did not find any significant associations, except for the TLR2 Pro631His 
(rs5743704) polymorphism, which was significantly associated with having positive 
anti-topoisomerase autoantibody titers in both the Dutch and the Spanish discovery 
cohort (respectively p=0.01 OR: 4.45; 95%CI:1.36-12.54 and p=0.02 OR: 3.01 
95%CI:1.07-7.77). When we performed a meta-analysis we found a significant 
effect for all 3 populations together as well (p=0.003 OR: 2.24 95%CI:1.24-4.04) 
(table 2, supplementary Tables 2-14).
Table 2.  Distribution of the genotypes and alleles of the TLR2 variant (Pro631His) in the discovery 
cohort
cohort phenotype n CC CA AA p  A p
Italy SSC 165 0.95 0.05 0.00 0.51 0.97 0.6
LcSSc 116 0.94 0.06 0.00 0.51 0.97 0.79
DcSSc 40 0.98 0.03 0.00 0.57 0.99 0.44
ACA 60 0.97 0.03 0.00 0.56 0.98 0.32
Anti-Topo 74 0.93 0.07 0.00 0.99 0.97 0.99
Controls 88 0.93 0.06 0.01 0.96
The Netherlands SSC 82 0.89 0.11 0.00 0.35 0.95 0.52
LcSSc 63 0.89 0.11 0.00 0.41 0.94 0.63
DcSSc 18 0.94 0.06 0.00 0.91 0.97 0.99
ACA 23 0.96 0.04 0.00 0.82 0.98 0.71
Anti-Topo 20 0.70 0.30 0.00 0.01 0.85 0.01
Controls 249 0.93 0.07 0.00 0.96
Spain SSC 186 0.94 0.06 0.00 0.34 0.97 0.35
LcSSc 129 0.92 0.07 0.01 0.48 0.96 0.52
DcSSc 51 0.90 0.08 0.02 0.15 0.94 0.24
ACA 74 0.96 0.04 0.00 0.45 0.98 0.57
Anti-Topo 31 0.81 0.16 0.03 0.01 0.89 0.02
 Controls 181 0.92 0.07 0.01  0.95  
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cohort phenotype n CC CA AA p  A p
Mantel-Haenszel SSC 433 0.55
Meta-analysis LcSSc 308 0.68
DcSSc 109 0.22
ACA 157 0.21
Anti-Topo 125 0.003
Controls 518
Replication cohort.
Since the allele frequency of the associated polymorphism was relatively low 
(average 3%), we used a large replication set consisting of an additional 1170 SSc 
patients and 925 controls to validate the findings. This replication cohort was 
composed of an additional  Italian and Dutch population, but also from different 
ethnic  cohorts encompassing German, Swedish and British SSc patients and 
healthy controls. In this replication cohort we found an association with positive 
anti-topoisomerase autoantibodies and the TLR2 Pro631His variant in the Italian, 
German and Dutch population (respectively p=0.02 (OR: 3.15 95%CI:1.04-8.68), 
p=0.001 (OR: 3.72 95%CI:1.64-6.62), p=0.02 (OR:3.26 95%CI:1.07-8.93) (Table 
3). When we combined the results from the replication cohort in a meta-analysis we 
found a strong overall association (p=0.0001 OR: 2.73 95%CI:1.85-4.04). In 
addition, an association with the dcSSc subtype of the disease was observed, 
which fits the observation that anti-topoisomerase positivity is usually found in 
DcSSc (p=0.02 OR: 1.67 95%CI:1.08-2.58) (table 3). 
Table 3. Distribution of the TLR2 genotypes and alleles of the Pro631His variant in the replication 
cohort
cohort phenotype n CC CA AA A p
Italy SSc 158 0.94 0.06 0.00 0.03 0.99
LcSSc 97 0.95 0.05 0.00 0.03 0.99
DcSSc 44 0.89 0.11 0.00 0.06 0.15
ACA 88 0.95 0.05 0.00 0.03 0.79
Anti-Topo 39 0.85 0.13 0.03 0.09 0.02
Control 231 0.94 0.06 0.00 0.03
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cohort phenotype n CC CA AA A p
Sweden SSc 193 0.92 0.08 0.00 0.04 0.55
Limited 117 0.94 0.06 0.00 0.03 0.99
Diffuse 50 0.86 0.14 0.00 0.07 0.08
ACA 109 0.95 0.05 0.00 0.03 0.79
Anti-Topo 48 0.88 0.10 0.02 0.07 0.07
Control 167 0.94 0.06 0.00 0.03
Germany SSc 312 0.94 0.06 0.00 0.03 0.74
Limited 163 0.93 0.07 0.00 0.04 0.99
Diffuse 121 0.89 0.11 0.00 0.06 0.24
ACA 146 0.93 0.07 0.00 0.04 0.99
Anti-Topo 116 0.79 0.19 0.02 0.10 0.001
Control 247 0.93 0.07 0.00 0.04
The Netherlands SSc 238 0.97 0.03 0.00 0.02 0.05
Limited 66 0.95 0.05 0.00 0.03 0.58
Diffuse 31 0.88 0.12 0.00 0.06 0.31
ACA 61 0.95 0.05 0.00 0.03 0.58
Anti-Topo 29 0.86 0.14 0.00 0.11 0.02
Control 196 0.92 0.08 0.00 0.04
United Kingdom SSc 269 0.94 0.06 0.00 0.03 0.33
Limited 172 0.96 0.04 0.00 0.02 0.1
Diffuse 59 0.89 0.11 0.00 0.06 0.99
ACA 169 0.95 0.05 0.00 0.03 0.18
Anti-Topo 54 0.87 0.13 0.00 0.07 0.27
 Control 84 0.99 0.01 0.00 0.05
Mantel-Haenszel SSc 1170 0.22
meta-analysis Limited 615 0.24
Diffuse 305 0.02
ACA 573 0.19
Anti-Topo 286 0.0001
Control 925
When we combined both discovery and replication cohort we observed a strong 
association of the TLR2 Pro631His variant with anti-topoisomerase positive SSc 
(p<0.00001 OR: 2.55 95%CI:1.85-3.52) (figure 1). These results remained 
significant after Bonferroni correction for multiple testing.
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Figure 1. Combined effects of the TLR2 Pro631His variant on susceptibility for anti-topoisomerase 
positive SSc (anti-topo). Meta-analysis performed using allele frequencies.
The role of the TLR2 variant in SSc disease severity.
Since we were interested whether this functional polymorphism, which seemed to 
promote a pro-inflammatory environment could play a role in the severity of SSc, 
we used a follow-up cohort consisting of 964 SSc  patients, which were at least 
evaluated once a year for complication development. Patients were followed for 
either 15 years or the time till death, the follow-up period started at the onset of the 
first symptom after the development of Raynaud’s phenomenom. We evaluated the 
decrease of both FVC and DLCO below 75% of the percentage predicted, the 
development of pulmonary arterial hypertension measured by right heart 
catheterization, the development of pulmonary fibrosis by high resolution CT and 
the disease duration till  time of death. Although the TLR2 ligands did not influence 
patient survival, pulmonary fibrosis or kidney involvement, patients carrying this 
variant progressed to right heart catheterization proven PAH (total  PAH n=40) 
significantly sooner compared with those patients not carrying the risk allele (Log-
Rank p=0.003, Cox proportional hazards ratio: 5.61 (95%CI: 1.53-20.58)) (figure 
2). There was no significant effect of ATA titers on the development op PAH that 
otherwise might have biased the observed results.
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Figure 2.  Effect of  the TLR2 Pro631His variant on SSc complication development. No significant 
effects on death (A), development of either a deterioration of forced vital capacity (FVC) (C), diffusion 
capacity of the lung for carbon monoxide (DLCO) (D) below 70% of predicted or on the development of 
pulmonary fibrosis and kidney involvement (E and F) were observed. However, we found an association 
with the development of pulmonary arterial hypertension (Log-Rank p=0.003, Cox proportional hazards 
ratio: 5.61 ((95%CI: 1.53-20.58)) (B). Kaplan-Meier graphs were created for 964 patients for a period of 
15 years starting at the onset of the first non-Raynaud’s symptom.
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The TLR2 variant alters the level of cytokine response upon stimulation
Since this polymorphism has previously been shown to influence the expression 
and function of the TLR2 receptor with regard to antigen uptake, we were 
interested whether this polymorphism influenced the inflammatory response 
evoked by the TLR2 ligand Pam3Cys. For this purpose we isolated DCs from 12 
patients with and without the rare TLR2 allele and compared the response upon 
stimulation. After 24 hrs of stimulation, interestingly, we found that cells from 
patients carrying the TLR2 variant exhibited a marked increase in production of IL6 
(TNFa) upon stimulation with its ligand (both p<0.0001) (figure 3A). Myeloid DCs 
from patients revealed similar results as those observed in monocyte-derived DCs. 
(both p<0.0001) (figure 3B). No significant differences were present between the 
current two groups used considering gender, clinical phenotype or medication, 
controlling for a confounding effect.
Figure 3. Effects on expression of interleukin 6 (IL6) and tumor necrosis factor alpha (TNFa) in both 
carriers of the CC (n=9) and CA(n=3) genotypes after stimulation with medium or TLR2 agonist 
Pam3CSK4 in monocyte derived dendritic cells. The expression of both IL6 and TNFa is significantly 
increased in carriers of the CA variant (both p<0.0001).
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Discussion
Since accumulating evidence suggests a role for TLRs in SSc, we investigated 
whether genetic  variants in five different TLR genes influenced SSc susceptibility, 
severity and cellular function. After an initial study with 3 different ethnic cohorts we 
found that only one out of fourteen polymorphisms investigated was associated 
with SSc. More specifically, a rare variant in TLR2 was found to be associated with 
SSc patients being positive for anti-topoisomererase antibodies. This association 
was validated in a large replication cohort consisting of multiple European 
nationalities. Considering the size and power of the study it is unlikely that the 
observed effects are coming forth from a type 1 error. A recent genome wide 
association in SSc, investigated possible associations of tagSNPs with SSc and 
clinical  phenotypes. This study did not investigate possible associations with auto-
antibody profiles and did not include this SNP as a haplotype marker, explaining 
the absence of this SNP coming forth from this effort (13). 
The associated polymorphism, TLR2 Pro631His confers an amino acid change 
which has previously been functionally investigated. HEK cells transfected with the 
variant have slowed internal trafficking of TLR2 that not seems to follow 
conventional pathways. In addition carriers of the variant express more TLR2 
variant then wildtype TLR2 on their celmembrane (14). This could explain our 
observation that dendritic  cells patients carrying the variant displayed a more 
potentiated cytokine response. Although the numbers of donors carrying the minor 
variant are relatively small compared to the number of donors investigated that do 
not carry the variant, these results seem to be consistent across monocyte derived 
dendritic  cells and myeloid dendritic  cells. Moreover, the production of IL-6 and 
TNF-a shows little variation within the groups carrying or not carrying the minor 
TLR2 variant. Interestingly, anti-topo autoantibodies are able to bind to fibroblasts 
and subsequently attract monocytes in vitro (15). Anti-topo autoantibodies are 
present in the earliest stages of disease but also in healthy individuals (16,17). A 
hypothesis would be that anti-topo autoantibodies bind to fibroblasts and attract 
monocytes. When these monocytes carry the pro-inflammatory TLR2 variant, both 
fibroblasts and monocytes might be contributing to a more pronounced 
inflammatory response and subsequently to a higher risk to develop full-blown 
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disease. Interestingly, several  autologous TLR2 ligands can develop during tissue 
injury (18,19). In this light it is interesting to note that endothelial  cells were shown 
to express TLR2, which in the case of having the TLR2 rare variant, might result in 
an augmented inflammatory response upon stimulation contributing to 
development of PAH. However, these hypotheses remain to be further investigated.
In conclusion, we show that TLR2 is involved in SSc phenotype, which might be 
explained by its altered function upon binding of its ligands. Further research is 
justified to better determine the precise role of TLR2 in disease onset and or 
perpetuation. Since, neutralizing antibodies against multiple TLRs are about to 
enter the clinical  arena, more knowledge on the role of TLR2 in SSc may lead to a 
broadening of the therapeutic armamentarium for this severe condition. 
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Supplementary Table 1. The clinical characteristics of  the 6 SSc cohorts included in this 
study.
Population
The
Spain Germany Sweden Italy United KingdomNetherlands
Number 323 188 312 193 337 269
Age (years (SD)) 59 (15) 58 (13) 57(12) 53 (14) 55(13) 54 (12)
Disease duration (months 
(SD)) 137 (84) 144 (90) 113 (109) 82 (73) 140 (138) 155 (92)
Female % 79.0 81.8 88.4 76.9 82.3 81.2
Limited phenotype % 74.6 72.2 59.5 82.4 73.3 74.2
Positivity anti-topo % 23.2 26.8 26.7 16.9 32.9 12.4
Positivity ACA % 32.2 46.7 41.4 37.1 32.1 37.3
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Supplementary Table 2: Overview of  the genotype and allele frequencies of  TLR2 
rs1898830 in the individual populations.
cohort phenotype n  GG GA AA p G p
Italy SSc 170 0.16 0.35 0.48 0.95 0.34 0.87
lcSSc 121 0.15 0.35 0.50 0.96 0.32 0.79
dcSSc 44 0.18 0.36 0.45 0.85 0.36 0.62
ACA 64 0.19 0.34 0.47 0.79 0.36 0.59
Anti-Topo 79 0.13 0.33 0.54 0.73 0.29 0.36
Controls 88 0.16 0.36 0.48 0.34
The Netherlands SSc 82 0.07 0.41 0.52 0.75 0.27 0.79
lcSSc 62 0.13 0.40 0.47 0.61 0.33 0.36
dcSSc 18 0.17 0.39 0.44 0.54 0.36 0.34
ACA 57 0.12 0.39 0.49 0.79 0.32 0.55
Anti-Topo 21 0.05 0.38 0.57 0.94 0.24 0.59
Controls 252 0.09 0.38 0.52 0.28
Spain SSc 177 0.13 0.38 0.49 0.41 0.32 0.87
lcSSc 128 0.13 0.39 0.48 0.68 0.32 0.86
dcSSc 48 0.15 0.33 0.52 0.34 0.31 0.99
ACA 73 0.15 0.34 0.51 0.27 0.32 0.83
Anti-Topo 29 0.07 0.38 0.55 0.76 0.26 0.45
 Controls 179 0.09 0.44 0.47  0.31  
Mantel-Haenszel SSc 429 0.92
meta-analysis lcSSc 311 0.68
dcSSc 110 0.46
ACA 194 0.44
Anti-Topo 129 0.16
Controls 519
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Supplementary Table 3: Overview of  the genotype and allele frequencies of  TLR4 
rs7873784 in the individual populations
cohort phenotype n  CC CG GG p C p
Italy SSc 175 0.77 0.22 0.01 0.155 0.88 0.21
lcSSc 119 0.80 0.19 0.01 0.23 0.89 0.13
dcSSc 44 0.80 0.20 0.00 0.37 0.90 0.26
ACA 63 0.78 0.21 0.02 0.65 0.88 0.4
Anti-Topo 78 0.77 0.23 0.00 0.31 0.88 0.27
Controls 85 0.72 0.25 0.04 0.84
Netherlands SSc 81 0.68 0.27 0.05 0.39 0.81 0.21
lcSSc 63 0.67 0.29 0.05 0.41 0.81 0.21
dcSSc 17 0.71 0.24 0.06 0.71 0.82 0.61
ACA 23 0.57 0.39 0.04 0.14 0.76 0.09
Anti-Topo 19 0.84 0.16 0.00 0.6 0.92 0.34
Controls 239 0.74 0.23 0.03 0.86
Spain SSc 170 0.74 0.26 0.01 0.22 0.86 0.4
lcSSc 121 0.73 0.26 0.01 0.38 0.86 0.6
dcSSc 48 0.75 0.25 0.00 0.44 0.88 0.43
ACA 71 0.72 0.28 0.00 0.37 0.86 0.68
Anti-Topo 28 0.68 0.32 0.00 0.59 0.84 0.99
 Controls 184 0.71 0.26 0.03  0.86  
Mantel-Haenszel SSc 426 0.58
meta-analysis lcSSc 303 0.66
dcSSc 109 0.34
ACA 157 0.95
Anti-Topo 125 0.25
Controls 508
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Supplementary Table 4: Overview of  the genotype and allele frequencies of  TLR4 
rs4986791 in the individual populations
cohort phenotype n TT TC CC p T p
Italy SSc 169 0.00 0.13 0.87 0.075 0.07 0.08
lcSSc 114 0.00 0.12 0.88 0.077 0.06 0.09
dcSSc 43 0.00 0.19 0.81 0.013 0.09 0.03
ACA 62 0.00 0.18 0.82 0.025 0.09 0.03
Anti-Topo 74 0.00 0.08 0.92 0.52 0.04 0.53
Controls 82 0.00 0.05 0.95 0.02
Netherlands SSc 82 0.00 0.12 0.88 0.99 0.06 0.99
lcSSc 64 0.00 0.09 0.91 0.6 0.05 0.67
dcSSc 17 0.00 0.24 0.76 0.155 0.12 0.15
ACA 23 0.00 0.09 0.91 0.49 0.04 0.67
Anti-Topo 20 0.00 0.20 0.80 0.29 0.10 0.3
Controls 239 0.00 0.12 0.88 0.06
Spain SSc 179 0.01 0.09 0.90 0.86 0.05 0.73
lcSSc 128 0.00 0.09 0.91 0.93 0.05 0.99
dcSSc 50 0.02 0.10 0.88 0.15 0.07 0.31
ACA 74 0.00 0.09 0.91 0.55 0.05 0.93
Anti-Topo 29 0.03 0.03 0.93 0.08 0.05 0.99
 Controls 187 0.00 0.09 0.91  0.05  
Mantel-Haenszel SSc 430 0.21
meta-analysis lcSSc 306 0.61
dcSSc 110 0.01
ACA 159 0.26
Anti-Topo 123 0.32
Controls 508
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Supplementary Table 5: Overview of  the genotype and allele frequencies of  TLR4 
rs4986790 in the individual populations
cohort phenotype n  GG GA AA p G p
Italy SSc 172 0.00 0.07 0.93 0.149 0.03 0.16
lcSSc 120 0.00 0.12 0.88 0.26 0.06 0.36
dcSSc 43 0.00 0.21 0.79 0.02 0.10 0.04
ACA 86 0.00 0.07 0.93 0.09 0.03 0.12
Anti-Topo 77 0.00 0.09 0.91 0.77 0.05 0.78
Controls 87 0.00 0.13 0.87 0.07
Netherlands SSc 82 0.01 0.12 0.87 0.99 0.07 0.59
lcSSc 64 0.02 0.09 0.89 0.54 0.06 0.99
dcSSc 17 0.00 0.24 0.76 0.34 0.12 0.27
ACA 23 0.00 0.09 0.91 0.87 0.04 0.99
Anti-Topo 20 0.00 0.20 0.80 0.34 0.10 0.5
Controls 243 0.00 0.12 0.88 0.06
Spain SSc 181 0.01 0.10 0.90 0.79 0.06 0.61
lcSSc 129 0.00 0.10 0.90 0.77 0.05 0.85
dcSSc 51 0.02 0.10 0.88 0.16 0.07 0.44
ACA 73 0.00 0.10 0.90 0.9 0.05 0.99
Anti-Topo 31 0.03 0.06 0.90 0.12 0.06 0.52
 Controls 187 0.00 0.09 0.91  0.05  
Mantel-Haenszel SSc 435 0.67
meta-analysis lcSSc 313 0.45
dcSSc 111 0.02
ACA 182 0.51
Anti-Topo 128 0.32
Controls 517
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Supplementary Table 6: Overview of  the genotype and allele frequencies of  TLR7 
rs3853839 in the individual populations
cohort phenotype n  GG GC CC p G p
Italy SSc 142 0.04 0.31 0.65 0.84 0.19 0.61
lcSSc 97 0.04 0.36 0.60 0.79 0.22 0.99
dcSSc 35 0.05 0.20 0.75 0.4 0.15 0.26
ACA 51 0.05 0.39 0.56 0.7 0.24 0.59
Anti-Topo 63 0.04 0.28 0.68 0.71 0.18 0.44
Controls 69 0.06 0.31 0.63 0.22
Netherlands SSc 66 0.01 0.18 0.80 0.95 0.10 0.63
lcSSc 52 0.02 0.18 0.80 0.93 0.11 0.99
dcSSc 13 0.00 0.19 0.81 0.99 0.09 0.75
ACA 18 0.04 0.13 0.83 0.37 0.11 0.99
Anti-Topo 16 0.00 0.20 0.80 0.91 0.10 0.78
Controls 133 0.02 0.20 0.77 0.13
Spain SSc 140 0.09 0.24 0.67 0.87 0.21 0.84
lcSSc 98 0.09 0.21 0.70 0.94 0.20 0.65
dcSSc 41 0.06 0.31 0.63 0.38 0.22 0.99
ACA 55 0.10 0.14 0.75 0.45 0.17 0.41
Anti-Topo 25 0.10 0.26 0.65 0.94 0.23 0.85
 Controls 146 0.10 0.22 0.67  0.22  
Mantel-Haenszel SSc 347 0.46
meta-analysis lcSSc 247 0.71
dcSSc 89 0.35
ACA 125 0.63
Anti-Topo 104 0.46
Controls 348
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Supplementary Table 7: Overview of  the genotype and allele frequencies of  TLR7 
rs179008 in the individual populations (females only)
cohort phenotype n  TT  TA  AA p  T p
Italy SSc 139 0.03 0.25 0.71 0.89 0.16 0.58
lcSSc 95 0.03 0.27 0.71 0.78 0.16 0.55
dcSSc 34 0.05 0.21 0.74 0.75 0.15 0.56
ACA 50 0.02 0.34 0.65 0.6 0.19 0.99
Anti-Topo 63 0.05 0.20 0.75 0.77 0.15 0.51
Controls 68 0.05 0.27 0.68 0.18
Netherlands SSc 66 0.08 0.35 0.57 0.86 0.26 0.73
lcSSc 52 0.09 0.37 0.54 0.67 0.28 0.45
dcSSc 14 0.06 0.29 0.65 0.91 0.21 0.99
ACA 18 0.04 0.43 0.52 0.86 0.26 0.69
Anti-Topo 16 0.10 0.15 0.75 0.15 0.18 0.67
Controls 204 0.07 0.33 0.59 0.24
Spain SSc 142 0.06 0.29 0.66 0.98 0.20 0.92
lcSSc 102 0.07 0.31 0.62 0.7 0.22 0.43
dcSSc 40 0.02 0.24 0.74 0.72 0.14 0.33
ACA 58 0.04 0.32 0.64 0.96 0.20 0.99
Anti-Topo 23 0.03 0.31 0.66 0.99 0.19 0.99
 Controls 146 0.05 0.29 0.66  0.19  
Mantel-Haenszel SSc 348 0.99
meta-analysis lcSSc 249 0.48
dcSSc 88 0.19
ACA 126 0.84
Anti-Topo 102 0.4
Controls 418
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Supplementary Table 8: Overview of the genotype and allele frequencies of TLR7 
rs2302267 in the individual populations (females only)
cohort phenotype n  TT TG GG p T p
Italy SSc 139 0.84 0.16 0.01 0.8 0.92 0.72
lcSSc 94 0.83 0.16 0.01 0.99 0.91 0.87
dcSSc 35 0.84 0.16 0.00 0.27 0.92 0.99
ACA 50 0.87 0.11 0.02 0.51 0.93 0.83
Anti-Topo 63 0.80 0.20 0.00 0.6 0.90 0.57
Controls 70 0.82 0.18 0.00 0.91
Netherlands SSc 67 0.94 0.04 0.03 0.48 0.95 0.18
lcSSc 52 0.89 0.05 0.06 0.17 0.92 0.81
dcSSc 14 0.89 0.06 0.06 0.59 0.92 0.99
ACA 18 0.91 0.00 0.09 0.77 0.91 0.99
Anti-Topo 16 0.90 0.10 0.00 0.31 0.95 0.99
Controls 202 0.90 0.04 0.06 0.92
Spain SSc 141 0.93 0.06 0.01 0.22 0.96 0.05
lcSSc 101 0.94 0.06 0.01 0.43 0.96 0.08
dcSSc 39 0.92 0.08 0.00 0.51 0.96 0.32
ACA 56 0.94 0.06 0.00 0.43 0.97 0.1
Anti-Topo 24 0.90 0.07 0.03 0.86 0.93 0.99
 Controls 149 0.90 0.06 0.04  0.93  
Mantel-Haenszel SSc 347 0.09
meta-analysis lcSSc 247 0.55
dcSSc 89 0.49
ACA 124 0.19
Anti-Topo 103 0.78
Controls 421
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Supplementary Table 9: Overview of  the genotype and allele frequencies of  TLR7 
rs5743781 in the individual populations (females only)
cohort phenotype n  CC CT TT p C p
Italy SSc 138 0.00 0.01 0.99 0.99 0.00 0.99
lcSSc 94 0.00 0.01 0.99 0.83 0.00 0.99
dcSSc 34 0.00 0.00 1.00 0.48 0.00 0.99
ACA 89 0.00 0.01 0.99 0.4 0.00 0.99
Anti-Topo 63 0.00 0.01 0.99 0.99 0.01 0.99
Controls 70 0.00 0.01 0.99 0.01
Netherlands SSc 66 0.00 0.00 1.00 N.A. 0.00 N.A.
lcSSc 51 0.00 0.00 1.00 N.A. 0.00 N.A.
dcSSc 14 0.00 0.00 1.00 N.A. 0.00 N.A.
ACA 46 0.00 0.00 1.00 N.A. 0.00 N.A.
Anti-Topo 15 0.00 0.00 1.00 N.A. 0.00 N.A.
Controls 192 0.00 0.00 1.00 0.00
Spain SSc 149 0.01 0.02 0.98 0.86 0.01 0.99
lcSSc 102 0.00 0.02 0.98 0.71 0.01 0.71
dcSSc 41 0.00 0.04 0.96 0.52 0.02 0.99
ACA 58 0.00 0.00 1.00 0.45 0.00 0.33
Anti-Topo 25 0.00 0.03 0.97 0.99 0.02 0.99
 Controls 144 0.00 0.02 0.98  0.01  
Mantel-Haenszel SSc 353 0.88
meta-analysis lcSSc 248 0.73
dcSSc 89 0.78
ACA 194 0.24
Anti-Topo 103 0.78
Controls 406
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Supplementary Table 10: Overview of  the genotype and allele frequencies of  TLR8 
rs3764879 in the individual populations (females only)
cohort phenotype n CC CG GG p C p
Italy SSc 142 0.08 0.37 0.55 0.78 0.27 0.73
lcSSc 96 0.10 0.40 0.50 0.92 0.30 0.81
dcSSc 35 0.07 0.27 0.66 0.32 0.20 0.19
ACA 51 0.13 0.42 0.45 0.75 0.34 0.48
Anti-Topo 63 0.06 0.35 0.58 0.62 0.24 0.41
Controls 71 0.08 0.42 0.51 0.29
Netherlands SSc 67 0.06 0.29 0.65 0.75 0.20 0.7
lcSSc 52 0.05 0.26 0.69 0.96 0.18 0.89
dcSSc 14 0.12 0.41 0.47 0.06 0.32 0.08
ACA 18 0.04 0.17 0.78 0.45 0.13 0.65
Anti-Topo 16 0.05 0.25 0.70 0.79 0.18 0.99
Controls 198 0.04 0.29 0.67 0.18
Spain SSc 138 0.15 0.33 0.52 0.65 0.32 0.41
lcSSc 98 0.14 0.35 0.51 0.74 0.31 0.42
dcSSc 39 0.16 0.29 0.55 0.73 0.31 0.67
ACA 58 0.13 0.29 0.58 0.9 0.27 0.9
Anti-Topo 23 0.07 0.34 0.59 0.99 0.24 0.6
 Controls 146 0.12 0.33 0.55  0.28  
Mantel-Haenszel SSc 347 0.55
meta-analysis lcSSc 246 0.56
dcSSc 88 0.79
ACA 127 0.98
Anti-Topo 102 0.34
Controls 414
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Supplementary Table 11: Overview of the genotype and allele frequencies of TLR8 
rs3764880 in the individual populations (females only)
cohort phenotype n AA AG GG p A p
Italy SSc 141 0.09 0.36 0.55 0.99 0.27 0.99
lcSSc 96 0.10 0.40 0.50 0.82 0.30 0.46
dcSSc 35 0.07 0.27 0.66 0.68 0.20 0.39
ACA 51 0.13 0.42 0.45 0.53 0.34 0.25
Anti-Topo 62 0.06 0.35 0.59 0.89 0.24 0.78
Controls 67 0.08 0.36 0.56 0.26
Netherlands SSc 65 0.06 0.30 0.64 0.92 0.21 0.72
lcSSc 50 0.05 0.27 0.68 0.63 0.18 0.34
dcSSc 14 0.17 0.39 0.44 0.27 0.36 0.16
ACA 18 0.04 0.17 0.78 0.54 0.13 0.3
Anti-Topo 15 0.05 0.26 0.68 0.99 0.18 0.82
Controls 194 0.08 0.29 0.63 0.23
Spain SSc 138 0.17 0.30 0.53 0.91 0.32 0.99
lcSSc 101 0.15 0.33 0.52 0.7 0.31 0.92
dcSSc 37 0.20 0.24 0.57 0.91 0.32 0.99
ACA 58 0.12 0.25 0.63 0.42 0.25 0.19
Anti-Topo 22 0.11 0.29 0.61 0.61 0.25 0.39
 Controls 144 0.18 0.28 0.54  0.32  
Mantel-Haenszel SSc 344 0.87
meta-analysis lcSSc 247 0.88
dcSSc 86 0.94
ACA 128 0.41
Anti-Topo 100 0.3
Controls 406
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Supplementary Table 12: Overview of the genotype and allele frequencies of TLR8 
rs5741883 in the individual populations (females only)
cohort phenotype n TT TC CC p  T p
Italy SSc 141 0.09 0.29 0.62 0.76 0.24 0.38
lcSSc 96 0.07 0.28 0.66 0.96 0.20 0.89
dcSSc 35 0.14 0.30 0.57 0.41 0.28 0.16
ACA 51 0.05 0.27 0.69 0.82 0.18 0.87
Anti-Topo 63 0.10 0.34 0.56 0.4 0.27 0.15
Controls 70 0.07 0.25 0.68 0.20
Netherlands SSc 54 0.16 0.26 0.57 0.05 0.29 0.09
lcSSc 42 0.17 0.26 0.57 0.05 0.30 0.07
dcSSc 11 0.14 0.21 0.64 0.68 0.25 0.6
ACA 15 0.16 0.26 0.58 0.29 0.29 0.37
Anti-Topo 12 0.13 0.27 0.60 0.24 0.27 0.62
Controls 200 0.15 0.12 0.73 0.21
Spain SSc 142 0.08 0.30 0.62 0.99 0.23 0.99
lcSSc 102 0.08 0.31 0.61 0.99 0.23 0.99
dcSSc 39 0.08 0.29 0.63 0.99 0.22 0.99
ACA 57 0.10 0.32 0.58 0.79 0.26 0.52
Anti-Topo 23 0.10 0.24 0.66 0.94 0.22 0.99
 Controls 154 0.08 0.30 0.62  0.23  
Mantel-Haenszel SSc 337 0.18
meta-analysis lcSSc 240 0.3
dcSSc 86 0.3
ACA 123 0.49
Anti-Topo 98 0.27
Controls 424
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Supplementary Table 13: Overview of  the genotype and allele frequencies of  TLR8 
rs5744088 in the individual populations (females only)
cohort phenotype n GG GC CC p G p
Italy SSc 142 0.79 0.18 0.03 0.73 0.88 0.36
lcSSc 97 0.80 0.17 0.02 0.51 0.89 0.33
dcSSc 35 0.80 0.18 0.02 0.92 0.89 0.53
ACA 51 0.86 0.11 0.03 0.35 0.91 0.17
Anti-Topo 63 0.75 0.22 0.04 0.99 0.85 0.87
Controls 71 0.74 0.21 0.04 0.85
Netherlands SSc 66 0.70 0.19 0.11 0.59 0.80 0.36
lcSSc 51 0.73 0.16 0.11 0.43 0.81 0.66
dcSSc 14 0.67 0.22 0.11 0.46 0.78 0.6
ACA 18 0.70 0.26 0.04 0.83 0.83 0.99
Anti-Topo 16 0.75 0.15 0.10 0.48 0.83 0.81
Controls 206 0.74 0.19 0.07 0.83
Spain SSc 142 0.76 0.20 0.04 0.86 0.86 0.99
lcSSc 102 0.72 0.23 0.06 0.55 0.83 0.48
dcSSc 40 0.88 0.12 0.00 0.28 0.94 0.08
ACA 58 0.71 0.25 0.04 0.56 0.84 0.99
Anti-Topo 25 0.77 0.13 0.10 0.71 0.84 0.67
 Controls 150 0.78 0.17 0.05  0.86  
Mantel-Haenszel SSc 350 0.98
meta-analysis lcSSc 250 0.8
dcSSc 90 0.21
ACA 128 0.33
Anti-Topo 104 0.87
Controls 426
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Supplementary Table 14: Overview of  the genotype and allele frequencies of  TLR9 
rs187084 in the individual populations
cohort phenotype n CC CT TT p  C p
Italy SSc 176 0.18 0.47 0.35 0.48 0.42 0.45
lcSSc 120 0.18 0.53 0.30 0.93 0.44 0.76
dcSSc 44 0.18 0.39 0.43 0.17 0.38 0.24
ACA 65 0.20 0.46 0.34 0.61 0.43 0.73
Anti-Topo 77 0.18 0.45 0.36 0.45 0.41 0.44
Controls 87 0.18 0.54 0.28 0.45
Netherlands SSc 83 0.13 0.51 0.36 0.49 0.39 0.28
lcSSc 64 0.13 0.52 0.36 0.53 0.38 0.32
dcSSc 18 0.17 0.44 0.39 0.68 0.39 0.61
ACA 23 0.17 0.48 0.35 0.84 0.41 0.88
Anti-Topo 19 0.05 0.58 0.37 0.42 0.34 0.31
Controls 247 0.17 0.54 0.30 0.44
Spain SSc 183 0.19 0.45 0.36 0.89 0.42 0.65
lcSSc 129 0.16 0.45 0.40 0.66 0.38 0.41
dcSSc 50 0.22 0.42 0.36 0.89 0.43 0.82
ACA 73 0.18 0.42 0.40 0.86 0.39 0.62
Anti-Topo 31 0.19 0.45 0.35 0.99 0.42 0.99
 Controls 180 0.18 0.44 0.38  0.40  
Mantel-Haenszel SSc 442 0.18
meta-analysis lcSSc 313 0.18
dcSSc 112 0.48
ACA 161 0.52
Anti-Topo 127 0.33
Controls 514
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Abstract
Aim: To further elucidate the role of Pre-B-cell  colony-enhancing factor (PBEF) in 
systemic sclerosis (SSc) related pulmonary complications.
Methods: We measured PBEF serum expression levels in serum of patients with 
and without pulmonary complications by ELISA. Next, these levels were correlated 
with previously described functional polymorphisms genotyped using custom 
Taqman 5´allelic discrimination assays. Furthermore, the effect of these 
polymorphisms on development of pulmonary arterial hypertension (PAH) in time 
was assessed using a follow up cohort consisting of 964 SSc patients. Next, we 
were interested in the effect of these polymorphisms on SSc development in 
general and we genotyped DNA from 2737 SSc patients and 1913 matched 
healthy controls, both from 8 different ethnic populations. 
Results: PBEF levels were significantly higher in patients with PAH compared to 
patients without, and to patients with other pulmonary complications (P=0.02). Next 
we found that two polymorphisms in the promoter region of PBEF influence protein 
expression levels, having no minor alleles at both loci resulted in a significantly 
higher PBEF level in serum (p<0.001) Carrying of no minor variants at these loci 
was associated with less PAH development during 15 years of follow up compared 
to carriers of minor alleles (Log Rank p=0.02, HR 2.38, 95%CI: 1.2-5.3). 
Interestingly, the combined PBEF -1543CC -1001TT genotype, hence carrying no 
minor alleles, was found associated with SSc susceptibility (p=0.009 OR 1.20 (95% 
CI 1.05-1.37). 
Conclusion: Our data identify PBEF as a novel candidate gene that influences the 
development of PAH and SSc susceptibility.
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Introduction
Systemic  sclerosis (SSc) is a connective tissue disease in which patients suffer 
from extensive fibrosis of the skin and internal  organs. Furthermore, SSc is 
characterized by endothelial  cell damage and immune dysfunction (1). Among 
multiple other disease manifestations, the pulmonary complications are often 
regarded as the most severe and life threatening. Frequently encountered 
complications are pulmonary arterial hypertension (PAH), pulmonary fibrosis and 
decreasing forced vital  capacity (FVC) and diffusion capacity of the lungs for 
carbonmonoxide (DLCO). A recent microarray analysis of SSc patients with PAH 
identified Pre B-cell colony-enhancing factor (PBEF) as a potentially interesting 
molecule that was increasingly expressed in peripheral blood leucocytes of PAH 
positive patients (2). PBEF has been associated with pulmonary pathology 
numerous times. For instance, PBEF is able to mount the production of pro-
inflammatory cytokines such as IL1β, IL6, IL10 and TNFα by human monocytes 
and CXCL8 expression by pulmonary epithelial cells (3). This spectrum of 
mediators is increased in SSc patients (4). In addition, it is postulated that PBEF 
plays an important role in pulmonary homeostasis. PBEF is upregulated by 
mechanical stretch and induces pulmonary artery permeability (5-8). Genetic 
variants in PBEF have been found to mediate the extent of lung inflammation and 
survival in acute lung injury (7,9). 
Taken together, it is tempting to speculate that PBEF is involved in PAH 
development as observed in SSc. For this reason we were interested to validate 
the observation of increased PBEF levels in PAH and investigated two promoter 
polymorphisms able to alter PBEF expression levels for their contribution to in vivo 
PBEF levels, the development of PAH throughout time and SSc susceptibility 
overall.
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Methods
Patients and Controls
All included patients fulfilled the 1980 American College of Rheumatology (ACR) 
classification criteria for SSc (10). The local ethical  committee from each center 
approved the study. Both patients and controls were included in the study after 
written informed consent. All  patients included in this study were classified as 
having limited cutaneous (lcSSc) or diffuse cutaneous SSc (dcSSc) using the 
criteria postulated by LeRoy (11). Controls were derived from the same country and 
region as the patients were derived from. Controls have been extensively tested for 
population stratification on a genome wide basis previously (12, 13). The presence 
of pulmonary fibrosis was investigated by a high resolution computed tomography 
scan. Restrictive syndrome and diffusion capacity of the lungs was defined as a 
forced vital capacity (FVC) < 70% of the predicted value and a diffusion capacity of 
the lung for carbon monoxide (DLCO) of less than 70% of predicted. Pulmonary 
arterial hypertension was diagnosed by right heart catheterization and considered 
confirmed if the mean pulmonary artery pressure was greater than 25 mmHg at 
rest with a normal  wedge pressure (<15mmHg). For the measurement of PBEF in 
serum we included 40 Dutch SSc patients. Furthermore, we used follow up data on 
PAH development, FVC and DLCO decline, and development of pulmonary fibrosis 
from 964 Dutch, Swedish and Italian patients, starting at the date of onset of the 
first non-Raynauds symptom and ending at 15 years, the patients were evaluated 
at least once a year for these complications. The population used for genotyping of 
the two PBEF functional variants was composed of 2740 SSc patients and 1913 
healthy controls matched by geographical region, age and gender. Six case-control 
sets were of European ancestry; a Spanish cohort: 228 SSc patients and 265 
controls; a Dutch cohort: 203 SSc patients and 277 controls; a German cohort: 312 
SSc patients and 247 controls; a British cohort: 269 SSc patients and 39 controls: 
an Italian cohort 323 SSc patients and 89 controls; and 193 Swedish patients and 
167 controls. In addition, we included two distinct ethnic SSc cohorts resident in 
the USA in the PBEF -1001T>G and PBEF -1543C>T genotyping; 1047 Caucasian 
American SSc patients and 692 matched controls and 165 Hispanic  American  SSc 
patients and 137 matched controls (Table 1). 
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Table 1. The basic and clinical characteristics of the 8 SSc cohorts included in the genotyping.
 Phenotype
Population
Dutch Spanish German Swedish Italian UK
American 
white
American 
Hispanic
n 203 228 312 193 323 269 1047 165
Age (years, SD) 58 (13) 58 (13) 57(12) 53 (14) 55(13) 54 (12) - -
Disease 
duration 
(months,SD)
131 (82) 144 (90) 113 (109) 82 (73) 140 (138) 155 (92) - -
Female % 71.0 83.8 88.4 76.9 94.3 81.2 73.9 74.4
lcSSc % 78.5 70 54.5 82.4 72.3 74.2 60.8 41.1
ATA+ % 22.1 18.4 26.7 16.9 32.9 12.4 16,5 22
ACA+ % 26.2 46.7 41.4 28.3 32.1 37.3 29 7
Pulmonary 
fibrosis on CT 
scan %
32.3 30.7 37.2 46.2 32.1 43.2 - -
FVC (<70% 
predicted) %
26.1 29.1 18.5 21.1 15.3 30.1 - -
DLCO (<70% 
predicted)%
33 45.1 50.2 35.8 67.2 11.5 - -
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Protein Expression 
PBEF protein was detected using a human EIA kit (Phoenix pharmaceuticals, 
Burlingame, CA), according to the manufacturer’s instructions. Absorption was 
measured at 450 nm, and data were analyzed using Revelation version 4.22 
software (Dynex Technologies, Denkendorf, Germany). Since PBEF levels have 
been suggested to be influenced by obesity and gender, only female SSc patients 
included and the effect of body mass index (BMI) on PBEF expression levels was 
assessed by regression analysis (14,15). 
Genotyping
We assessed two functional polymorphisms in the PBEF promoter region for their 
role in SSc  susceptibility and clinical phenotype. Genotyping was performed using 
5' nuclease (Taqman) assays with custom primers and probes (Applied 
Biosystems, Foster City, CA). For PBEF -1001T>G (rs9770242) the forward primer 
sequence was 5'-ACGGGCCAAGCCTTTGA-3', reverse primer sequence was 5'-
CCAACTCGTTTCCCAGGATTTAAAG-3', and reporter sequence was 5'-TCAGTG/
TTCGCACCCTG-3'. Corresponding PBEF -1543C>T sequences were 5'-
G C A A A G A T C A T G G A A G T G G A A G G T A - 3 ' , 5 ' -
CCTCGTTGCTGAAAATAATTGTAAGTGT-3', and 5'-CACCAG/AGCACTCAC-3'.
Data analysis
Significance levels were calculated with 2x2 contingency tables and Fisher’s exact 
test by using SPSS 16.0. Homogeneity of OR among cohorts was calculated using 
Breslow-Day and Woolf Q methods and the calculation of the pooled OR was 
performed under a fixed-effects model (Mantel-Haenszel meta-analysis). For the 
power calculation in the pooled analysis of the SSc patients (n=2737), we 
considered a minor allele frequency of 0.23 for both variants. This study reaches a 
power of 80% to detect the effect of a polymorphism at an OR of 1.17 in a log 
additive model, and a power of 99% at an OR of 1.23. For analysis of quantitative 
traits the student’s t test was applied. Survival analysis was performed using 
Kaplan-Meier curves and significance levels were calculated with Log Rank 
(Mantel-Cox) statistics. Cox Proportional Hazards Survival Regression was used to 
determine relative risks. Combined effects were investigated by multivariate 
regression analyses. Multiple testing was not applied to the PBEF expression 
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analyses, since these represent only two separate, subsequent and planned 
comparisons, namely the validation of previously reported increased PBEF levels 
in PAH positive SSc  patients and validation of previously reported expression 
influencing polymorphisms. On the results of genotyping of the 8 separate cohorts 
we applied a Bonferroni correction with a threshold of 0.01, which was based on 
tests for allele (both polymorphisms), genotype (both polymorphisms) and the 
haplotype with no minor variants, totaling 0.05/5=0.01. It has to be noted that, this 
is somewhat too strict since these comparisons are not fully independent. Capped 
lines represent standard error of the mean throughout the figures in the 
manuscript. Linkage disequilibrium was assessed using Haploview V4.2 software.
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Results
Firstly, we investigated whether PBEF protein levels are indeed higher expressed 
in SSc patients with PAH, as postulated previously on the mRNA level  (2). When 
we compared the expression levels of PBEF in patients with (n=10) and without 
(n=30) PAH, we found a significant increase (P=0.02) of PBEF in those patients 
with PAH (mean 27.41 SEM 1.92) compared to no PAH (mean 20.26 SEM 0.65). 
Noteworthy, this population only included non-obese, female subjects, since being 
female and/or obese has been described as a factor influencing PBEF expression 
(12,13). We did not find any significant effect of having pulmonary fibrosis, a low 
FVC% or DLCO% predicted on PBEF expression (Figure 1a).
Secondly, we hypothesized that two polymorphisms, PBEF -1543C>T and PBEF 
-1001T>G, previously associated with pulmonary disease and able to influence 
PBEF expression, might be involved in the development of PAH as well. We 
therefore validated whether these polymorphisms really were able to affect 
expression levels in 39 SSc patients. Indeed, we found a significant effect of the 
PBEF -1001G allele on expression levels (p=0.02). A similar trend was observed 
for the minor variant of the PBEF -1543 variant, although this did not reach 
statistical significance. When overlooking the results we theorized that there might 
be an additive effect of the two minor variants on expression of PBEF. For this 
reason we compared PBEF expression between the patients that carried no or ≥ 1 
minor allele. The latter analysis revealed that PBEF was highest in those patients 
expressing no minor variants (p<0.001) (Figure 1b). To untangle the effect of the 
various identified factors with an impact on PBEF expression, we performed a 
multivariate regression analysis with the variants coming forward from the above 
mentioned univariate tests. This analysis showed that both PAH (p=0.018 
beta=0.35) and carrying minor variants (p=0.007 beta=-0.407 have their own 
independent significant effect on PBEF expression levels. The model is displayed 
in table 2. However, we did observe a significant correlation between PAH and 
carrying minor variants (Pearson correlation = -0.327 P=0.23).
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Table 2. Multivariate regression model for the effect of pulmonary arterial hypertension and minor 
variants on PBEF protein expression
 B Std. Error Beta t P
(Constant) 28.332 3.036 9.333 0
PAH 4.324 1.742 0.35 2.482 0.018
minor variants -4.716 1.633 -0.407 -2.888 0.007
These observations on the genetic  and functional  level propelled us to further 
investigate the role of functional variants in PBEF with special  emphasis on PAH 
development. When we compared the development of PAH (total  events n=40, 
population at risk is 964) between patients carrying no expression affecting variants 
(PBEF -1543CC and -1001TT genotype) and patients carrying one or two minor 
variants we found that patients with no variants had a lower frequency of PAH 
incidence compared to carriers of either the PBEF -1001G minor allele or the 
PBEF-1543T after 15 years. However only carriers of the PBEF -1001G were at 
higher risk for developing PAH (Log Rank P=0.02, HR 2.38, 95%CI: 1.2-5.3) 
(Figure 1c).
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Figure 1. A) PBEF is uniquely higher expressed in SSc patients with PAH (n=10) compared to patients 
without PAH (n=30) (P=0.02) B) Carriers of minor variants at PBEF-1001 express significantly less 
PBEF protein in their serum (P=0.02), when carrying no minor variants at PBEF promoter positions 
-1543 and -1001 PBEF expression was most notably attenuated (P<0.001) C) Kaplan-Meier curve 
showing a significant increase of PAH development during 15 years follow-up in the patients carrying 
one or more minor variants at the PBEF-1001 position compared to carriers of no minor alleles (Log 
Rank P=0.02, HR 2.38, 95%CI: 1.2-5.3). Carrying a minor allele at the PBEF -1543 position did not 
significantly influence susceptibility for PAH in time, although the total number of PAH cases is higher in 
this genetic subgroup as well. 
Next, we were interested whether these variants have an effect on SSc 
susceptibility overall. Hardy Weinberg Equilibrium was within proportions in all 
populations separately. Overall linkage disequilibrium (R2) between the two SNPs 
is 0.095 and was not significantly different between the populations. Based on the 
observation that patients with PAH more often carry no minor variants at the PBEF 
-1543 and -1001 promoter sites we were interested whether this combination could 
also influence SSc susceptibility overall. To analyze this, we compared the 
frequency of subjects being homozygous for the major alleles of both variants 
(PBEF -1543CC and -1001TT genotype) in SSc  patients and healthy controls. This 
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led to the observation that the lack of both minor alleles markedly increased the 
risk to develop SSc, in the Swedish (p=0.007 OR 1.94: (95%CI: 1.21-3.10)) and 
Italian (p=0.02 OR 1.94 (95%CI: 1.10-3.43) population. In a meta-analysis 
including all populations, we confirmed this association (p  =0.009 OR 1.20 (95% CI 
1.05-1.37) (Figure 2). After applying the Bonferroni correction (treshold p=0.01) 
this result remains significant. Altogether, variations in the promoter region of 
PBEF seem protective against developing SSc. 
Figure 2 Effects of the combined PBEF -1001TT and  -1543CC genotypes on SSc susceptibility.
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Discussion 
In this study we show that PBEF is higher expressed in SSc patients with PAH, the 
expression is influenced by two polymorphisms in the PBEF promoter region, and 
that these variants together play a role in the risk for developing SSc and PAH.
Although no study investigated the combined effects of PBEF -1001 and -1543 
variants on PBEF expression, there have been several interesting studies 
scrutinizing the variants separately. The two PBEF promoter variants investigated 
in this study have previously been associated with lower serum levels of PBEF. 
More specifically, patients with vascular disease, carrying minor variants at PBEF 
-1543 (annotated as PBEF -1535 in the referenced study), had significantly lower 
levels of PBEF in their plasma similar to the trend observed in our and other 
studies. Intriguingly, this study also shows that carriers of this minor variant have 
decreased levels of hs-CRP, interleukin 6 and TNF-α (16). Ineffective up regulation 
of these molecules due to low PBEF levels might be a partial  explanation why 
carrying minor variants is a protective feature for SSc  susceptibility, mainly by 
affecting its inflammatory component. On the other hand, this variant seemed to 
attenuate binding of an interleukin 1-beta induced, yet unidentified, 
transcriptionfactor to PBEF in pulmonary endothelial  cells (7). The PBEF -1001 
minor variant has been shown to reduce PBEF mRNA expression levels in visceral 
fat and plasma PBEF protein expression, which is in line with our findings as well, 
although it has to be noted that one study investigating the effect of this 
polymorphism in acute lung injury patients did not observe a significant effect of 
this polymorphism on PBEF protein levels (7, 17, 18). 
Whereas the combination of the PBEF -1543CC and PBEF -1001TT genotypes 
contributes to the risk of developing SSc, this particular combination of genotypes 
seems to be protective for the development of PAH after onset of SSc. These 
findings might reflect the pleiotrophic actions of the PBEF molecule. On one hand 
PBEF is able to influence vascular homeostasis, including permeability of the 
pulmonary arteries, on the other hand it is known as a strong pro-inflammatory 
protein (5-7). In regard to this study it translates into the finding that carriers of no 
variants are able to up regulate PBEF efficiently, these subjects would be more 
197
prone to the pro-inflammatory effects of PBEF but also more able to benefit from its 
pulmonary regulatory effects. PBEF has not previously been implicated in PAH 
pathogenesis and is not directly related to the few previously identified risk factors. 
Nevertheless, our finding is in line with a report describing higher DNA transcription 
levels of PBEF in leukocytes of SSc  patients with PAH (2). However, this 
hypothesis will need further substantiation in future functional experiments. 
Noteworthy, these polymorphisms have not been found in a recent genome wide 
association study in SSc, possibly attributable to the fact that no haplotype analysis 
was performed with the genome wide data yet and that these polymorphisms are 
not present as markers on the GWAS genotyping platform used. (13)
Several  studies have showed an association of PAH with different genetic  variants, 
but did not correct for disease duration (19, 20). This is a potential  bias since the 
longer disease is present the proportion of patients with PAH will  increase as well. 
In addition, these studies did not only include patients diagnosed with PAH on the 
basis of right heart catheterization, but also included those with PAH based on 
isolated DLCO<50% predicted and with unexplained dyspnoea. These criteria are 
prone to introduce bias, because they are not fully specific  for PAH. In this light, 
this is the first large study that implicates a functional polymorphism in the 
development of PAH in time using follow up data and robust diagnostic  methods for 
PAH evaluation. 
This study harbors some weaknesses as well. First, the relatively small sample 
size used for the PBEF expression analysis may under- or overestimate the results 
of this analysis. Second, the expression levels were only investigated in female 
patients, which are the vast majority of SSc  patients. This makes the results not 
automatically applicable to male SSc  patients. Although the results of the meta-
analysis survive Bonferroni correction, it seems that the Swedish and Italian cohort 
mostly produce the observed significant effect. For this purpose a large replication 
study in an independent cohort is of high interest. In addition, the present study 
lacks the direct biomechanical evidence necessary to understand the exact role of 
this protein in SSc and PAH.
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Taken together, here we identify the PBEF gene as a novel factor that is implicated 
in the development of SSc related PAH and influences the susceptibility for SSc as 
well. However, further research is warranted to identify the precise functional and 
mechanistic processes involved.
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Supplementary table 1.  Genotype and allele frequencies of  the PBEF 1001T>G 
polymorphism and Mantel-Haenzel analysis for combined effects
Cohort Phenotype n TT TG GG
P vs 
controls G
P vs 
controls
Italy SSc 323 0.58 0.35 0.07 0.78 0.24 0.70
lcSSc 213 0.58 0.36 0.06 0.85 0.24 0.65
dcSSc 84 0.66 0.27 0.07 0.41 0.21 0.71
control 89 0.59 0.36 0.05 0.22
Sweden SSc 193 0.61 0.36 0.03 0.55 0.21 0.39
lcSSc 117 0.6 0.33 0.07 0.88 0.23 0.90
dcSSc 50 0.57 0.43 0 0.19 0.21 0.54
control 167 0.58 0.36 0.06 0.24
Spain SSc 228 0.57 0.36 0.07 0.80 0.25 0.48
lcSSc 154 0.57 0.37 0.06 0.64 0.25 0.46
dcSSc 58 0.55 0.35 0.1 0.95 0.28 0.89
control 265 0.55 0.36 0.09 0.27
Germany SSc 312 0.56 0.36 0.08 0.20 0.27 0.08
lcSSc 163 0.51 0.37 0.12 0.01 0.31 0.01
dcSSc 121 0.62 0.33 0.05 0.91 0.21 0.71
control 247 0.6 0.35 0.05 0.22
United 
Kingdom SSc 269 0.55 0.37 0.08 0.74 0.27 0.44
lcSSc 172 0.54 0.37 0.09 0.81 0.27 0.51
dcSSc 59 0.57 0.36 0.07 0.65 0.25 0.34
control 39 0.48 0.41 0.11 0.31
The 
Netherlands SSc 201 0.59 0.36 0.05 0.47 0.23 0.94
lcSSc 129 0.6 0.33 0.07 0.99 0.23 0.92
dcSSc 49 0.53 0.45 0.02 0.13 0.24 0.73
control 277 0.61 0.32 0.07 0.23
Caucasian 
Americans SSc 1047 0.55 0.38 0.07 0.90 0.26 0.59
lcSSc 604 0.55 0.38 0.07 0.90 0.26 0.62
dcSSc 434 0.58 0.35 0.07 0.63 0.25 0.46
control 690 0.55 0.38 0.07 0.27
Hispanic 
Americans SSc 165 0.5 0.43 0.07 0.49 0.29 0.30
lcSSc 66 0.57 0.35 0.08 0.27 0.25 0.11
dcSSc 94 0.46 0.47 0.07 0.64 0.31 0.67
 control 136 0.46 0.43 0.11  0.33  
Total (Mantel-
Haenszel) SSc 2738 0.56 0.37 0.07 0.79 0.25 0.58
lcSSc 1618 0.56 0.37 0.08 0.76 0.26 0.94
dcSSc 949 0.57 0.36 0.06 0.31 0.24 0.21
control 1910 0.56 0.37 0.07 0.26
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Supplementary table 2. Genotype and allele frequencies of  the PBEF  1543 C>T 
polymorphism and Mantel-Haenzel analysis for combined effects
Population Phenotype n CC CT TT
P vs 
controls T
P vs 
controls
Italy SSc 321 0.64 0.3 0.06 0.03 0.21 0.09
lcSSc 213 0.66 0.27 0.07 0.01 0.2 0.07
dcSSc 82 0.57 0.4 0.03 0.39 0.21 0.23
control 89 0.5 0.45 0.05 0.27
Sweden SSc 192 0.53 0.39 0.08 0.15 0.27 0.18
lcSSc 118 0.57 0.34 0.09 0.20 0.26 0.39
dcSSc 50 0.54 0.39 0.07 0.32 0.27 0.38
control 165 0.57 0.4 0.03 0.23
Spain SSc 228 0.58 0.34 0.08 0.40 0.25 0.28
lcSSc 154 0.58 0.33 0.09 0.32 0.26 0.24
dcSSc 58 0.6 0.34 0.06 0.99 0.23 0.78
control 265 0.61 0.34 0.05 0.22
Germany SSc 310 0.6 0.35 0.05 0.82 0.23 0.55
lcSSc 163 0.62 0.33 0.05 0.62 0.21 0.33
dcSSc 121 0.56 0.38 0.06 0.95 0.25 0.74
control 247 0.58 0.36 0.06 0.24
United 
Kingdom SSc 267 0.62 0.33 0.05 0.33 0.22 0.20
lcSSc 171 0.63 0.33 0.04 0.33 0.21 0.28
dcSSc 58 0.6 0.32 0.08 0.32 0.25 0.14
control 39 0.73 0.22 0.05 0.16
The 
Netherlands SSc 203 0.6 0.35 0.05 0.30 0.23 0.12
lcSSc 130 0.56 0.39 0.05 0.50 0.24 0.33
dcSSc 50 0.63 0.31 0.06 0.55 0.22 0.29
control 277 0.53 0.39 0.08 0.27
Caucasian 
Americans SSc 1046 0.59 0.36 0.05 0.51 0.22 0.35
lcSSc 603 0.59 0.36 0.05 0.74 0.23 0.50
dcSSc 433 0.59 0.37 0.04 0.33 0.22 0.46
control 690 0.58 0.36 0.06 0.24
Hispanic 
Americans SSc 164 0.71 0.27 0.02 0.91 0.16 0.67
lcSSc 66 0.70 0.28 0.02 0.70 0.16 0.73
dcSSc 93 0.72 0.25 0.03 0.89 0.16 0.77
 control 137 0.73 0.25 0.02  0.15  
Total 
(Mantel-
Haenszel)
SSc 2731 0.60 0.34 0.05 0.52 0.23 0.37
lcSSc 1618 0.61 0.34 0.06 0.59 0.23 0.50
dcSSc 945 0.60 0.36 0.05 0.63 0.22 0.50
control 1909 0.59 0.36 0.06 0.23
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Identification of a functional epistatic 3-locus 
model that is associated with Systemic 
Sclerosis
Beretta L*, Broen JCA*, van Bon L,  Cossu M, Rueda B, Simeón CP, 
Vicente E, Castellvi I, Spanish Systemic Sclerosis group, Coenen 
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Abstract
Objective: To investigate whether epistatic  interactions of immunity modulating 
genes influence the susceptibility to Systemic Sclerosis (SSc) and clinical 
phenotypes
Methods: Five-hundred-eighty-eight systemic sclerosis patients and 580 ethnically 
matched healthy controls recruited from 3 cohorts (Italy, Netherlands, Spain) were 
genotyped for 19 single nucleotide polymorphisms (SNPs) in 9 immunity mediating 
genes. Single-locus and gene-gene interaction analysis were conducted via the 
chi-square test and via the multifactor dimensionality reduction method. Functional 
experiments were then conducted on peripheral blood mononuclear cells (PBMCs) 
isolated from healthy individuals. Quantitative real-time polymerase-chain-reaction 
(RT-PCR) was used to asses specific mRNA levels after stimulation with specific 
agonists, according to the epidemiological results. 
Results: None of the studied SNPs was statistically associated with SSc  or SSc 
subsets. A 3-factor epistatic  model involving the rs187084 SNP in the toll-like 
receptor 9 (TLR9) gene, the rs1800587 SNP in the interleukin 1-α (IL-1α) gene and 
the rs9770242 SNP in the pre-B cell-enhancing factor (PBEF) gene was 
significantly associated with the occurrence of the diffuse cutaneous subset 
(dcSSc) (p<0.05 after 100-fold permutation testing and Bonferroni adjustment). In 
functional  experiments, PBMCs incubated with 10 ng/mL IL-1α and with 4 µg/mL 
CpG-DNA (a TLR agonist), but not with any of the single agents alone, markedly 
over-expressed PBEF mRNA, thus demonstrating the functional interlink among 
these genes. 
Conclusion: The epidemiological  as well  as the functional results we provide may 
help to explain the complex genetic architecture of SSc and to unveil its subtle 
pathogenesis. 
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Introduction
Systemic  sclerosis (SSc) is a complex autoimmune disease characterized by 
fibrosis of the skin, widespread vasculopathy and involvement of internal organs. 
The pathogenesis of SSc  involves the interplay between inflammation and immune 
system activation, endothelial dysfunction and overt fibrosis (1). Common 
polymorphisms in immune regulatory genes have been identified which influence 
the susceptibility to SSc and its clinical  phenotypes consistently throughout 
different populations (2-9). However, other associations were not validated (10-18) 
or showed inconsistent results (19-26). The inability to replicate an initial 
association may stem from different reasons including study design, population 
stratification or phenotype definition (27, 28). As recently suggested, when main 
effects fail  to replicate, gene-gene interaction (epistasis) should also be considered 
as a potential  source of variance (29). Considerable evidence has been published 
demonstrating the importance of epistasis in complex human diseases, which is 
considered to be an ubiquitous and fundamental component of the genetic 
architecture of common diseases (30).
From a statistical point of view, the study of epistasis is challenging and hindered 
by several computational limitations, including the problem of the sparseness of 
data into the multidimensional space (31), the loss of power when adjusting for 
multiple testing to decrease type I error (32, 33) and the loss of power in presence 
of multicollinearity (34). To circumvent these issues several methods have been 
developed and/or applied to detect gene-gene or gene-environment interactions in 
genetic-association studies (http://www.epistasis-list.org). Each of these 
computational approaches has its own strengths and weaknesses, however, 
regardless of the method, it is well recognized that it is difficult to make biological 
inferences from statistical models of epistasis (34). Indeed, high- and low-risk 
assignments that result either from generative (e.g. conventional statistic) or 
discriminative (e.g. data-mining) modeling usually do not show a clear trend and 
distribution across the multidimensional space and are not-easily interpretable. A 
solution to this problem has been proposed by Moore and co-workers (35); here, 
information theory measures were used to gauge the relative contribution of 
epistatic  attributes to statistical  models of gene-gene interaction and graphical 
models (36) were used to quickly identify additive and non-additive interaction 
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effects. Nonetheless, to which extent these graphical and mathematical models 
would fit the biological process of epistasis at the cellular or organism level is 
presently unknown. As a consequence, high-order epistatic  models described in 
the literature so far, do merely report an association between high-risk multilocus 
combinations and diseases without validating their findings in in vitro or in vivo. In 
the present work we show that in a candidate-gene case-control  association study 
conducted in a large population of SSc patients, gene-gene interaction may be 
more informative than single-locus analysis, providing, at one time functional 
evidence for the epistatic model we describe.
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Methods
Patients and Controls
Five-hundred-fifty-eight SSc  patients recruited from 3 cohorts (Italy: 207; 
Netherlands: 145; Spain: 236 patients) and 580 healthy ethnically and 
geographically-matched controls were considered. All  the patients fulfilled the 
American College of Rheumatology 1980 classification criteria for the classification 
of SSc (37) and were classified as having the limited cutaneous (lcSSc) or the 
diffuse cutaneous (dcSSc) subset, according to LeRoy et al (38) and the patients’ 
autoantibody profile was determined by reviewing the patients’ medical records. 
Disease onset was defined on the basis of the patient’s recall  of the first non-
Raynaud feature clearly attributable to SSc (39)
The study was approved by the local ethics committees and both patients and 
controls provided written informed consent for the research.
Genotyping 
Nineteen single-nucleotide polymorphisms (SNPs) in 9 immunomodulatory genes 
were genotyped both in patients and controls via the TaqMan SNP genotyping 
assays (Applied Biosystems): toll-like receptor (TLR) 2, rs1898830 and rs5743704; 
TLR4, rs4986790, rs4986791 and, rs7873784; TLR9, rs187084; pre-B cell-
enhancing factor (PBEF), rs9770242 and -1543 C>T; interleukin (IL) 1α, 
rs2856838, rs1800587, rs3783557 and rs3783525; CD69, rs17806015, rs6416258, 
rs11052877 and rs12368445; adenosine monophosphate deaminase-1 (AMPD1) 
rs17602729; IL4 rs2243250; IL13 rs20541. Primers for the studied SNPs are 
available upon request to the authors.
Statistical analysis
The distribution of genotypes was tested for Hardy-Weinberg equilibrium with the 
goodness-of-fit χ2 test. Missing genotypes were imputed via the k-nearest neighbor 
method (40) using the Orange data-mining suite (available at: http://www.ailab.si/
orange/), whenever less than 20% of genotypes was available, subjects were 
excluded. Single SNP association analysis performed using the χ2 test or the 
Fischer’s exact test (when the expected cell  count was below 5); results were 
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declared significant at the 0.05 threshold after Bonferroni  adjustment fro multiple 
comparisons. To assess the combined effect of the studied SNPs in all populations, 
we also performed a meta-analysis using Mantel-Haenszel statistics with fixed 
effects, checking that the percentage of total variation across studies that is due to 
heterogeneity (I2) was below 50% (41). Gene-gene interaction analysis was 
performed using the multifactor dimensionality reduction (MDR) algorithm (42, 43) 
(available at: http://www.epistasis.org). The MDR algorithm was optimized with a 
“scaling” approach (sMDR) incorporating LD as described in the Supplementary 
Notes. Three-thousand synthetic datasets and 24000 runs of the algorithm were 
used to determine the specific  sMDR power (after 100-fold permutation testing and 
Bonferroni adjustment). For gene-gene interaction analysis all the three available 
populations were pooled together to increase the power to detect epistasis (44). 
Before pooling, we verified that the marginal  distribution of the genetic  variants did 
not differ across ethnicities, which makes biases unlikely (45). We further discarded 
the existence of stratification by applying the methodology described by Pritchard 
and Rosenberg (46); in this case, only the candidate loci themselves were used in 
the test for stratification. Finally, when more SNPs were in linkage disequilibrium 
(LD), the SNP/LD block with the highest χ2 test value, that is the SNP that 
contributed most to differences across ethnicities, was chosen for the stratification 
tests. 
Functional study, cell cultures. 
To provide an interpretation of gene-gene interactions models we used measures 
of interaction theory and interactions graphs to visualize the nature of the 
dependencies of the attributes included in the best epistatic model. All these 
features are implemented in the MDR package. Graphical models were then 
interpreted in relation to the current knowledge about the involved genes and 
functional  experiments conducted accordingly (see results). Experiments were 
conducted on peripheral blood mononuclear cells (PBMCs) isolated by Ficoll-
Hystopaque density gradient centrifugation from 6 healthy individuals. Cells were 
incubated for 12 hours with 10 ng/mL IL-1α for 24 hours or with 4 µg/mL CpG-DNA, 
a specific TLR9 agonists (47). In parallel, PBMCs were pre-stimulated with 10 ng/
ml IL-1α for 12 hours after which PBMCs were co-cultured with 4 µg/mL CpG-DNA 
for another 12 hrs. In all these experiments PBEF mRNA expression was 
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measured using real-time polymerase-chain reaction (RT-PCR). Delta CT  between 
GAPDH and PBEF of the stimulated cells were compared with the dCT  of the 
unstimulated cells.  All the experiments were conducted in triplicate.
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Results
Clincal  and demographic  characteristics of the three SSc cohorts are reported in 
Table 1. After genotyping, imputation and exclusion of instances with low call rate, 
the dataset was reduced to 437 SSc patients and 506 controls. In this set, single 
SNP association analysis revealed no significant association with SSc or SSc 
subsets in the three separate populations. Similarly, meta-analysis revealed no 
significant association with any of the studied SNP.
 Table 1. Demographics
Variable Netherlands (n=145) Spain (n=236) Italy (n=207)
Age (years, SD) 54 (12) 55 (14) 53(11)
Disease duration (months,SD) 131 (85) 141 (92) 148 (132)
Females (%) 72.3 87.6 90.0
lcSSc (%) 75.2 72.6 73.4
Positivity anti-topo (%) 23.9 21,8 43.8
Positivity ACA (%) 26.1 55.5 36.3
In absence of detectable main genetic effects, we performed gene-gene interaction 
analysis. In the pooled population, gene-gene interaction analysis yielded no 
statistically significant results when comparing SSc with controls or lcSSc with 
controls. On the contrary, a 3-factor model involving the TLR9 rs187084, IL-1α 
rs1800587 and the PBEF rs9770242 SNP resulted to be predictive of dcSSc at a 
significance level  of 0.025 after 100-fold permutation testing. The epistatic model 
involving these SNPs had a sensitivity = 0.584 and a specificity = 0.609 to predict 
dcSSc occurrence in our sample population. 
To better gauge the contribution of the abovementioned epistatic attributes, as well 
as the magnitude of their interacting effects on the dcSSc  status, graphical 
representations based on information theory, as implemented in the MDR package, 
were performed. There, we observed that, the rs9770242 (PBEF) SNP had the 
highest degree of individual  effect on dcSSc  susceptibility, however the highest 
amount of information (e.g. the highest synergy) is obtained joining the rs187084 
(TLR9) to the rs1800587 (IL-1α), genetic  variant (Figure 1). When indeed TLR9 
and IL-1α are interleaved together (35) they provide redundant information with 
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that provided by the PBEF gene. Accordingly, we postulated that PBEF would be 
the main contributing factor to dcSSc occurrence and that IL-1α would modify/
modulate TLR9 signaling to produce PBEF responses. 
Figure 1  - Interaction graph for the best epistatic model. The interaction model describes the percent 
of the entropy that is explained by each factor or two-way interaction. The percentage in the node 
expresses the amount of label’s uncertainty eliminated by the node’s attribute and the connection the 
relative mutual information, a red or orange line suggests a positive information gain which can be 
interpreted as a synergistic or nonadditive relationship while a blue line suggests a loss of information 
which can be interpreted as redundancy or correlation. The maximum information gain is observed 
between the rs187084 (toll-like receptor 9) and the rs1800587 (interleukin-1α) single nucleotide 
polymorphisms.
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Functional experiments were driven according to the abovementioned model and, 
namely, to test the biological effect of TLR9/IL-1α interaction on PBEF. Here, we 
observed that the incubation with IL-1α or CpG-DNA alone did not lead to a 
significantly  increased PBEF expression in PBMCs from healthy individuals. In 
contrast, pre-stimulation with IL-1α and consecutive CpG-DNA-mediated 
stimulation led to a significant increase of PBEF expression compared to PBMCs 
that were either not stimulated or stimulated with IL-1α or CpG-DNA alone (p< 
0.03, Figure 2). 
Figure 2 - Interaction effect between IL-1α and TLR9 in PBMCs. Fold-increase of pro-B cell-enhancing 
factor (PBEF) mRNA expression upon stimulation with either intereukin-1 alpha (IL-1α), toll-like receptor 
9 (TLR9) agonist CpG-DNA or prestimulation with IL-1α and subsequent TLR9 stimulation in peripheral 
blood mononuclear cells (PBMCs). Comparing dCT values, we observed a significant increase in PBEF 
mRNA production by PBMCs upon a prestimulation with IL-1α and subsequent TLR9 stimulation, 
compared to the unstimulated PBMCs and PBMCs stimulated with IL-1α alone  (p=0.03) in 8 healthy 
controls.   
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Discussion
Susceptibility to SSc as well as to other complex human diseases does result form 
the interplay between several genetic and environmental  factors. Whilst a number 
of single-locus case-controls studies (2-9) as well as a recent genome-wide 
association study from our collaborative group (48) have been very successful  in 
identifying a handful of specific genetic variants that underly the susceptibility to 
SSc, it is disappointing that still only a small  proportion of its heritability has been 
accounted for. It is  likely that  the ‘missing heritability’ of complex human diseases 
may be in part explained by epistasis (30, 49, 50). Evidence for such interactions 
has emerged, for instance, from reworking data from the Wellcome Trust Case–
Control Consortium data sets (51) but are still lacking in other autoimmune 
disease, such as SSc.
The present study is the first successful attempt to fully demonstrate both 
epidemiologically and functionally, the existence of a genetic  biological network in 
SSc and in multifactorial human diseases. The network we describe is “bi-
compartmental”, in the sense that we could sort out one main factor (PBEF) that 
interacts with a two-gene complex (IL-1α/TLR9). With stimulation experiments in 
PBMCs we indeed confirmed that co-stimulation with IL-1α and TLR9 agonist is 
capable of modulating PBEF mRNA expression. The precise mechanism of the 
IL-1α/TLR9 interaction is presently unknown. Since CpG-DNA alone is not 
sufficient to boost IL-1α gene expression (52), we speculate that this interaction 
acts downstream of TLR/IL-1 receptors following specific  ligand activation. Whether 
the net result of this interaction is a qualitative or a quantitative modification of the 
interleukin-1 receptor associated kinase (IRAK)-pathway and/or of the MyD88 
signaling that characterize TLR9 responses (53), needs to be verified in further 
experiments. 
Several  lines of evidence suggest that PBEF may be relevant in SSc  susceptibility 
and phenotypical expression. PBEF has a longevity promoting effect on smooth 
muscle cells, fibroblasts and neutrophils (54). Next to this, PBEF in combination 
with SIRT1 is able to up regulate fibroblast growth factor 2 (FGF2) (55), a mediator 
that is found to be abundantly expressed in SSc  skin and, together with TGF-β, 
strongly promotes fibrosis (56). The production of IL6, IL10 and TNFα, that are 
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found to be increased in SSc (57), can be mounted through PBEF as well (58). 
Additionally, PBEF may contribute to the deregulation of metalloproteinases (59), a 
well-known phenomenon that contributes to skin fibrosis in SSc, especially in those 
patients with the most extensive cutaneous involvement (60). Finally, PBEF may 
consistently alter endothelial  function and vascular homeostasis (61), two 
pathophysiological processes that play a relevant role in the early stages of fibrosis 
development (1). Taken together, an enhancement of PBEF expression through the 
TLR9 and IL-1α interaction could impel  the inflammation, matrix remodelling and 
subsequent fibrosis as observed in dcSSc. 
In summary, in the present work we identified a unique epistatic  three locus 
interaction model comprising IL-1α, TLR9 and PBEF that is associated with an 
increased susceptibility to dcSSc. We then constructed a theoretical  model to 
biologically explain the epidemiological correlate of this interaction and verified the 
model in vitro. Accordingly, we described a novel  interaction between IL-1α and 
TLR9 that promotes PBEF gene expression. To our knowledge, this is the first time 
that a statistical model  of gene-gene interaction is shown to be biologically 
functional  in any human disease. The results we provide may help to unveil the 
complex genetic architecture and pathogenesis of SSc, and highlight new 
biological pathways playing a role in the pathogenesis of SSc.
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Supplementary notes 1
A scaling approach to multifactor dimensionality reduction (MDR) analysis and 
power analysis.
The multifactor dimensionality algorithm is by far the most popular method used to 
detect epistasis in candidate-genes case-controls studies (http://www.epistasis-
list.org). In the version proposed by the developers, k-fold cross-validation (where k 
is usually equal to 5 or 10) is used to sort out the causative genetic variants that 
epistatically interact within a given dataset (Ritchie et al, 2001). The causative 
variants are those that maximize the balanced accuracy (BA) function (e.g. the 
mathematical mean of sensitivity and specificity) in the k training sets. To properly 
select the interacting model, to reduce overfitting and to estimate its capability of 
generalization, BA values in the k testing sets are then calculated. The statistical 
significance of the testing BA values can eventually be computed by the use of 
resampling techniques, such as permutation testing (Moore et al, 2006; Greene et 
al, 2009). The combination of cross-validation and permutation testing ensures a 
reasonable power of the method and minimizes type I errors.
Running MDR in any dataset and tracking the top list of models in a given 
dimension (a function embedded in the last available version of the software), it is 
clear that models that do not rank first may have higher testing BA values than the 
topmost model. Similarly, in synthetic datasets, it may happen that the causative 
loci  are not those with the highest mean training BA values. The inclusion of these 
model in the analysis could thus theoretically improve the discriminative ability of 
MDR. Nonetheless, if these model  were considered by the user, the background 
noise would be amplified and the threshold for significance should be corrected for 
the higher number of tests and become more conservative. The price paid to 
maintain stable the type I error would be a loss of power. Nevertheless, our 
working hypothesis is that the inclusion of additional  models into the analysis would 
help to wade through the noise and dampen the negative effect of the increasing 
number of tests.
To proof our point we developed a modified version of the MDR algorithm, 
henceforth labelled as scaling MDR (sMDR). In the sMDR method, the thresholds 
for significance are established before the MDR algorithm is run. This can be 
accomplished either randomly permuting n-times the studied dataset or creating a 
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null population with the same characteristics of the latter and then extracting n 
samples from that. MDR is then run in each of the null samples and h top models 
(Top1,2,…,h) per dimension are sorted out. Testing BA values for the Toph  ranking 
models are then computed. The testing BA value of any model is corrected 
whenever the testing BA values of the models with a lower index are higher. Let’s 
suppose, for instance, that BA1=0.45, BA2=0.48 and BA3=0.42, then BA3 values will 
be corrected to 0.48. The upper bound of the 95th percentile (or higher if required) 
of the testing BA1,2,…,h values from the n samples are used to derive the 0.05 
significance level  (or lower if required). MDR is then run in the studied dataset and 
the top models/dimension are sorted out. The testing BA value for the 1st model  is 
then compared to the significance threshold for the testing BA1 values; if values are 
higher the model is declared significant, non-significant otherwise. In the latter 
case, the scaling procedure is applied and the testing BA values for the 2nd model 
is compared to the significance threshold for the testing BA2 values. The procedure 
is repeated until a significant model is found up the hth model.
The power of the sMDR algorithm was tested via simulation in synthetic datasets. 
Since we are also aiming at determining the power of the sMDR algorithm in the 
systemic sclerosis (SSc) population, a few constrains were applied to simulation. 
Firstly, with a try-and-error approach we generated different penetrance functions 
for a triplet of biallelic  genetic loci, with minor allele frequencies equal to 0.1, 0.2 or 
0.3 (Table 2.1-10). The broad-sense heritability (H2) of all the model was set to a 
relatively low value (=0.10); the environmental contribution to SSc pathogenesis is 
indeed thought to be low and we do not expect H2 to be any lower. For each 
epistatic  model, a population of 65000 individuals with the case-control status 
linked to the causative triplet was built. We then incorporated linkage disequilibrium 
(LD) in data simulation. The 2nd SNP of the triplet was linked to a single SNP with 
the same MAF (r2=0.8) whilst the 3rd SNP of the triplet was linked to 2 SNPs with 
the same MAF (r2=0.8). To these 6 SNPs (the triplet and the 3 linkage SNPs), 14 
additional  loci  unlinked to the case-control-status with MAF ranging from 0.05 to 
0.5 were added. Among these 14 SNPs, we considered 2 LD blocks of 2 SNPs and 
3 LD blocks of 3 SNPs each (r2=0.8). From this population we then draw 100 
samples with 500 controls and 125 cases (case to control  ratio = 1:4) or 500 
controls and 250 cases (1:2) or 500 controls and 375 cases (1:1.25). These 
population would simulate the control vs diffuse SSc  (dcSSc) or the control vs 
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limited SSc (lcSSc) or the control vs SSc comparison, where the dcSSc:lcSSc ratio 
is 1:2. Null distributions were then generated where instead of the triplet and of the 
triplet-linked loci, we considered an additional single locus and two additional  LD 
blocks with 2 and 3 SNPs, respectively. One-hundred null samples were drawn 
from the null distribution with a case:control ratio as above and 0.05 or 0.025 
thresholds for significance were derived. The scaling parameters (h) was set to 10 
and 5 cross-validations were used. Specific  power was estimated as the number of 
times sMDR identified the causative triplet of SNP out of 100 dataset/model/
case:control  ratio at the desired significance threshold. A wider-sense power was 
estimated incorporating LD; in this case a positive hit was considered whenever 
the sMDR method sorted out the causative triplet or a triplet containing one of the 
loci in linkage with the triplet. 
Simulation results depicted in table 1 clearly demonstrate that: a) sMDR retains a 
higher power than plain MDR to correctly identify the causative triplet of loci in the 
simulated datasets; b) due to a “ceiling” effect, the increase in power is more 
pronounced for models where MDR performs poorly (e.g. in the dcSSc vs controls 
comparison or when MAF are low); c) Incorporation of LD increases the power of 
both the MDR and the sMDR algorithm.
Overall these results indicate that sMDR is powerful enough to detect a causative 
triplet of loci  or a set of loci in LD with the causative triplet in the SSc  dataset we 
are currently analyzing. 
Application of dMDR to the SSc dataset
To determine the thresholds for significance, the SSc/controls population as well  as 
the lcSSc/controls and dcSSc/controls populations were was randomly permuted to 
generate 100 null datasets/population. Five cross-validations were used and the 
scaling parameter h was set to 10 and the top 95th percentile of the testing BAh 
values were derived from the null  SSc/controls distribution, whilst for the null lcSSc/
controls and null dcSSc/controls distributions the top 97.5th percentile were 
derived. Alpha level were thus set to 0.05 in the former case and, to account for 
multiple tastings, to 0.025 in the latter. The sMDR method was then applied to the 
populations under analysis considering the abovementioned significance levels.
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Table 1 - Power for the Multifactor Dimensionality  reduction (MDR) algorithm in the epistatic 
3-factor models employed for simulation
Power
Plain MDR Scaling MDR Plain MDR + LD Scaling MDR + LD
Model # Cases:Controls 0.05 0.025 0.05 0.025 0.05 0.025 0.05 0.025
1 1:4 36 36 48 46 49 48 55 53
1:2 76 76 93 93 93 92 98 98
1:1.25 81 81 98 98 98 98 100 100
2 1:4 38 37 56 53 56 55 67 64
1:2 95 94 97 95 95 94 97 95
1:1.25 98 98 100 99 97 96 100 100
3 1:4 50 50 68 68 69 69 75 74
1:2 83 83 96 96 98 98 100 100
1:1.25 83 83 100 100 99 99 100 100
4 1:4 39 38 50 48 51 50 54 52
1:2 76 73 86 83 89 85 87 84
1:1.25 83 82 99 97 98 97 100 99
5 1:4 52 51 58 56 61 60 64 62
1:2 91 91 99 98 96 96 100 100
1:1.25 94 94 100 100 98 98 100 100
6 1:4 55 55 64 64 68 68 70 70
1:2 91 91 98 98 97 97 100 100
1:1.25 94 94 100 100 98 98 100 100
7 1:4 83 83 97 96 95 95 99 98
1:2 97 95 99 99 98 98 99 99
1:1.25 98 98 100 100 100 100 100 100
8 1:4 84 84 95 95 91 91 96 96
1:2 98 98 100 100 99 99 100 100
1:1.25 98 98 100 100 99 98 100 100
9 1:4 82 81 92 89 91 90 96 94
1:2 98 98 100 100 99 99 100 100
1:1.25 97 97 100 100 99 99 100 100
10 1:4 41 41 57 57 53 52 62 61
1:2 67 66 91 90 88 87 95 94
1:1.25 89 89 98 98 98 98 100 100
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Table 2.1-10 – Penetrance functions for the different models employed for simulation
Model 1 – MAF (A) = 0.1; MAF (B) = 0.1; MAF (C) = 0.1
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC
0,56775 0,82226 0,58733 0,78310 0,07831 0,70479 0,70479 0,46986 0,97888
Cc
0,74395 0,29366 0,58733 0,43071 0,72437 0,97888 0,46986 0,23493 0,46986
cc
0,78310 0,23493 0,03916 0,45028 0,19578 0,09789 0,70479 0,19578 0,93972
Model 2 – MAF (A) = 0.2; MAF (B) = 0.1; MAF (C) = 0.1
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC
0,49332 0,75343 0,53816 0,69064 0,07176 0,53816 0,61889 0,43053 0,89694
Cc
0,60992 0,66374 0,48435 0,34084 0,89694 0,89694 0,43053 0,35878 0,43053
cc
0,69961 0,26908 0,03588 0,41259 0,71755 0,08969 0,17939 0,35878 0,86106
Model 3 – MAF (A) = 0.3; MAF (B) = 0.1; MAF (C) = 0.1
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,32223 0,60243 0,35025 0,50436 0,04203 0,35025 0,43431 0,33624 0,63045
Cc 0,47634 0,57441 0,44832 0,15411 0,91065 0,77055 0,33624 0,29421 0,40629
cc 0,54639 0,30822 0,09807 0,26619 0,70050 0,35025 0,02802 0,28020 0,63045
Model 4 – MAF (A) = 0.1; MAF (B) = 0.2; MAF (C) = 0.2
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,45657 0,66410 0,49807 0,83012 0,08301 0,68485 0,58108 0,45657 0,93389
Cc 0,58108 0,51883 0,49807 0,31130 0,62259 0,95464 0,64334 0,31130 0,47732
cc 0,76786 0,14527 0,08301 0,45657 0,64334 0,68485 0,24904 0,20753 0,97539
Model 5 – MAF (A) = 0.2; MAF (B) = 0.2; MAF (C) = 0.2
AA Aa aa
226
BB Bb bb BB Bb bb BB Bb bb
CC 0,28569 0,45451 0,23375 0,53243 0,01299 0,35062 0,44152 0,31166 0,59736
Cc 0,36361 0,37659 0,28569 0,14285 0,61034 0,92201 0,22076 0,31166 0,45451
cc 0,48048 0,11687 0,03896 0,25972 0,62333 0,38958 0,09090 0,12986 0,12986
Model 6 – MAF (A) = 0.3; MAF (B) = 0.2; MAF (C) = 0.2
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,2574 0,4095 0,2223 0,4563 0,0351 0,3159 0,3978 0,2925 0,5382
Cc 0,3276 0,3627 0,2574 0,1287 0,6435 0,5967 0,1989 0,2808 0,2574
cc 0,4329 0,1638 0,0351 0,234 0,5616 0,2808 0,0819 0,234 0,5265
Model 7 – MAF (A) = 0.1; MAF (B) = 0.3; MAF (C) = 0.3
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,12075 0,43168 0,36225 0,41113 0,04725 0,37001 0,37001 0,24668 0,51391
Cc 0,38850 0,15750 0,07350 0,22612 0,37275 0,50925 0,23625 0,12075 0,23625
cc 0,41113 0,13125 0,42000 0,23640 0,10278 0,05139 0,47250 0,10278 0,63000
Model 8 – MAF (A) = 0.2; MAF (B) = 0.3; MAF (C) = 0.3
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,11303 0,45214 0,33910 0,40076 0,08221 0,34938 0,38020 0,25690 0,51379
Cc 0,39048 0,16441 0,04110 0,20552 0,39048 0,46241 0,23634 0,10276 0,20552
cc 0,42247 0,16441 0,41103 0,24662 0,15414 0,04110 0,49324 0,15414 0,65765
Model 9 – MAF (A) = 0.3; MAF (B) = 0.3; MAF (C) = 0.3
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,12640 0,50560 0,36771 0,41368 0,12640 0,36771 0,43666 0,28728 0,57455
Cc 0,43666 0,18386 0,04596 0,22982 0,43666 0,49411 0,26429 0,11491 0,22982
cc 0,47113 0,24131 0,21833 0,27578 0,22982 0,03447 0,51710 0,17237 0,74692
227
Model 10 – MAF (A) = 0.3; MAF (B) = 0.2; MAF (C) = 0.1
AA Aa aa
BB Bb bb BB Bb bb BB Bb bb
CC 0,23625 0,46125 0,25875 0,43875 0,06750 0,31500 0,35438 0,28125 0,51750
Cc 0,31500 0,38250 0,29250 0,09000 0,70875 0,58500 0,18000 0,27000 0,24750
cc 0,41625 0,22500 0,05625 0,21375 0,56250 0,28125 0,02250 0,22500 0,50625
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Abstract
Objectives: To investigate the role of X-chromosomal inactivation (XCI) in systemic 
sclerosis and its effects on Foxp3 expression in T regulatory cells.
Methods: A total of 217 female SSc patients and 107 female healthy controls were 
included. From these subjects DNA was isolated from total  PBMCs, plasmacytoid 
dendritic  cells, T  cells, B cells, myeloid dendritic cells and monocytes after 
magnetic  bead separation. All samples were assessed for skewed XCI patterns 
with the HUMARA assay. Outcome was assessed with linear regression. Next, 
CD4+CD25+ cells were isolated and intracellular Foxp3 expression was assessed 
by flowcytometry.
Results: Skewing is not associated with increased age in SSc, in contrast to the 
control  population (r=0.45, p<0.0001). Taking this into account, we found a 
significantly higher frequency of skewed XCI in SSc patients (P=0.001) compared 
to controls. No difference in skewing was observed between the immune cell 
subsets. In addition, we found a higher concentration of Foxp3+ cells, exhibiting a 
lower Foxp3 MFI in the SSc patients with profound XCI skewing (both p<0.001), 
associated with less efficient suppressive activity (p=0.012).
Conclusions: Skewed XCI plays a role in susceptibility to SSc, is not restricted  and 
influences Foxp3 expression and suppressive capacity of Tregs.
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Introduction
Systemic  sclerosis (SSc) is a severe autoimmune disease that is characterized by 
extensive fibrosis of the skin and internal organs culminating in high morbidity and 
premature death. Females develop SSc more often than males, reported ratios 
range from 5:1 up to 12:1 (1). Intriguingly, it was suggested that women with SSc 
contain a significantly higher frequency of peripheral blood cells with skewed X-
chromosomal inactivation (XCI) patterns compared to their healthy counterparts 
(2,3). XCI is a dosage compensation mechanism evolved to level  differences 
between males and females in X-chromosomal gene expression. As a 
consequence of this, females are functional mosaics for inactivation of the paternal 
or maternal  X-chromosome (4). First, it was thought that X-chromosomal 
inactivation (XCI) encompasses the inactivation of all  genes on one X-
chromosome. However, a recent landmark study destabilized this paradigm by 
showing that at least 15% of the genes can escape XCI in physiologic  conditions 
and are therefore expressed on two X chromosomes. In addition, heterogeneity 
was observed in the patterns of gene inactivation among females (5). Although 
inactivation of the X-chromosome is apparent to be permanent for all descendants 
of a cell, the XCI pattern alters with age. The frequency of skewed XCI in 
peripheral blood cells increases in elderly compared to younger healthy females 
(6). No studies investigated the potential  functional  relevance of XCI skewing in 
SSc, despite the fact that key immunomodulatory genes map to the X-
chromosome. One of these concerns forkhead box p3 (Foxp3), which is essential 
for regulatory T cells (Tregs) (7,8) Based on our recent study demonstrating 
markedly diminished suppressive capacity of Tregs in SSc  (9), we here 
investigated whether XCI is present in a large cohort of well-documented SSc 
patients and to identify whether a skewed XCI could explain the aberrant Treg 
function.
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Study design
Study population 
A total of 217 female SSc patients and 107 female healthy controls were included, 
originating from the Boston University Medical Center in Boston, Massachussets, 
USA and the Radboud University Nijmegen Medical  Centre in Nijmegen, The 
Netherlands. All patients met the American College of Rheumatology preliminary 
criteria for the classification of SSc  (10). Both patients and controls were included 
in the study after written informed consent. The study was approved by the local 
ethical  committees / institutional  review boards. The mean age of the patients was 
50 years (SD 14.5) and 46 years for healthy controls (SD 19.5).
Evaluation of XCI status utilizing the HUMARA assay
From each subject 200ng of DNA was used to evaluate XCI status according to 
methods described previously (11). Briefly, peak height of the shorter allele was 
divided by peak height of the longer allele and compensated for amplification bias 
using undigested controls. The skewing ratio was inverted if necessary to obtain a 
value of ≥1. A cell  population with random XCI would be expected to show ratios 
equal or close to 1, which is an even distribution of 50% for each chromosome. For 
each person the ratio between the two chromosomes was calculated and the 
corresponding percentages are used throughout this article. 
Isolation of cell subsets, assessment of FoxP3 expression and suppressive 
capacity
From 25 SSc patients and 9 controls we isolated PBMCs from heparinized venous 
blood by density-gradient centrifugation. Subsequently, BDCA4+, CD3+, CD19+, 
CD1C+ and CD14+ cells were isolated by magnetic cell separation techniques 
according to the manufacturer's protocol. DNA from all cell-types was extracted. 
After isolation the CD3+ fraction was stained with phycoerythrin, allophycocyanin 
and fluorescein isothiocynate conjugated mouse monoclonal antibodies against 
human CD4, CD25 and CD127. Intracellular staining of CD4+CD25+ cells for 
FoxP3 was performed according to the manufacturer (Miltenyi Biotec, Inc.) 
Assessment of expression was performed with a LSRII FACScan flow cytometer 
and emerging data were processed with FlowJo software. To assess Treg cell 
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suppressive capacity, CD25highCD127low cells were sorted. CD25highCD127low cells 
and unsorted CD3+ T  cells were transferred into RPMI 1640 media supplemented 
with; 2nM L-glutamine, 100 U/ml  penicillin-streptomycin, and 10% FCS. To assess 
the suppressive capacity of Tregs (CD25highCD127low), the unsorted T cells were 
brought to a concentration of 2x106 cells/ml and stimulated with phytohaemaglutin. 
Tregs from healthy controls and SSc patients were added to autologous unsorted 
CD3+cells at fixed ratios 1:20 for 5 successive days. After 4 days of culture, [3H]Tdr 
was added for the remaining 24 hrs of cultures. The cells were harvested onto 
glass fiber filters and [3H]thymidine incorporation was assessed on a beta 
scintillation counter. The ability of Tregs to suppress proliferation was determined 
as the percentage of inhibition calculated as 1- (experimental counts per minute/
control counts per minute) x 100%. 
Statistical analysis
Significance levels were calculated with linear regression taking into account the 
variables; age, the interaction between SSc-control status and age and affected 
status or the clinical  phenotype of interest. Furthermore, Pearson correlations and 
Students t-test were calculated using SPSS 18.0 software. P values below 0.05 
were considered as statistically significant. Values are displayed as mean plus/
minus SEM.
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Results
Firstly, we investigated whether age has an effect on the degree of skewing 
observed in both the SSc  patients and controls. We observed a clear association 
with increasing age in the control  population (r=0.45, p<0.0001), whereas this 
correlation was not present in the SSc  population, this resulted in different 
association results per age group (Figure 1). 
Figure 1: Correlation between age and skewing. A) There is a significant correlation between age and 
the degree of skewing present in the control population (r=0.45, P<0.0001) B) No correlation is present 
in the SSc population. C) Comparison of skewing between SSc and controls in different age groups, 
associations with skewing and SSc are present in subjects <30 years of age (P=0.006), 31-40 years 
(P=0.016) and 41-50 years (P=0.042) but are not significantly different between cases and controls after 
50 years of age.
For this reason, we corrected for age effects with a linear regression model. In line 
with previous reports, we found a significantly higher frequency of skewed XCI in 
SSc patients (p=0.001) , lcSSc patients (p=0.008), dcSSc patients (p=0.005) and 
anti-topoisomerase autoantibody positive patients (p=0.008) compared to controls 
(Table 1). Since a skewed XCI pattern could reflect expansion of a subset of 
immune cells, we next evaluated the skewed XCI pattern in purified T cells (CD3+), 
B cells (CD19+), monocytes (CD14+), plasmacytoid dendritic cell (BDCA+), and 
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myeloid dendritic  cells (CD1c+) from SSc patients and healthy controls (purity 
>98%, data not shown). All purified cell  subsets showed a pattern of skewing 
similar to that seen in total PBMCs without any statistical differences. 
Table 1.  Clinical characteristics of patients included in this study and their association with skewing 
percentages by multiple linear regression, taking into account age effects. 
Phenotype n Proportion of total P *
SSc 192 0.001
lcSSc 94 0.49 0.008
dcSSc 98 0.51 0.005
Controls 84
ACA+ 43 0.22 0.260
Anti-Topo + 47 0.24 0.008
PAH+ 39 0.20 0.295
Pulmonary Fibrosis + 69 0.36 0.266
Methotrexate 31 0.16 0.394
Azathioprine 31 0.16 0.783
Cyclophosphamide 23 0.12 0.179
Prednisolone 75 0.39 0.777
*All comparisons are performed with controls except PAH and Pulmonary Fibrosis, these were 
compared between patients with and without these clinical hallmarks.
XCI has functional consequences in that we demonstrated a clear association 
between skewed XCI (defined as a skewing ratio > 2 or 67%) and a lower mean 
fluorescence intensity of Foxp3 in CD4+CD25highCD127- compared to the patients 
with no skewing (P <0.001), in addition patients with no skewing have lower Foxp3 
percentage positive cells compared to controls (P<0.001). Intriguingly, a higher 
percentage of Foxp3 (P<0.001) positive cells was observed in skewed SSc cases. 
To test the suppressive ability of Tregs in association with XCI, we studied the 
capacity of CD25highCD127- cells from subjects with clear skewing (n=7) (skewing 
ratio > 2 or 67%), weak skewing (n=3) (defined as a skewing ratio between 55% 
and 67%) and no skewing (n=5) (defined as a skewing ratio <1.10 or 52%) to 
suppress the proliferation of CD4+ effector cells.(Figure 2).
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Figure 2: Effect of XCI skewing on CD4+CD25highCD127- cells. A) Percentage of FoxP3 positive 
CD4+CD25highCD127- cells in SSc patients with clear skewing (n=10) compared to patients (n=12) and 
controls (n=6) with no skewing (Both P<0.001). In addition, we observed a significant difference in the 
percentage positive in the controls with no skewing compared to the SSc patients with no skewing 
(n=4).  B) Mean fluorescence intensity (MFI) of Foxp3 is different in patients with skewed XCI (n=10) 
compared to patients without skewing (n=12) and to healthy controls with skewing (n=4) (Both 
P<0.0001) no differences were observed between patients and controls (n=6) with no skewing. B) C). 
Suppressive capacity of CD4+CD25highCD127- cells from SSc patients and controls without XCI skewing 
(SSc n=5, HC n=4), clear XCI skewing (SSc n=7, HC n=4) and weak skewing (SSc n=3, HC n=2). 
Significant differences are present in the patients with skewing compared to the healthy controls and 
patients with no skewing (respectively P=0.007 and P=0.012).
The Treg populations in the no skewing, weak skewing and healthy control group 
had a similar suppressive capacity, whereas SSc patients displaying a clear 
skewing pattern exhibited a markedly diminished suppressive capacity of 30 % ± 
10 compared to patients with no skewing (p=0.012) and healthy controls (p=0.007) 
Figure 2C). No significant differences in the number of surviving Tregs for each 
skewing and control group were observed after finishing the experiment, excluding 
biased results caused by early in vitro death of Tregs with skewed XCI.
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Discussion
In this study we show that skewed XCI patterns are associated with SSc. In line 
with this, we demonstrate that XCI in SSc is not present in a specific  cell subset, 
suggesting that this phenomenon is already present in precursor cells. Besides, 
our data firmly underscore the functional relevance of XCI in SSc by the strong 
association with a deregulated Treg capacity. There has been an ongoing 
discussion on the validity of the HUMARA assay in the determination of clonality in 
the past years (12). However, this discussion mainly focused on the ability of the 
HUMARA assay to detect clonality in elderly females. In the present study the vast 
majority of subjects is younger than 65 years and the results presented reflect the 
degree of skewing on a continuous scale without strictly assigning the subjects in 
groups with and without clonal expansion. Therefore this criticism does not apply to 
our findings (13). Important to note is that whenever one of the X-chromosomes is 
inactivated, both the human androgen receptor gene and FOXP3 on this 
chromosome are silenced as well (5). 
Human populations are outbred and differences between two X chromosomes are 
consequently present. It has been shown previously that these genetic differences 
influence hematopoietic stem cell kinetics, apparently leading to skewed XCI with 
aging (14). XCI skewing takes place in healthy females around the age of 55 years 
(15). Interestingly, the peak age at onset of SSc  is close to this age, ranging from 
49 to 64 years, depending on ethnic background (16). This is similar to that 
observed in other autoimmune diseases associated with skewed XCI patterns (17). 
We show that the increased XCI skewing in SSc takes place throughout all cells 
investigated, signifying that increased hematopoietic  kinetics resulting from the 
autoimmune disease might accelerate the normal aging-associated process of XCI 
skewing. 
However, this process appears to have a striking and unexpected effect on Treg 
function. Recently, it was shown that only Tregs and not other cell  subsets 
selectively inactivate X-chromosomes carrying FOXP3 mutations (18). In contrast, 
we show that in SSc skewed XCI is associated with decreased FoxP3 expression. 
This suggests that altered X-linked genetic  factors that influence hematopoietic 
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stem cell kinetics underlie the XCI skewing observed in SSc. These factors seem 
to prevail over the ability of Tregs to selectively inactivate X chromosomes that 
harbour regions less effective in cis and trans regulation of Foxp3. Recently, a 
study was published describing cis acting, non-coding, regulatory DNA elements in 
the Foxp3 gene and their impact on Treg fate. Intriguingly, mice deficient for one of 
these regulatory elements were able to induce expansion of Foxp3+ cells as partial 
compensation for impaired Foxp3 induction (19). A similar mechanism could 
underlie our observations of decreased MFI and increased percentage of cells 
positive for Foxp3. Since peripheral blood cells have high regeneration rates, 
differences present between the two X chromosomes, might affect suppressive 
capacity of Tregs in the timeframe following skewing, making these females even 
more susceptible to autoimmune disease (20,21). Taken together, we present data 
that implicates XCI in the pathogenesis of SSc by deregulating FoxP3 expression, 
causing Treg dysfunction. It is tempting to speculate that XCI impacts on immune 
regulation in other autoimmune disorders as well.
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Abstract
Aim: To assess telomere length in peripheral  blood and immune cell subsets of 
healthy controls, limited and diffuse systemic sclerosis patients.
Methods: Relative telomere length of 182 SSc patients and 100 healthy controls 
was assessed using quantitative PCR. From 25 SSc  patients and 9 healthy 
controls B cells, T cells, monocytes, plasmacytoid- and myeloid dendritic  cells were 
isolated for immune cell specific telomere analyses.
Results:  We observed a significant age related telomere attrition in healthy 
controls (n=100) and lcSSc patients (n=104) (Both p< 0.001), but not in dcSSc 
patients. In the immune cell  subset specific  analysis we observed significant 
shorter telomeres in B cells and myeloid dendritic  cells of both lcSSc and dcSSc 
patients (B-Cells p=0.014, p=0.002 & myDCs p=0.019, p=0.004 respectively). 
PDCs and T cells were significantly shorter in dcSSc patients only (p=0.001 and 
p=0.003 respectively).
Conclusions: Aberrances in telomere shortening are a feature of SSc, reflecting a 
difference in clinical subsets at the cellular level.
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Introduction
Systemic  sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, 
immune system activation and fibrosis of the skin and internal organs, which 
affects predominantly females (1). Over the last years, scientific  research focusing 
on the factors underlying SSc pathogenesis and susceptibility intensified but, untill 
now, both a cure and an unequivocal disease model remain to be elucidated. 
However, during the passed years important steps forward have been made in the 
understanding of genetic  susceptibility risks for SSc development. SSc does not 
inherit in a Mendelian fashion, but appears multifactorial, with an onset later in life. 
This implies that the combined effect of multiple small  genetic variations in concert 
with environmental exposures determines the risk to develop SSc  (2). Recently, 
this fact was further documented by a genome wide association study in SSc, 
showing that there was not one genetic  factor posing enough risk to be fully 
accountable for SSc  development (3). Despite extensive efforts, the identification of 
environmental  factors ultimately determining the development of SSc  in a 
genetically susceptible host remains to be established (4). A currently expanding 
field of research in SSc, providing a novel  echelon for investigation situated 
between environment and genetics, is the realm of epigenetics. 
Among other epigenetic processes, telomere length aberrations have been 
implicated in SSc. Telomeres are specialized nucleoprotein complexes at the end 
of eukaryotic chromosomes. They comprise tandem TTAGGG repeat arrays bound 
to a variety of proteins with roles in chromosomal protection, nuclear attachment 
and replication. Telomeres function to cap the chromosome, preventing 
chromosomal fusions and the recognition of the chromosome end as a DNA break. 
Telomeres facilitate chromosomal attachment within the correct sub-cellular 
compartment and have a critical role in DNA replication. The proteinaceous 
component of the telomere helps maintaining its structural integrity and functions in 
sensing, signalling and repair of DNA damage (5). The length of telomeric DNA 
repeats shortens during the ageing of cultured fibroblasts, peripheral  blood 
lymphocytes and colon epithelia, but shortening is also under polygenic  and 
environmental  influence (6,7). As a consequence, telomere length reflects the 
“miles on the clock” of a certain individual or cell  type. The pivotal role of this 
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complex is the protection of chromosomes from DNA damage by initiating cellular 
senescence, or apoptosis (8). 
Increased chromosomal damage has been repeatedly reported in SSc 
lymphocytes as well as fibroblasts, (9-14). Interestingly, two previous studies, 
prompted by the observation of increased chromosomal damage in SSc, 
addressed telomere length in SSc  patients and came to ambiguous conclusions 
(15,16). However, both studies used dissimilar methodology and clinical disease 
subsets in their investigations. To better gauge these previous findings, our study 
aims to evaluate telomere attrition in an independent, clinically well-defined SSc 
cohort. Moreover, we aim to investigate whether there are differences in telomere 
attrition between different immune cell subsets in SSc. 
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Study design
Patients and Controls
The study population was composed of 182 SSc patients and 100 healthy controls 
matched by geographical region and age. The population consisted of two case-
control  sets of European ancestry; a UK cohort: 90 SSc patients and 46 controls; a 
Dutch cohort: 92 SSc patients and 54 controls. All the patients fulfilled the 1980 
American College of Rheumatology (ACR) classification criteria for SSc (17). The 
local ethical  committee from each center approved the study. Both patients and 
controls were included in the study after written informed consent. All patients 
included in this study were classified as having limited cutaneous (lcSSc) or diffuse 
cutaneous SSc (dcSSc) using the criteria postulated by LeRoy (18). Patients with 
scleroderma changes limited to the skin distal to elbows and/or knees, regardless 
of facial involvement, fulfill  the definition for lcSSc. Those SSc  patients with more 
proximal scleroderma skin changes were classified as having dcSSc. 
DNA/RNA isolation from peripheral blood leukocytes and cell subsets
Peripheral blood samples (10 ml) collected in EDTA tubes were obtained from each 
patient and stored at -80°C before DNA isolation. Genomic  DNA was extracted 
from leucocytes in peripheral  venous blood according to standard protocols. From 
25 SSc  (12 dcSSc  and 13 lcSSc) patients and 9 controls, derived from the Boston 
University Medical  Center (Boston, MA, USA) leucocytes were isolated from 
heparinized venous blood by density-gradient centrifugation. Subsequently, 
BDCA4+ (plasmacytoid dendritic cells), CD3+ (T cell), CD19+ (B cell), CD1C+ 
(myeloid dendritic  cells) and CD14+ (monocyte) cells were isolated by magnetic 
cell  separation techniques according to the manufacturer's protocol  and as 
described previously (19). RNA was purified by AllPrep DNA/RNA columns 
(Qiagen, Valencia, CA), and cDNA was synthesized by I-script (Bio-Rad, Hercules, 
CA). 
Telomere length analysis
DNA was extracted from PBLs following standard procedures and telomere lengths 
in the DNA samples were determined by Q-PCR, following the method of Cawthon 
as described previously (18). Telomere length determination was performed using 
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a Roche Light Cycler LC480. Telomere length analyses were performed in triplicate 
for each sample, using a single-copy gene amplicon primer set (acidic ribosomal 
phosphoprotein, 36B4) and a telomere-specific amplicon primer set. Quality control 
parameters employed for the amplifications comprised using a cut off of 0.15 for 
the standard deviation (SD) of the threshold cycle (Ct) for sample replicates. At an 
SD above 0.15 the sample was reanalyzed. 
Relative telomere length was estimated from Ct scores using the comparative Ct 
method after confirming that the telomere and control gene assays yielded similar 
amplification efficiencies. This method determines the ratio of telomere repeat copy 
number to single copy gene number (T/S) ratio in experimental samples relative to 
a control sample DNA. This normalised T/S ratio was used as the estimate of 
relative telomere length (Relative T/S). The inter-assay variation was assessed by 
comparing the relative telomere estimates (T/S ratio) estimates across assays for 
the positive controls, which were assayed on every assay plate. 
Statistical analyisis
Statistical  analysis was performed using SPSS version 15 (SPSS Inc, Chicago, 
Illinois). Pearsons correlations were performed to establish any relationships 
between telomere length and the various parameters such as age and gene 
expression levels. Telomere length comparison between the diffent cohorts, 
disease groups and cell subsets was achieved using the Mann-Whitney test. 
Telomere length was corrected for age using ANCOVA analysis. Correction for 
multiple testing was performed using the Bonferroni correction.
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Results
PBLs from diffuse SSc patients do not display age-related telomere attrition
Telomere lengths were determined for the PBLs from both the Scottish and Dutch 
cohort. However, to limit the confounding factors of the differences in the 
socioeconomic backgrounds of both cohorts, analysis of telomere attrition was 
performed on the two cohorts separately. For both the Scottish and Dutch cohort, 
we observed no significant differences in average age-corrected telomere length 
between controls, SSc, lcSSc and dcSSc. In the Scottish cohort, both the healthy 
controls as well as the lcSSc patients displayed evidence of age-related telomere 
attrition, with increasing age, telomeres were observed to significantly shorten 
(controls p=0.009, lcSSc  p<0.001). Conversely, there was no noticeable change in 
the telomere lengths of Scottish dcSSc  patients over an approximately 50 year 
period. Similar patterns were observed for the Dutch cohort, again the lcSSc 
patients displayed telomere attrition with increasing age (p=0.03), whereas the 
dcSSc patients maintained telomere length with increasing age. However, it has to 
be noted that the Dutch healthy controls did not display age-related telomere 
attrition, though this is perhaps due to the relatively young and narrow age range of 
this particular cohort (median Age=38yrs, interquartile range 30-49yrs). In the 
combined analysis both controls and lcSSc showed significant telomere attrition 
with age in contrast to the dcSSc patients (both p<0.001) (Figure 1).
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Figure 1: Significant age related telomere attrition in healthy controls (n=100) and lcSSc patients 
(n=104) (Both p< 0.001), but not in dcSSc patients.
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Marked differences in telomere length of immune cell subsets from SSc patients
To address the question whether differences in telomere length are present 
between immune cell subsets in SSc, we isolated B cells, T  cells, monocytes, 
myeloid dendritic cells and plasmacytoid dendritic cells. No significant differences 
in the age of the SSc, SSc subtypes and healthy controls were present. 
In comparing healthy controls with SSc patients it was observed that for all the cell 
subsets, bar the monocoytes, telomere lengths were longer in the healthy controls. 
B-Cells (p=0.001, median relTS 1.15 vs 0.78), MDCs (p=0.008, median relTS 0.84 
vs 0.62), PDCs (p=0.025, median relTS 0.84 vs 0.62) and T-Cells (p=0.004, 
median relTS 1.02 vs 0.78) from SSc  patients had significantly shorter telomeres 
than the healthy controls. Interestingly for the B-Cell and myDCs this phenomenon 
seemed to be ubiquitously present in both the lcSSc and dcSSc subset (B-Cells 
p=0.014, p=0.002 and myDCs p=0.019, p=0.024 respectively). Conversely for both 
the PDCs and T-Cells we observed that these subsets presented with shorter 
telomeres in only the dcSSc population in comparison to the healthy controls 
(p=0.001 and p=0.003 respectively).  The telomere lengths of PDCs and T-Cells 
from lcSSc  patients were not significantly different from the controls. Evidence of 
dcSSc specific  significant telomere shortening in PDCs (P=0.001) was 
strengthened by the determination that dcSSc PDCs had shorter telomeres than 
lcSSc  PDCs (P=0.005). In contrast to the other cell subtypes, no significant 
differences were observed in the telomere length of monocytes between the 
different disease phenotypes (Figure 2). However, after stringent correction for 
multiple testing using the Bonferroni corection; (5 cell  subsets, three tests in each 
subset equals a corrected significance threshold of 0.05 divided by 15 tests is a 
treshold of p=0.0033), we have to conclude that only the observations of shorter 
telomeres in T cells, B cells and pDCs of dcSSc patients compared to healthy 
controls remain significant. 
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Figure 	  2.	   Signiﬁcant	   shorter	   telomeres	   in	   B	   cells	   and	  myeloid	   dendri6c	   cells	   of	   both	   lcSSc	   (n=13)	   and	   dcSSc	  
(n=12)	  pa6ents	   (B-­‐Cells	  p=0.014,	   p=0.002	  &	   myDCs	   p=0.019,	   p=0.004	   respec6vely)	   compared	   to	  controls	  (n=9).	  
PDCs	  and	  T	  cells	  were	  signiﬁcantly	  shorter	  in	  dcSSc	  pa6ents	  only	  (p=0.001	  and	  p=0.003	  respec6vely).
Discussion
In this study we describe an increased rate of age-related telomere shortening in 
lcSSc, in contrast to a decrease in dcSSc. Moreover, we show marked differences 
in telomere length in immune cell subsets of the clinical  phenotypes of SSc. Two 
previous studies addressed telomere length in SSc. An initial study investigated 
telomere lengths of peripheral blood leukocytes (PBLs) and fibroblasts from 43 
SSc patients, 182 SSc  family members and 96 age-matched controls restriction 
fragment length polymorphism (RFLP) and chemiluminescent labelled probes. 
They observed an average loss of telomeric  DNA in PBLs from SSc patients and 
their family members of 3 kb compared to the controls. This loss withstood 
correction for age and disease duration. Of interest, although telomeres in SSc 
fibroblasts were shorter overall compared to healthy control  fibroblasts, this 
difference was not significant (15). This study used a different methodology than 
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our study and did not differentiate between lcSSc and dcSSc  in their analysis, 
making it difficult to compare these results directly to our study. However, if they 
included particularly lcSSc patients at a higher age, these results would be well 
comparable with our results and those from a second study, showing increased 
telomere attrition in lcSSc patients, deviating from healthy controls at a higher age 
(15). The second study focused solely on females with the lcSSc phenotype. Forty-
three lcSSc patients with an age ranging from 37 to 80 years were included. The 
difference between the lcSSc  and control telomere lengths was only significant 
beyond the fifth decade. Below 50 years of age, no difference was observed 
between healthy females and females with lcSSc (16). 
Considering our and previous observations it seems likely that telomeres shorten 
as a consequence of a higher turnover of PBLs and their precursor cells caused by 
the autoimmune disease SSc. However, there seems to be a marked difference 
between the immune cell  subsets affected in dcSSc. In this clinical phenotype, 
PDCs and T cell  seem to be more affected by telomere shortening compared to 
lcSSc. This might imply that these cells play a relatively larger role in dcSSc 
pathogenesis than in lcSSc. Although not significant after correction for multiple 
testing, B cells and myDC have shorter telomeres in both the limited and diffuse 
subform and the observed trend suggests involvement of these cells in both clinical 
phenotypes. Monocytes are not affected by telomere shortening in SSc, reflecting 
possibly no involvement or better counterbalancing mechanisms. Next to a higher 
demand on precursor cells, the decrease in telomere length of immune cell subsets 
might also be caused by a lack of telomere-repair gene or protein expression, such 
as telomerase, by the SSc  immune cells. Another possibility is that mechanisms 
that trigger apoptosis upon reaching a telomere attrition treshold are not 
functioning adequately. This would keep immune cells with short telomeres 
circulating in the blood, decreasing average telomere length for these cells in our 
measurements. If this last possibility is true, it would also mean that there is a 
proportion of immune cells with a higher than normal content of DNA damage, 
more prone to derail into autoimmune reactivity (21). 
In summary, for the first time in a large cohort, this study shows that there are 
marked differences between age related telomere attrition in clinical subforms of 
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SSc and that these differences are also reflected on the level  of immune cell 
subsets. To better position these observations as a downstream or a causative 
effect, future investigations into the function of telomere maintaining genes and 
proteins are necessary, next to validation of these findings in a larger collection of 
immune cell subsets from SSc patients.
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 Chapter 12
General discussion
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General discussion
The aim of this thesis was to decipher part of the genetic  background that underlies 
SSc susceptibility. Considering the manuscripts presented in this thesis, it can be 
concluded that this goal was reached. On the other hand it is still  a small 
contribution in elucidating the role of genetics in SSc  pathogenesis and 
susceptibility. Like in any other multifactorial  disease, there is an extensive 
interplay between different genetic and environmental  factors. Although this thesis 
scratches the surface of investigating interplay between genes in chapter 9, much 
work still needs to be done in this field. Prerequisites for such interaction studies 
are larger patient cohorts and dense genetic information. The studies described in 
this thesis, like all  the other efforts in the area of genetic  SSc research, evolved 
along with the revolution in genetic research possibilities. This project started with 
investigating single variants in candidate genes, (e.g. STAT4, FAS, CD89) moved 
to haplotype construction to perform whole candidate gene screening (OX40L) and 
subsequently to validating clinical relevance of SNPs and epigenetic influences. 
At the point that genome wide screening methods came available, the use of 
simple candidate gene studies seemed to become redundant.  Along with many 
others we observed that the main gaps in value of genetic  research lie in the realm 
of functional  validation and clinical translation, or freely put: “Functional validation 
is the bogeyman of genetic  research” (according to Prof. J.A. Todd). Next to a 
genome wide association study (GWAS) being performed by our group in 
collaboration with many others, we started aiming at implementing these main 
omissions of genetic  research in multifactorial  disease within SSc genetic research. 
For this purpose a clinical follow-up database was constructed, to be able to 
predict the development of complications in time based on genetic  markers. This is 
of particular use since the frequency of many complications in SSc increases 
based on disease duration. In addition, genotyping experiments were combined 
with multiple immune cell subset isolations derived from both healthy controls and 
SSc patients, encompassing B cells, T cells, plasmacytoid dendritic  cells, 
monocytes and myeloid dendritic  cells. Of these cell  subsets both RNA and DNA 
were isolated, and they were used to investigate the functional consequences of 
the genetic observations in a cell  specific  matter. In addition ELISA was used to 
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better gauge the effect of variants on protein levels in the blood of patients. These 
efforts resulted in the findings described in part II of this thesis. For some variants 
we were able to indeed show an effect of genetic variants on susceptibility, 
complication development and functional  impact (e.g. TLR2, PBEF), for others we 
did not observe a relevant effect (CD89, IL4, IL13 and corresponding receptors). 
The approach of combining clinical follow-up data and functional implication in 
multiple immune cells allowed us to draw some more sustainable conclusions than 
the ones based on candidate gene studies alone. In addition, the use of follow-up 
data provided information about time related complication development, an area 
that was scarcely explored by SSc genetic  research in a proper manner before. It 
is to be hoped that these studies will be able to form a foundation for a bridge 
across the gap of multifactorial  genetics, functional relevance and clinical reality in 
SSc.
Another field that has rapidly increased during the last years is epigenetics. 
Methylation, microRNA regulation and age related DNA changes have become of 
high interest. These processes have been found implicated in SSc previously, as 
described in the introduction. In part III of this thesis previous findings of skewed X 
chromosome inactivation were validated in our cohort. In addition, it was 
investigated whether there were any differences between cell subsets, as well  as if 
skewing affected regulation of genes located on the X chromosome. Although 
these findings are still quite preliminary in the sense that they provide little 
mechanistic  data, they might prove to be important in the misbalance between 
males and females that are affected by SSc. To really pinpoint the changes that 
occur during this process, a databank with DNA, RNA and protein information on 
multiple time points, in multiple immunecells needs to be established. In this way 
changes in the amount of skewing can be pursued, as well as its impact on gene 
and protein expression in time. In addition, telomeres shortening in B cells and 
plasmacytoid dendritic cells from SSc patients, not corresponding to the declines 
associated with age is described in this thesis. This can be partially explained by 
increased proliferation of these immune cell  subsets, but also indicates that these 
cells are not able to cope with the shortening correctly, either by going into 
apoptosis or by appropriately increasing telomerase expression to restore telomere 
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function. This epigenetic  malfunctioning might contribute to the increased numbers 
of these cells observed in SSc.  
Taken all  these investigations together with other genetic research in SSc, there is 
a vast body of evidence implicating genetics in SSc pathogenesis. This data is still 
partially contradictory, which is probably attributable to the relatively small sample 
sizes used. This is a common problem in genetic  research. Luckily, and despite 
SSc being a rare disease, multi-centre initiatives to investigate the role of genetics 
in SSc are increasing. This will  ultimately lead to more homogenous results, 
although some rare variants might need very large populations (e.g. 10,000 SSc 
samples) before being uncovered as risk factor. One of the most interesting 
findings is that the genetic background of SSc seems to be very similar to that of 
other AID. This observation is partially biased because a large number of candidate 
genes are selected based on the principle of involvement in other AID. 
Interestingly, genetic variants associated with SLE seem to be directive for the 
candidate genes investigated in SSc, whereas RA seems to be the most prominent 
other concomitant autoimmune disease present in families of patients with SSc. 
Although RA has a higher prevalence than SLE, this might signify that genes 
involved in RA might also be good indicators for candidate studies in SSc. This is 
underlined by non-hypothesis driven approaches, in this case GWAS, which have 
yielded susceptibility genes found associated in SLE, RA and Sjögrens syndrome 
as well. An important gap in our understanding of the genetics involved in SSc  is 
the lack of functional  validation of genetic  findings in immune cells or fibroblasts. 
This is becoming more apparent to researchers as there is a marked increase in 
studies that, next to describing genetic  aberrances, aim at validating these results 
functionally. This will ultimately lead to a better understanding of the genetic 
component, but also identify functional pathways present in SSc pathogenesis. To 
date, the single most important step forward in the field of SSc genetics are the 
large GWAS recently published. These studies indicate that common disease 
variants are involved in SSc and strongly implicates the HLA region. Genome wide 
association studies are a powerful  tool, but have shortcomings. The analysis of 
data is still  very rudimentary because it assesses significance for each SNP 
separately. In a multifactorial disease, one would expect that clusters of genetic 
variants contribute together to the total genetic  disease susceptibility. The logical 
267
step would be to investigate these clusters and thus to identify those combinations 
of variants that cumulate to the total genetic susceptibility risk.This field, which is 
currently expanding, is the gene-gene interaction analysis, which is able to 
discover additive effects and might be able to explain a larger part of SSc  disease 
risk than the current genetic  markers alone. It is to be hoped that this will  further 
evolve along with increasing computer power, required to deal  with the high 
computational burden posed by these analyses.
Future directions
The cohorts of patients that are investigated for genetic  risk factors in SSc  have 
steadily increased over the last years and will keep on expanding. However, larger 
sample sizes are still necessary to identify common variants with small effects. For 
this purpose it is likely that even more global collaboration between SSc DNA 
databanks and rheumatologists will  emerge in the upcoming years. The 
observation that common genetic  variants are not the only factors contributing to 
SSc susceptibility, together with the similar genetic background present in other 
AID, indicates that rare variants, epigenetic changes or environmental  triggers are 
able to determine which autoimmune disease will develop in a susceptible person. 
This opens the door in the next years for new technologies such as next generation 
full  exome/genome sequencing, which is able to identify rare genetic variants, and 
DNA methylation profiling. Rare variants are likely to affect SSc susceptibility, but 
may differ between patients and are possibly de novo or evolutionary “young” 
mutations. Therefore, this technique will be especially powerful in families with 
SSc. Studies addressing methylation patterns are of high interest in SSc, since 
these are able to identify those regions of the genome that are part of the 
epigenetic  inheritance involved in SSc pathogenesis. This would be extremely 
informative in a MZ twin study, since it might explain a proportion of the 
discordance observed in twins from SSc patients. Furthermore, studies that would 
shed light on the development of chromosomal aberrances in SSc might point to 
processes involved early in the disease onset. In addition a lot is expected from 
screening micro-RNA’s for post transcriptional  regulation of gene expression. This 
novel  level of gene expression regulation might be an important step in 
understanding the development of AID on a certain genetic  background. Another 
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leap forward will be the transition to personal genomics. Next to traditional risk 
factors used in clinics for diagnostic  and treatment processes, common genetic risk 
factors, rare variants and epigenetics will be used to determine risks for developing 
complications or response to treatment. In SSc it would be particularly interesting 
to identify genetic  risk factors that play a role in development of scleroderma renal 
crisis, pulmonary hypertension and pulmonary fibrosis. When these variants are 
known, physicians are able to identify patients at risk early and start preventive 
treatment of these incurable and often fatal complications.  Genetic  research in the 
field of SSc will  probably sail the winds of changes in genetic  research 
methodology in the upcoming years, which hopefully will bring us to the brink of 
understanding this complex disease.  
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Summary
Systemic  sclerosis (SSc) is a systemic autoimmune disease which particularly 
affects the connective tissue. The disease is rare with currently about 1600 patients 
in the Netherlands and an estimated incidence of 3 to 22.8 per million per year. 
Women are more often affected than men; the literature reports a range of 3-14 
women against one man. Although more risk factors are identified, the 
pathogenesis of SSc remains largely unresolved.
The disease appears to be based on a triad of processes, vasculopathy, immune 
activation and fibrosis. The vasculopathy first manifests itself as Raynaud's 
phenomenon. This cold and stress triggered discoloration of the fingers and feet 
from white to blue to red is always present in SSc. On the other hand, only very 
few people with Raynaud's develop full-blown SSc. Exacerbation of the 
vasculopathy may result in ischemia; causing digital  ulcers, necrosis and loss of 
the fingerpads. Manifestations of vasculopathy that occur later in the disease are 
renal crisis and pulmonary arterial hypertension. The second pillar of the disease 
process, immune activation, is characterized by the production of auto-antibodies, 
B-and T-cell activation and perivascular infiltrates. The current hypothesis is that 
these immune cells produce cytokines that incite fibroblasts to produce excessive 
collagen matrix, leading to fibrosis or sclerosis of the skin and internal  organs. The 
diagnosis of SSc can be made by using the criteria of the American College of 
Rheumatology. If there is scleroderma (sclerosis of the skin) or if two of the 
following symptoms are present: 1) sclerodactyly, 2) digital  ulcers or loss of 
fingertip, or, 3) bibasilar pulmonary fibrosis. Based on the pattern of skin sclerosis, 
a classification can be made in limited SSc  (lcSSc) and diffuse SSc (dcSSc), both 
subforms have characteristic  autoantibodies and complications. In more detail, 
lcSSc  is characterized by a long-standing history of Raynaud's phenomenon. 
Fibrosis of the skin is present on the hands, face, feet and forearms. In addition, 
the presence of anti-centromere antibodies is very common (70-80%) and patients 
with lcSSc more often develop pulmonary hypertension. Diffuse SSc patients, 
usually suffered less than one year from Raynaud's before full-blown SSc  unveils 
itself. In addition, interstitial  pulmonary fibrosis, gastrointestinal  fibrosis, renal 
failure and myocardial problems occur early in the disease process. The skin on 
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the acra and trunk is fibrotic. Thirty percent of dcSSc have anti-topoisomerase 
antibodies. Although the prognosis and treatment of SSc has improved in recent 
years, the disease remains incurable. Since complications for each clinical subform 
are different, the prognosis differs for lcSSc and dcSSc. Limited SSc has a 10-year 
survival  of 75% -79%, diffuse SSc 53% -62%. However, when pulmonary 
hypertension develops in the lcSSc patients the survival drops to about 10% over 5 
years.
This thesis is divided into three parts. The first part is based on four studies into 
genetic variants, each covers one chapter. In chapter 2, a variant of the STAT4 
gene is discussed, which is involved in the functioning of T cells. The variant is 
more common in patients with SSc and therefore plays a role in the susceptibility to 
developing the disease. In chapter 3, a genetic  variant of FAS is scrutinized; this 
gene is involved in initiating regulated cell  death. The variant is linked to the 
expression of FAS in cells. It appears that patients with positive anti-centromere 
antibody titers and limited disease carry this variant more often than healthy 
people. In the fourth section a variant in CD89 is described; this variant plays no 
role in SSc and RA. The fifth chapter confirms a previously reported association of 
a polymorphism in the TNFSF4 gene using a large European population of SSc 
patients.
The second part dives deeper into the role that genetic  variants play in the 
functioning of immune cells and the development of clinical complications. In 
chapter 6 it is shown that various polymorphisms in the genes for interleukins 4 
and 13, and their receptors, play no significant role in the development of SSc, 
associated complications and production of these cytokines. This is in contrast to 
the findings in chapter 7, where after an evaluation of various genetic  variants in 
Toll  like receptors, we show that a variant of the Toll like receptor 2 gene 
predisposes for developing diffuse SSc and pulmonary arterial hypertension (PAH). 
Furthermore, it is demonstrated that this variant, if present on dendritic cells, 
increases the release of inflammatory proteins. Chapter 8 starts with the 
observation that expression of the PBEF protein is higher in SSc  patients with PAH. 
Next it is shown that this expression is influenced by two previously described 
variants in the promoter region of the PBEF gene. These variants also seem to 
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play a role in the development of PAH during the period of illness. The variant also 
seems to be involved in the susceptibility to develop SSc. In the final  chapter of this 
section, we analyze a modified analysis method for interactions between different 
genes and variants (called epistasis) This pointed to a genetic  interaction between 
a variant in the PBEF gene, TLR9 and Interleukin 1-alpha, which could be 
validated at a functional level using cell systems.
The third part investigates processes that take place at a higher level  of regulation 
than the DNA-sequence (epigenetics). Chapter 10 investigates the phenomenon of 
X chromosomal  inactivation in SSc. Normally, women have two X chromosomes of 
which one is randomly inactivated. As women age, this random inactivation 
increasingly shifts to a skewed distribution. Chapter 10 shows that women with 
SSc display X skewing already early in life. Furthermore, the expression of a gene 
on the X chromosome, Foxp3, is affected in regulatory T  cells. These cells play an 
important role in suppressing inflammatory responses, and seem to be rendered 
less capable doing so by this X chromosomal process. In the last chapter, the 
length of telomeres in immune cells from healthy controls and SSc patients was 
examined. Telomeres are the ends of chromosomes that shorten with each cell 
division and thus shorten in aging cells. In patients with SSc, telomeres shorten in 
a different fashion as compared to healthy individuals. Next to this, there are clear 
differences in telomere length between different immune cell types that are 
specifically for limited or diffuse SSc. This may reflect a difference in the 
involvement of these cells in different subtypes of SSc.
This thesis makes a modest contribution to the understanding of genetic processes 
that play a role in SSc. The challenge for the coming years lies in translating 
genetic findings into the clinic, as therapeutic targets and complication predictors.
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Samenvatting
Systemische sclerose (SSc) is een systemische auto-immuunziekte die met name 
het bindweefsel aantast. De ziekte is erg zeldzaam met momenteel ongeveer 1600 
patiënten in Nederland en een geschatte incidentie van 3-22,8 per miljoen per jaar. 
Vrouwen zijn vaker aangedaan dan mannen, de literatuur rapporteert een spreiding 
van 3-14 vrouwen tegenover 1 man. Hoewel er steeds meer, met name 
genetische, risicofactoren bekend worden blijft de pathogenese van SSc 
grotendeels onopgehelderd. 
De ziekte lijkt te zijn gefundeerd op een trias van processen; vasculopathie 
(vaatafwijkingen), immuunactivatie en fibrose (verlittekening). De vasculopathie uit 
zich over het algemeen als eerste in de hoedanigheid van het fenomeen van 
Raynaud. Deze koude en stress gevoelige verkleuring van de vingers en tenen van 
wit naar blauw naar rood komt altijd voor bij SSc, maar andersom krijgen maar 
zeer weinig mensen met het fenomeen van Raynaud SSc. Bij verergering van de 
vasculopathie kunnen digitale ulcera (zweren aan de vingers), necrose 
(versterving) en verlies van de vingertoppen ontstaan door een tekort aan 
zuurstoftoevoer. Uitingen van vasculopathie die later in het ziekteproces optreden 
zijn pulmonale arteriële hypertensie en renale crise (ernstige long en 
nierafwijkingen). De tweede pijler van het ziekteproces is immuunsysteem 
activatie, dat zich kenmerkt door de productie van auto-anti-lichamen, B- en T-cel 
activatie en perivasculaire infiltraten. De huidige hypothese is dat deze 
immuuncellen cytokines produceren die fibroblasten aanzetten tot productie van 
overmatige collagene matrix, leidend tot fibrose oftewel  sclerose van de huid en 
interne organen. De diagnose SSc is te stellen volgens de American College of 
Rheumatology wanneer er sprake is van sclerodermie (sclerosering van de huid) of 
wanneer twee van de volgende symptomen aanwezig zijn: 1) sclerodactylie, 2) 
digitale ulcera of verlies vingertop 3) bibasilaire pulmonale fibrose.  Intrigerend is 
dat op basis van het patroon van huidsclerose een indeling gemaakt kan worden in 
gelimiteerde SSc  (lcSSc) en diffuse SSc (dcSSc), met beide karakteristieke auto-
antilichamen en complicaties. In meer detail; lcSSc kenmerkt zich door een 
anamnese van een al  jaren bestaand Raynaud’s fenomeen. Bij onderzoek is er 
sclerose van de huid aanwezig op handen, gezicht, voeten en onderarmen, 
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daarnaast zijn er vaak teleangectasien en huid calcificaties waar te nemen 
(calcinosis cutis). De aanwezigheid van anti-centromeer antilichamen bij 
laboratorium onderzoek komt zeer vaak voor (70-80%). Patiënten met lcSSc 
hebben vaker pulmonale hypertensie dan patiënten met diffuse SSc. Diffuse SSc 
patiënten hebben daarentegen korter dan 1 jaar last van het fenomeen van 
Raynaud. Daarnaast treedt vroeg in het ziekteproces interstitiële longfibrose, 
gastrointestinale fibrose, nierfalen en myocardiale problematiek op. De patiënt 
heeft met name last van kortademigheid, zuurbranden en verminderde 
urineproductie.  Bij onderzoek van de huid bevindt zich de sclerose proximaal op 
het lichaam. Dertig procent van dcSSc hebben anti-topoisomerase antilichamen. 
Ongeveer 1/3 van alle SSc patienten heeft dcSSc en 2/3 lcSSc. Alhoewel de 
prognose en behandeling van SSc  de laatste jaren verbeterd is, blijft de ziekte 
ongeneeslijk. Voortvloeiend uit de verschillende orgaancomplicaties passende bij 
de gelimiteerde en diffuse vorm van SSc is ook de prognose verschillend. 
Gelimiteerde SSc  heeft een 10 jaars survival  van 75%-79%, diffuse SSc echter 
53%-62%. Ontstaat er echter pulmonale hypertensie gedurende het ziektebeloop 
van de gelimiteerde vorm, dan zakt de survival alsnog naar ongeveer 10% over 5 
jaar. 
Dit proefschrift is ingedeeld in drie onderdelen. Het eerste onderdeel beschrijft een 
viertal genetische varianten, behandeld per hoofdstuk. In hoofdstuk 2 wordt een 
variant van het STAT4 gen besproken, een gen betrokken bij onder andere het 
functioneren van T cellen. Deze variant komt vaker voor bij  patiënten met SSc en 
speelt daarom mogelijk een rol  bij de gevoeligheid voor het ontwikkelen van de 
ziekte. In hoofdstuk 3 komt een genetische variant van FAS aan de orde, dit gen is 
betrokken bij gereguleerde celdood. Deze variant is in staat om de expressie van 
FAS in cellen te veranderen. Het blijkt dat patiënten met antilichamen tegen 
centromeren en gelimiteerde ziekte, vaker deze variant dragen dan gezonde 
mensen en andere SSc  patiënten. In het vierde hoofdstuk wordt beschreven dat 
een variant in CD89 geen rol speelt in SSc. In het vijfde hoofdstuk wordt een 
eerdere associatie van een polymorfisme in het TNFSF4 gen met SSc bevestigd in 
een grote populatie Europese SSc patienten.
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Het tweede onderdeel van het proefschrift duikt dieper in de rol die genetische 
varianten spelen in het functioneren van immuuncellen en de ontwikkeling van 
klinische complicaties. In hoofdstuk 6 is beschreven dat een aantal polymorfismen 
in de genen voor interleukines 4 en 13, en hun receptoren, geen rol van betekenis 
spelen in het ontwikkelen van SSc  en de bijpassende complicaties en productie 
van deze cytokines. Dit in tegenstelling tot de bevindingen in Hoofdstuk 7, alwaar 
na een evaluatie van genetische varianten in toll  like receptors aangetoond wordt 
dat er een variant in het TLR2 gen bestaat die een grotere kans geeft op het 
ontwikkelen van diffuse SSc en PAH. Daarnaast wordt aangetoond dat deze 
variant in dendritische cellen een toename geeft van ontsteking stimulerende 
eiwitten. Hoofdstuk 8 start met de observatie dat de expressie van het eiwit PBEF 
hoger is in SSc patienten met PAH, vervolgens wordt aangetoond dat deze 
expressie onder invloed staat van twee eerder beschreven varianten in de 
promoter regio van het PBEF gen. Deze varianten lijken ook een rol te spelen in de 
ontwikkeling van PAH gedurende de ziekteperiode. Daarnaast lijkt de variant een 
rol te spelen in de gevoeligheid voor ontwikkeling van SSc. In het laatste hoofdstuk 
van dit onderdeel wordt een nieuwe analysemethode toegepast om na te gaan of 
er interacties tussen verschillende genen en varianten bestaan (epistase 
genoemd). De analyse geeft aan dat er een genetische interactie is tussen een 
variant in het PBEF gen, TLR9 en Interleukine 1-alpha, die ook in vitro lijkt te 
bestaan.
Het derde onderdeel  ontstijgt het niveau van de DNA code en kijkt naar processen 
die daar net boven plaatsvinden. Normaal  gesproken hebben vrouwen een tweetal 
X chromosomen waarvan er één “random” oftewel willekeurig wordt uitgeschakeld. 
Naarmate vrouwen ouder worden verschuift deze willekeurige uitschakeling naar 
een “skewed” oftewel een voorkeursverdeling voor één van de 2 X chromosomen. 
Hoofdstuk 10 laat zien dat vrouwen met SSc  al vroeg in hun leven een 
voorkeursverdeling hebben. Daarnaast is de expressie van een gen op het X 
chromosoom, FOXP3, verlaagd in T  regulatoire cellen. Deze cellen spelen een 
belangrijke rol in het onderdrukken van ontstekingsreacties, en lijken daar, door dit 
X chromosomale proces, minder goed toe in staat. In het laatste hoofdstuk wordt 
de lengte van telomeren in immuuncellen van gezonde controles en SSc patienten 
onderzocht. Telomeren zijn de uiteinden van chromosomen die bij iedere celdeling 
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verkorten en dus korter worden bij veroudering van cellen. In patienten met SSc 
verkorten deze telomeren niet zoals in gezonde personen, daarnaast zijn duidelijke 
verschillen aan te wijzen tussen verschillende soorten immuuncellen die specifiek 
in gelimiteerde of diffuse SSc verkorte telomeren hebben. Mogelijk weerspiegelt dit 
een verschil  in betrokkenheid van deze cellen in de verschillende subtypes van 
SSc.
Dit proefschrift levert een bescheiden bijdrage aan het inzicht in genetische 
processen die een rol spelen bij  SSc. De uitdaging voor de komende jaren ligt 
echter in de vertaling van genetische bevindingen naar de kliniek in de vorm van 
therapeutische aangrijpingspunten en complicatie beperkingen.
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 Appendix II: Abbrevations
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ACR American College of Rheumatologists
AID Auto-immune disease(s)
ANA Anti Nuclear Antibodies
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anti-topo Anti-topoisomerase antibodies
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CTGF Connective Tissue Growth Factor
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DZ Dyzigotic
ELISA Enzyme-linked immunosorbent assay
EXOC2 Exocyst complex component 2
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FcαR1 receptor for Fc fragment of IgA
FOXP3 Forkhead Box P3
FVC Forced vital capacity
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G Guanine
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GRB10 Growth Factor Receptor-Bound protein 10
GWAS Genome Wide Association Study
HAPMAP haplotype map
HLA Human Leukocyte Antigen
HUMARA Human Androgen Receptor
HWE Hardy-Weinberg Equilibrium
ICAM-1 intercellular adhesion molecule 1
IFN Interferon
Ig Immunoglobulin
IL Interleukin
IL13RA1 Interleukin 13 receptor alpha 1
IL4R Interleukin 4 receptor
IRAK1 Interleukin 1 Receptor-Associated Kinase 1
IRF Interferon Regulatory Factor
JAK Janus Kinase
lcSSc limited cutaneous Systemic Sclerosis
LD linkage disequilibrium
M-H Mantel-Haenzel
MAF minor allele frequency
MDR Multi Dimensional Reduction
MHC Major Histocompatibiliy Complex
moDC monocyte derived dendritic cells
mRNA messenger Ribonucleic Acid
MyDC myeloid dendritic cells
MZ Monozygotic
n Number
NLRP1 NLR Family Pyrin Domain Containing 1
NOTCH Notch homolog 1, translocation associated
OR Odds Ratio
OX40L Tumor Necrosis Factor Receptor Superfamily, member 4
PAH Pulmonary Arterial Hypertension
PBEF Pre-B-Cell Colony-Enhancing Factor 1
PBL Peripheral Blood Leukocytes
PBMC Peripheral Blood Mononuclear Cells
Pcor Corrected p value
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PCR Polymerase Chain Reaction
PDC Plasmacytoid Dendritic Cells
PDGF Platelet Derived Growth Factor 
POL RNA polymerase
PTPN22 Protein Tyrosine Phosphatase Nonreceptor-type 22
Q-PCR Quantitative PCR
RA Rheumatoid Arthritis
RE Relative Expression
RF Rheumatoid factor
RFLP restriction fragment length polymorphism
RNA Ribonucleic Acid
RR Relative Risk
SD Standard Deviation
SLE Systemic Lupus Erythematosus
SNP Single Nucleotide Polymorphism
SOX5 SRY-BOX 5
SPARC Secreted Protein Acidic Cystine-Rich
SSc Systemic Sclerosis
STAT4 Signal Transducer and Activator of Transcription 4
T Thymine
T/S telomere repeat copy number to single copy gene number
TBX21 T-Box 21
TGF Transforming Growth Factor
Th T helper
TLR Toll Like Receptor
TNF Tumor Necrosis Factor
TNFSF4 Tumor Necrosis Factor Ligand Superfamily Member 4
TNIP TNFAIP3 interacting protein 1
TNPO3 Transportin 3
TOPO1 Topoisomerase
Tregs T reulatory cells
TYK Tyrosyne Kinase
UPAR UPA Receptor
USA United States of America
UTR Untranslated Region
XCI X Chromosomal Inactivation
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